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Abstract 
Homocysteine, an independent risk factor for cardiovascular disease, is methylated in 
the liver via the zinc metalloenzyme betaine-homocysteine methyltransferase (BHMT). 
Established assays for BHMT include a radiochemical assay, a colorometric assay, an HPLC 
assay and an in vivo microbiological assay. These techniques are either unsuitable for substrate 
specificity studies, or are unable to give kinetic measurements. BHMT was purified from liver 
and measured directly and kinetically by a novel 1H-NMR spectroscopic assay. The 
disappearance of substrates and the formation of products are monitored simultaneously. 
Using 2 mM glycine betaine and homocysteine as substrates in 20 mM phosphate 
buffer (pH = 7.5) and measuring the production of N,N-dimethylglycine the CV is 6.3% (n = 6) 
and the detection limit is 6 nkatal. An endpoint assay for BHMT activity was also developed 
and had CV = 5.3%, n = 6, with a detection limit of 2 nkatal.  The NMR spectroscopic assay 
was used to determine the substrate specificity with a library of alternative substrates. Analysis 
of betaine analogues with different chain length, α-substitution, substitution of the nitrogen 
and carboxyl moieties demonstrated that BHMT is inactive if there is any steric crowding of the 
nitrogen or α-carbon positions.  BHMT is capable of using group VI heteroatom betaines as 
methyl donors, with much faster rates than glycine betaine.  For glycine betaine the Km was 
0.19 ± 0.03 mM with a Vmax of 17 ± 0.7 nMol min-1 mg-1. The same assay was used to 
detect and partially characterise a BHMT activity from hagfish liver that is similar to that of the 
mammalian enzyme. 
NMR spectroscopy was adapted for measurements of glycine betaine in urine, along 
with other medically significant methylamines. These were shown to be valid for clinical use 
and in animal studies. A novel metabolite of the sulfonium analogue of glycine betaine 
(methylsulfinylmethanoate) was identified in rats.  
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Chapter 1 
 
Introduction 
 
 
 
Science is facts; just as houses are made of stones, so is science made of facts; but a pile of stones is 
not a house and a collection of facts is not necessarily science. 
- Henri Poincare 
 
Nothing shocks me. I'm a scientist. 
-     Harrison Ford, as Indiana Jones 
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CHAPTER 1: 
Introduction 
 
1.1 Cardiovascular Disease 
1.1.1 The CVD Epidemic 
 Cardiovascular disease (CVD) is one of the major causes of death in the developed and 
developing world.  The World Heath Organisation (WHO) classifies CVD as “diseases which 
affect the proper functioning of the heart and blood vessels”, a description which incorporates 
myocardial infarction, cerebrovascular diseases (strokes), transient ischaemic attacks (TIA), 
deep vein thrombosis (DVT) and other peripheral vascular diseases.1 According to the WHO, 
CVD kills some 17 million people every year, much of which can be attributed to poor lifestyle 
choices, such as smoking, diet and lack of physical activity.1 
 The New Zealand Heart Foundation estimates that 11% of the non-fatal disease 
burden in New Zealand is due to CVD, with 27,445 hospital admissions a year (1999 data).  
CVD is also the leading killer in New Zealand, responsible for 40% of all deaths.  These 
statistics are comparable over the developed world, although the toll for developing nations is 
much higher.  Worldwide, CVD is the single highest cause of mortality in women annually, with 
8.5 million deaths (one third of all female fatalities).  In developing countries, this figure 
accounts for over 50% of all female deaths.  Developing regions are unfortunately not alone; 
42% of all mortality in the European Union is due to CVD.1  CVD is not just a disease of the 
old; 36% of premature deaths in men and 27% of premature deaths in women in the United 
Kingdom are due to CVD [Figure 1.1]. 
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Figure 1.1 Total death rate and CVD-death rate for selected countries (1997-2001). 
 
1.1.2 Causes of CVD 
 There are many risk factors for CVD, including some metabolites of which the public 
are well informed.  The most ill-famed of these is cholesterol, which has featured prominently 
in the literature since the 1950’s.2   
 Smoking, high blood pressure, obesity, sex, age, race and genetics are all important 
factors involved in the incidence of CVD amongst many others.1  It was identified during the 
1960’s that homocysteine levels are also an important predictor of CVD.3  The link between 
homocysteine levels and CVD is now well established, although poorly understood.  The link 
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may be causal, with a modest 3 µM decrease in plasma homocysteine associated with a 16% 
decrease in TIA’s, 25% decrease in DVT and 24% decrease in strokes.4 
 
1.2 Homocysteine and Glycine Betaine 
1.2.1 Homocysteine Biochemistry 
 Homocysteine is a non-protein amino acid, created by the removal of a methyl group 
from methionine, an essential amino acid for human beings [Figure 1.2]. Methionine is 
converted to S-adenosyl methionine (SAM), which is used by as many as 200 different enzymes 
as a methyl-donor.  The product of this demethylation is S-adenosyl homocysteine, which can 
be hydrolysed into free homocysteine.  Homocysteine can then be remethylated into 
methionine by two pathways; the methionine synthase pathway (E.C. 2.1.1.13, MS), which 
uses N5-methylene tetrahydrofolate as a methyl donor, and betaine-homocysteine 
methyltransferase (E.C. 2.1.1.5, BHMT), using glycine betaine (or its analogues) as methyl 
donors [Figure 1.2]. 
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Figure 1.2 Homocysteine metabolism (abridged).  Homocysteine is remethylated by methionine 
synthase (MS) using tetrahydrofolate (THF), or by betaine homocysteine methyltransferase (BHMT) using 
glycine betaine and forming dimethylglycine (DMG).  This is recycled via adenosine triphosphate (ATP) 
to S-adenosylmethionine (SAM) and then to S-adenosylhomocysteine (SAH).  Homocysteine can also be 
broken down by cystathionine β-synthase (CBS) to ultimately form cysteine. 
 
 Homocysteine is also removed by the deconstruction of the backbone common to 
methionine and homocysteine (via cystathionine) ultimately to cysteine via the enzyme 
cystathionine β-synthase (CBS, E.C. 4.2.1.22) [Figure 1.2].5   
Recent studies have discounted the influence of homocysteine on CVD by treating CVD 
patients with folate, and vitamins B12 and B6.
6,7  All of these studies found that the folate and B 
vitamin therapy lowered total plasma homocysteine, but did not result in a lowered risk of 
further atherosclerotic events (with the exception of strokes, which were decreased).  The 
conclusion, that homocysteine cannot be a causative factor in CVD, is premature, since they 
have ignored the BHMT pathway.8  Furthermore, the results are difficult to reconcile with 
overwhelming data suggesting that homocysteine is implicated in CVD.4,9-14 
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1.2.2 Betaines 
 The term betaine refers to a class of compounds which are all zwitterionic (contain 
both a permanent positive and negative charge) at physiological pH.  Glycine betaine was the 
first betaine to be discovered, originally from sugar beet, Beta vulgaris, hence the later naming 
of the class of compounds.  Initially, glycine betaine was the only known compound that 
contains an N,N,N-methylated amino acid. 
 Since their original discovery, a number of other betaines have been isolated from 
nature, including many of the amino acids that have undergone similar methylation on the 
amine (or related heteroatom) moiety.  Some of these compounds are shown in Figure 1.3. 
N N
N CO2
CO2
S
S
CO2
CO2 As CO2
1 2 3
4 5 6
CO2
 
Figure 1.3 Some betaines used during the work for thesis.  Glycine betaine (1), proline betaine 
(stachydrine, 2), trigonelline (3), dimethylsulfoniopropionate (DMSP, 4), dimethyl thetin (DMT, 5), and 
arsenobetaine (6). 
 
 Betaines have been implicated in several functions of normal cellular activity.    These 
functions include regulating cell volumes and ionic strength, urea and solute protection of 
proteins (especially in the kidney) and methylation reactions (by acting as methyl donors).  Salt 
tolerant organisms accumulate glycine betaine and other related betaines.15-17  This 
accumulation restores cell volume, and balances osmotic pressure.18 
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 Betaines are utilised to protect against the macromolecular destabilising effect of urea 
on proteins.19,20  There are several proposed mechanisms for this protection, including the 
‘Preferential Exclusion Model’, in which macromolecules are protected by having a preferential 
interaction between betaine and the protein, over the urea and protein.21  In this model, the 
protection comes from the positive and negative charges distributed across the betaine 
molecule.22 
 It is the methyl-donor properties of betaines, and their implications for homocysteine 
metabolism which will be the focus of this thesis.   
 
1.2.3 Diet and Homocysteine 
 As Selhub points out, nutrition can play an integral part in homocysteine metabolism.23  
Figure 1.2 illustrates the requirements for several substrates, vitamins and cofactors.  
Methionine synthase requires folate and vitamin B12 as cofactors.  Both steps in the destruction 
of the methionine/homocysteine backbone (from homocysteine to cystathionine, then to 
cystine) require vitamin B6.  BHMT requires glycine betaine (which can be ingested or 
synthesized from choline) and zinc to facilitate the reaction between homocysteine and glycine 
betaine.  Clearly, deficiencies in these vitamins and mineral will result in impaired 
homocysteine metabolism. Glycine betaine is acquired through the diet, and can also be 
synthesized from choline (also obtained endogenously)  [Figure 1.4].24  It has been recently 
claimed that humans cannot convert choline to the betaine,25,26 and that humans are therefore 
dependent on dietary betaine,26 but this is probably based on a misinterpretation of earlier 
work27 that showed that humans had relatively low activity of choline dehydrogenase in liver 
compared with kidney activity, in contrast to the rat pattern. Dietary choline is undoubtedly an 
important source of glycine betaine and hence methyl groups in humans. 
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Figure 1.4 Oxidation of choline to produce methylene-tetrahydrofolate (THF).  Choline is oxidised in 
two steps to glycine betaine (via betaine aldehyde).  This is then demethylated by betaine homocysteine 
methyltransferase (BHMT) to dimethylglycine (DMG).  DMG can then demethylate to form sarcosine and 
one methylene tetrahydrofolate (CH2-THF).  Sarcosine can then be demethylated to glycine and one 
CH2-THF.  Finally, glycine can be metabolised into ammonia and carbon dioxide forming another 
CH2-THF. 
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1.2.4 Betaine Metabolism  
 The role of glycine betaine in homocysteine metabolism is not over once betaine has 
been demethylated by BHMT.  Dimethylglycine (DMG) can be transported from the cytosol to 
the mitochondrion to be oxidatively demethylated to form sarcosine, by the enzyme 
dimethylglycine dehydrogenase (DMGDH, E.C. 1.5.99.2), to form methylene-tetrahydrofolate.28  
This pathway continues to oxidatively demethylate sarcosine to give another methylene-
tetrahydrofolate, using sarcosine dehydrogenase (E.C. 1.5.99.1), resulting in glycine  [Figure 
1.4].28 
 Glycine can be further cleaved by the glycine cleavage system to form CO2, NH3 and a 
final methylene-tetrahydrofolate.  In total, one choline molecule gives (via glycine betaine) a 
total of four methyl groups, and can potentially remethylate a total of four homocysteine 
molecules to methionine (folate is also used in the synthesis of purines, serine and many other 
biomolecules) [Figure 1.4]. 
 The relative flux through each of these pathways is still a topic for debate.  Finkelstein 
and Mudd provided the first evidence of this, showing that under non-physiological conditions 
and using liver extracts, MS, BHMT and CBS contribute 27%, 27% and 46% of homocysteine 
consumption respectively.29  
 Despite the evident importance of BHMT it has been largely ignored in the literature, 
(by medical professionals in particular).  This is clearly evidenced by Selhub’s review of 1999  
“…remethylation pathway to methionine, which requires folate and vitamin B12 (or betaine in 
an alternative reaction)…”.23  The review largely ignores any potential BHMT influences on 
homocysteinaemia. 
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1.2.5 Homocysteine Disorders 
 The reference interval for plasma homocysteine concentration is 5-15 µM (10.08 ± 5.3 
µM).30,31  Folate, vitamin B12 deficiencies or mutations in methionine synthase (677C→T, for 
example) can result in plasma homocysteine concentrations of 20-50 µM.  Inborn errors in the 
CBS pathway (homozygous cystathionine β-synthase mutations) have been shown to increase 
plasma homocysteine concentrations, causing homocysteinaemia, giving plasma 
concentrations for homocysteine up to 400 µM.23  There is no known genetic defect in the 
BHMT gene leading to increased plasma homocysteine.  A polymorphism (742G→A; R239Q) 
has been located and identified within patients attending the Mayo Clinic (Rochester, 
Minnesota), but this was not correlated with increased homocysteine (but was speculated to 
be linked to CVD).32  This lack of BHMT mutations causing homocysteinaemia / 
homocysteinuria may be responsible for the lack of interest in BHMT.   
 Plasma homocysteine is the result of a cellular transportation mechanism, which 
removes homocysteine from the cytoplasm and maintains low cellular levels.33  High plasma 
homocysteine concentrations are associated with older age, high creatinine concentrations, 
smoking, coffee consumption, high alcohol consumption, nitrous oxide and L-dopa treatments.  
Plasma homocysteine is higher in men than women.23 
 Patients with renal disease often have elevated homocysteine, up to four times normal 
concentrations.34  The mechanism leading to this elevation is not clear, however, it may be a 
consequence of high excretion of glycine betaine and other cofactors associated with 
homocysteine metabolism.11,35  Cardiovascular disease is also elevated in these patients, 
although homocysteine has yet to be established as the causative agent. 
 The sequence of events which leads homocysteine to cause CVD is not clear either.  
Homocysteine is rapidly auto-oxidised in plasma, forming dimeric homocystine (homocysteine 
disulfide), homocysteine thiolactone, and mixed disulfides with various other thiols, including 
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protein cysteine residues.  Reactive oxygen species can be formed during this oxidation, 
including superoxide, peroxy species and hydroxyl radicals.34 
 Evidence is mounting indicating that homocysteine-induced damage to endothelial 
cells within the walls of the circulatory system (mediated by hydrogen peroxide) exposes 
smooth muscle cells and matrix, proliferating and activating platelets and leukocytes.34 
Endothelial cells are not completely defenceless against homocysteine.  Stamler et al showed 
that endothelial cells can produce nitric oxide, which combines with homocysteine in the 
presence of oxygen, detoxifying homocysteine to S-nitroso-homocysteine.36  This prevents 
peroxide production from homocysteine oxidation, relieving the oxidative stresses on the 
endothelial cells.  S-Nitroso-homocysteine also acts as a platelet inhibitor and vasodilator.34  
However, the endothelial cells cannot withstand this treatment indefinitely, damage to the 
endothelium eventually affects the production of nitric oxide, and oxidative damage begins in 
earnest. 
 Homocysteine also promotes the production of oxy-cholesterols, a highly atherogenic 
class of compounds, oxidises low-density lipoproteins, and increases lipid peroxidation.  This 
would potentially explain the multiplicative effect of homocysteine on other CVD risk factors 
(like cholesterol and lipid levels).11 
 
1.3 Betaine Homocysteine Methyltransferase 
1.3.1 BHMT 
 BHMT has a moderately large subunit of 44.5 kDa (calculated from the open reading 
frame of the human BHMT gene – coding for 406 amino acids).37   There has been a vigorous 
debate regarding the quaternary structure of BHMT.  Early reports suggested that BHMT was a 
hexamer (following size exclusion chromatography), while the tetramer was identified, but 
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largely discounted.38-40  More recent studies would suggest that BHMT is active as a tetramer, 
not as a hexamer.41,42  
 Early structures released by Evans et al showed a ‘dimer of dimers’; a tetrahedral 
arrangement of four subunits [Figure 1.5].  However, they could not describe any mechanism 
for this arrangement – there appeared to be little interaction between the subunits to allow 
this organisation. 
 
Figure 1.5 Evans et al crystal structure for recombinant BHMT (stereo-view).  The ‘dimerisation arm’ 
and ‘hook region’ of subunit A have been coloured red and green, respectively. 
 
 Their structure did, however, reveal the organization between subunits, leading to 
dimerisation.  They describe this region as the ‘hook region’, shown at the top of Figure 1.5.  
The hook-shaped loop at 362PYNP365 wraps about the corresponding hook region of the second 
subunit, forming a tight link and enabling dimerisation. 
 There is a second region named the ‘dimerisation arm’ that extends from the TIM 
barrel motif from residue 318 (visible in dark blue in Figure 1.5 above) and contributes inter-
chain interactions that assist in dimer formation.  The structure has a number of disordered 
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regions, from residues 2-10, 38-52, 76-99, 325-332 and 372-407; the active site, however, 
can be seen.  Molecular modelling of the region 372-407 at the C-terminal  end of the 
polypeptide predicted an α-helix, but this could not be resolved in the crystal structure.41 
 Gonzalez et al published the complete crystal structure in early 2004 [Figure 1.6].  
Their structure contains the remainder of the structure, revealing further information about the 
previously disordered regions.42  Their structure shows that the C-terminal region (residues 
372-407) does form an α-helix, and also form interactions between dimers, allowing 
tetramerisation.   
 
Figure 1.6 Gonzalez et al structure of Rat Liver BHMT (stereo-view).42  Zn2+ has been included as a 
brown ‘spacefilled’ point.  Subunits A and B are coloured by structure to show α-helix (pink) and β-
sheets (yellow). 
 
 BHMT is a zinc metalloenzyme,43 containing a highly conserved zinc binding motif of 
three cysteine residues, holding the zinc ions in an approximate tetrahedron.41  In rat, mouse, 
pig and human BHMT the zinc motif is always 214GVNCH218 and 293VRYIGGCCGFEPYHI317 (amino 
acid numbers for rat BHMT).44  
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1.3.2 BHMT Mechanism 
 In 1983, Awad et al found that a homocysteine analogue, S-(δ-carboxybutyl)-L-
homocysteine (CBH) was a potent inhibitor (Ki ~ 3.25 µM) of their recently isolated BHMT 
extract.45  They inferred that CBH was mimicking the transition state of the reaction, further 
implying that there was a direct transfer of a methyl group from glycine betaine to 
homocysteine in an SN2-type reaction [Figure 1.7]. 
 This information did not, however, give any information as to the enzyme 
conformational changes that may be occurring in the tertiary/quaternary structure of the 
protein which enable the methyl-transfer. 
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Figure 1.7 S-(γ-carboxybutyl)-L-homocysteine (CBH - top) and the proposed transition state for BHMT 
(bottom). 
  
 Further evidence came with the application of intrinsic tryptophan fluorescence to the 
mechanism of BHMT.46  Tryptophan is highly fluorescent, and its fluorescent properties are 
sensitive to changes in chemical environment.  Proteins that contain tryptophan will often 
undergo changes in fluorescence as they alter their conformational state.47  Site directed 
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mutagenesis can identify which tryptophan residues are responsible for the changes in 
fluorescence and, in turn, give information about the catalytic activity of the enzyme. 
 Castro et al identified a change in fluorescence intensity and emission wavelength (a 4 
nm shift) when methionine and homocysteine were incubated with recombinant human BHMT.  
No change was observed with BHMT in the presence of betaine or DMG.  When BHMT was 
incubated with homocysteine and betaine (or DMG) a second shift in emission wavelength (an 
8 nm shift) and intensity was seen.  An almost identical shift was seen with the incubation of 
BHMT with CBH. It was also revealed that betaine binding was only possible after 
homocysteine had bound.  Furthermore, fluorescence changes due to Trp 342 (part of the 
dimerisation arm) showed that betaine binding was assisted by the second monomer. 
 This experiment established that the mechanism for recombinant human BHMT was an 
ordered ‘bi-bi’ mechanism – homocysteine must bind before betaine can access its binding site 
and DMG must leave before methionine. 
 Systematic site directed mutagenesis of the seven tryptophan residues in BHMT 
identified Trp44 as being part of the active site, forming a hydrogen bond to the CBH 
carboxylate.  Due to changes in fluorescence emission wavelength for the mutated proteins, it 
is clear that tryptophans 169, 342, 352 and 373 undergo changes in environment during 
catalysis/substrate binding.  Tryptophans 331, 342 and 352 are all located on the dimerisation 
arm of the partner subunit – giving rise to interactions between subunits and catalytic activity. 
 The intrinsic fluorescence (IF) data also showed that BHMT has an ‘ordered bi-bi’ 
mechanism.  Enzyme mechanisms involving the binding of more than one substrate can be 
complicated.  In ordered bi-bi mechanisms each substrate binds in a defined order, the reaction 
occurs, and then the products leave the enzyme in a second, defined order [Figure 1.8].  Most 
often, the binding of one substrate creates the binding site for the second substrate.   
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Figure 1.8 Ordered bi-bi mechanism schematic.  Enzyme (E) initially binds substrate A, forming a 
complex (EA).  This then binds substrate B forming an EAB complex, which reacts to form the EPQ 
complex.  Product P leaves the enzymes, leaving complex EQ, followed by Q undocking from the 
enzyme, leaving free enzyme E. 
 
 The IF data presented by Castro et al showed that BHMT does not bind glycine betaine 
until after homocysteine has bound.  Furthermore, BHMT does not release methionine until 
after DMG has departed the binding site.  This also explains the strong inhibition by DMG, 
which would be expected to bind in the glycine betaine site, but would not react, giving an 
abortive complex.  Overall, the mechanism for BHMT activity is shown below in Figure 1.9. 
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Figure 1.9 BHMT mechanism as determined by IF spectroscopy.  BHMT binds homocysteine, and then 
glycine betaine (bet), forming a complex which reacts to give BHMT-Met/DMG complex.  DMG then 
leaves the complex giving BHMT-Met.  Methionine then leaves BHMT leaving the free enzyme. 
 
 
Observed complexes
Non-observed complexes
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1.3.3 BHMT Distribution 
 BHMT appears to be highly conserved in mammals, with the human BHMT gene 
sharing 88% identity to the porcine gene, and 94% amino acid identity.48  BHMT has been 
purified to homogeneity from horse and rat.38  These preparations lead to the conclusion that 
some 0.6-1.6% of all the soluble protein in the liver is BHMT.37  There have been claims that 
BHMT activity can be found in other taxa, including fungi (Aspergillus nidulans),49 and bacteria 
(Rhizobium meliloti and Pseudomonas denitrificans).49-51 
 BHMT has been located within the liver and kidneys of most mammals, but its 
distribution within other tissues seems to be species specific.51-53  In rats, there appear to be 
very low levels of activity in the kidney.51  BHMT has been found within the eye lens of rhesus 
monkey,54 in pancreas from sheep,55 and in brain tissue from human.56  No activity has been 
found in rhesus monkey or pig brain.  Sunden et al studied the mRNA for BHMT within 
different human tissues by northern analysis, and found that BHMT was expressed in the liver 
and kidney, but not the lung, heart, brain, skeletal muscle or pancreas.53  By western analysis, 
BHMT has been located in pig kidney cortex and liver, but again, not in the lung, heart, spleen 
or brain.53   
 The enzymes introduced earlier, involved in choline metabolism and oxidation 
(DMGDH and sarcosine dehydrogenase [Figure 1.4]) are also localised mainly in the liver and 
kidney.  Methionine synthase and CBS are all expressed ubiquitously; the only homocysteine 
methylation enzyme to show tissue specificity is BHMT. 
 Mammalian BHMT was shown to share similarities to N-terminal sequences of 
bacterial and eukaryotic methionine synthases, as well as having a common zinc binding 
motif.37  From this sequence, BHMT was allocated to the pfam 02574 family of thiol/selenol 
methyltransferases.  These proteins all facilitate the movement of a methyl group to or from a 
selenol or thiol group. 
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1.3.4 Methionine Synthase 
 Bacterial methionine synthase is an example of a one carbon transferase, which is used 
to convert homocysteine to methionine in E. coli.  It is also a member of the pfam 02574 family 
of S/Se-methyltransferases.  There are two enzymes which utilise this general reaction, 
however, the similarity is superficial, and only one of these belongs to the same pfam as 
BHMT.  One enzyme (cobalamin-dependent methionine synthase, metH) uses cobalamin as a 
cofactor to facilitate the reaction, while the other (cobalamin-independent methionine 
synthase, metE) functions without the assistance of cobalamin [Figure 1.10].  Both use N5-
methyl-tetrahydrofolate (Me-THF) as the methyl group donor, and produce methionine and 
tetrahydrofolate (THF) products.  The metH protein has homologues in animals (including 
mammals) and eubacteria, but not in plants or archaebacteria.  MetE has homologues in 
plants, archaebacteria, yeast, insects and eubacteria, but not in mammals.57 
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Figure 1.10 Methionine synthase reactions. A is the cobalamin dependent pathway, B is the 
cobalamin independent pathway. 
 
 In the metE pathway, homocysteine directly attacks the N5-methyl group; the metH 
enzymes involve the transfer of methyl groups to cobalamin, forming methyl-cobalamin.  These 
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are then used to methylate homocysteine, forming methionine and cob(I)alamin, followed by 
transfer of a methyl group from Me-THF to cob(I)alamin to regenerate the methyl-cobalamin 
and forming THF. 
 With regard to metE, tertiary amines are not good methyl-donors.  The pKa of the 
anionic THF leaving group is >30.  However, if protonation occurs before the methyl transfer, 
then the resulting secondary amine has a pKa of about 5.
58  Without the intervention of an 
enzyme, only one in every 100 molecules of Me-THF will be in a state ready for reaction.  What 
is more, the pKa of the thiol group on homocysteine is about 10 and is, therefore, not 
considered to be nucleophilic.59  Only about one in every 1000 molecules of homocysteine 
would be in a reactive thiolate form at pH~7. 
 In the event that a protonated Me-THF would react with a thiolate in an enzyme-free 
solution, proton transfer would be a more kinetically favourable process.  MetH avoids this 
problem by introducing a cobalamin intermediary to facilitate the methyl transfer.  However, in 
metE (and similarly in BHMT) there is no such intermediary, and thus the pKa of the Me-THF 
must be increased and the pKa of homocysteine must be lowered via some alternative 
mechanism. 
 MetH and metE both contain zinc, although the binding site varies between these two 
enzymes.  MetE uses a His-Zn-Cys with a second downstream Cys to hold zinc, while metH 
uses a Cys-Cys functionality with an upstream Cys, a similar motif to BHMT’s zinc binding site.  
Zinc plays an important role in all of these homocysteine remethylations, acting as a Lewis acid 
catalyst.  By binding to sulfur, zinc can decrease the pKa of homocysteine until the thiolate form 
predominates at neutral pH. 
 BHMT also contains the same binding motif, and binds homocysteine before any 
reaction takes place.44  It is not unreasonable to infer that similar mechanisms must be in play 
to allow the reaction between homocysteine and betaine.  Both THF and glycine betaine are 
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nitrogenous alkylating agents.  More importantly, there is evidence that in one eukaryote (the 
fungus Aspergillus nidulans) the same enzyme is responsible for both MS activity and BHMT 
activity.49  The BHMT activity in Aspergillus requires significant verification, as more recent 
research suggests that there may not be any activity at all.60 
 
1.3.5 BHMT Genetics 
 The gene coding for BHMT in humans, BHMT, was identified by Garrow and Park in 
1999.  It was found to contain 8 exons and 7 introns.61  The BHMT protein has been expressed 
and purified from cDNA in Escherichia coli (E. coli).37  It was found that there is a 
polymorphism, which appears to have no biological effect on BHMT biochemistry.62  There was 
an identifiable TATA protein binding site 25 base pairs 5’ to the transcriptional start site.  
Furthermore, there are 6 putative SP1 sites clustered about the TATA box, and further 5’ there 
are apparent HNF-1, HNF-3 and CAAT enhancer-binding protein sites.  These sites have all 
been identified as liver specific (or liver enriched) transcription factors.61 
 Interestingly, a BHMT-2 gene has been identified in mice and humans.63  mRNA 
corresponding to BHMT-2 has been located and identified in the liver and kidneys in humans, 
and is also found at reduced concentrations in the brain, heart, and skeletal muscle.  Mouse 
BHMT-2 cDNA is 79% identical to BHMT cDNA and the theoretical protein that it corresponds 
to (BHMT-2) is 69% identical (amino acid sequence) to the BHMT protein.63  The mouse BHMT-
2 cDNA is 87% identical to the human BHMT-2 cDNA and the amino acid sequences that they 
code for are 82% identical.63  Human BHMT-2 has a theoretical weight of 40.3 kDa, and 
shares 69% amino acid identity with human BHMT.63  
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1.3.6 BHMT Regulation 
 BHMT expression is highly regulated by hormones and also by feedback inhibition.  
BHMT is controlled via interactions with the BHMT protein, as well as by regulation of the 
expression of BHMT.  Early studies of BHMT showed that activity in rat liver was elevated after 
protein loading.64-66  Furthermore, methionine injections were able to stimulate increased 
activity of BHMT, while methionine synthase (MS) activities were suppressed, both by high 
protein intake and methionine injections.  Finkelstein et al concluded that MS was used to 
regulate methionine during periods of reduced dietary intake of methionine, while BHMT was 
used to reduce homocysteine concentrations and facilitate choline catabolism. 
 In 1982, Finkelstein et al undertook a study to further explore the effects of dietary 
stress on BHMT activity.67  By diminishing the intake of methionine, while also reducing choline 
concentrations, the group were hoping to observe steady activity in BHMT, and increased 
activity in MS.  It was discovered that, contrary to previous experience, BHMT activity was 
increased as well as MS.  Adding methionine to the diet suppresed the BHMT and MS levels to 
previous levels.  It was inferred from these results that BHMT was activated by increases in 
homocysteine levels, as well as betaine concentrations.  Thus, supplementing the diet with 
protein or methionine will produce higher homocysteine concentrations, and yield a greater 
activity of BHMT.  Reduction in methionine in the diet can produce a lowering in plasma 
homocysteine, creating a lowered BHMT activity. 
 Finkelstein et al observed the interactions between methyl-donor (betaine) and BHMT 
in the rat.68  It was found that betaine loading induced BHMT activity, implying that BHMT was 
regulated by tissue concentrations of glycine betaine.  Finkelstein et al hypothesised that BHMT 
was used to catabolise excess betaine. 
 Research on rats can be complicated by their coprophagic behaviour, and so work 
during the 90’s turned towards chickens.69  Chickens have a number of favourable aspects, 
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lending themselves to studies of one-carbon metabolism.  They utilise a BHMT enzyme in 
similar tissues to mammalian subjects at comprable concentrations with (what appears to 
have) similar enzymatic properties, do not practice coprophagy, and have diets which can be 
easily manipulated.  Emmert et al confirmed the increase in BHMT activity post methionine 
loading, but also showed that a deficiency of methionine elevated BHMT by 300-500%.  This 
could be enhanced by the addition of choline (a betaine precursor) into the diet. 
 It is clear that dietary betaine and methionine intake can influence BHMT expression; 
BHMT is also regulated by other factors, including developmental stage.  BHMT has been 
found in the lens of rhesus monkey eyes acting as a crystalin (while retaining catalytic 
activity).54  The inner nucleus of the eye contains cells which are preserved from embryonic 
tissue to adult, and have developmentally lost their nuclei; therefore no active production of 
protein can occur.  BHMT makes up ~10% of the total protein in the central regions of the 
monkey lens; five times the concentration reported for pig liver.37  BHMT must, therefore, be 
expressed during embryonic stages of development.  The lens cells produced later in life do not 
contain high BHMT activities; the protein must undergo developmental regulation. 
 The lens of monkey eye does not contain any significant level of betaine.  The lens is 
highly susceptible to osmotic stress, a contributing factor in some cataract development.  
Betaine is synthesised by the oxidation of choline in the mitochondrion, however, this organelle 
is lost in the cells of the inner lens.  No betaine production is possible, and so any betaine used 
by the BHMT present must have diffused from circulating levels (complicated by the lack of 
blood vessels in the lens).  In short, the presence of BHMT in the eye is unlikely to be due to 
catalytic requirements, unless high betaine is present during development. 
 In sheep, BHMT activities have been shown to vary with development, as do the 
activities of many other methyl transferases.  BHMT activity in the liver is at its highest 40 days 
after birth (~250 pmol/min/mg protein), after which the activities drop to around half those 
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levels (~125 pmol/min/mg protein).55  Strangely, sheep have high levels of BHMT activity in the 
pancreas, which also seems to undergo developmental changes, from relatively low activities 
during foetal stages (~100 pmol/min/mg protein) to levels 400% higher than the liver (~1000 
pmol/min/mg protein). 
 There is also considerable evidence that BHMT regulation occurs through hormonal 
control.  Finkelstein et al noted a change in hepatic BHMT activity in lab rats after treatment 
with various hormones.66  Hydrocortisone produced a 300% increase in activity, while thyroxine 
reduced activity to 35% of normal levels.  They also noted that activities were not affected by 
gender of the rat, implying that sex-hormones do not affect the BHMT enzyme.  Interestingly, 
stress has been observed to lower homocysteine in animals.70  It is tempting to draw a link 
between hydrocortisone and this stress response.  They conclude that there is an increased 
load on the cystathionine-β-synthase pathway – increasing the cysteine production to decrease 
the oxidative load which is experienced in acute stress. 
 Most recently interest has turned to BHMT playing a role in controlling osmotic stress 
within the kidney.  Betaine is an organic osmoprotectant, and is accumulated under 
hypertonicity in a number of different cells, particularly those of the kidney medulla.  As the 
medulla concentrates urine it undergoes extremes of osmotic pressures. 
 The medulla uses several mechanisms to accumulate and retain betaine, it can 
increase transport of betaine by increasing expression of a γ-aminobutyrate/betaine transporter 
(BGT1).71  The other major mechanism involves the oxidation of choline to betaine within 
medullary cells.  In the event of hypernatraemia, choline dehydrogenase activity increases in 
the kidney.72 
 Delagado-Reyes and Garrow showed that BHMT is also down-regulated during these 
hyperosmotic periods in the guinea-pig by feeding them on salted water.73  This treatment has 
two effects, increasing sodium concentration, and also dehydrating the animal (which responds 
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to the treatment by reducing its water consumption).  However, the effect was clear – protein 
concentration and BHMT activity dropped in the liver and the kidney.  The mechanism of this 
decrease was not investigated, and it may be due to decreased transcription or increased 
protein degradation. 
 The pioneering work of Finkelstein et al (1971) showed that the BHMT activity in rat 
liver is controlled by a number of hormones, with cortisol (increasing BHMT expression), 
thyroxine and insulin (both decreasing expression) being major candidates.66  Thyroxine control 
of mammalian BHMT expression had earlier been suggested,74 and has been subsequently 
demonstrated in chickens.75  Consensus binding sites for steroid hormone receptors are 
associated with the BHMT gene.61  Recently, the control of BHMT expression by insulin has 
been supported in rats,76,77 and the effect of corticosteroids confirmed.77 
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1.4 Assays for BHMT 
1.4.1 BHMT Assays 
 BHMT is an important enzyme, due to its potential links with heart disease.  Yet, 
despite its importance, relatively little attention has been drawn to it in the literature.  BHMT 
activity has been observed using three main methods, each of which has had advantages, and 
disadvantages. 
 
1.4.2  Radiochemical Assays 
 By providing BHMT with a source of radiolabelled glycine betaine and L-homocysteine, 
BHMT activity can be monitored by production of radiolabelled methionine after a known 
period.39,78,79  This method can be modified to give kinetic data, if the initial rate period is 
known, and the reaction can be terminated before the reaction reaches this point. 
 This technique suffers from one major problem.  The radiolabelled substrates can be 
difficult to synthesise in the laboratory if they are not commercially available.  In a study of 
substrate specificity and kinetics (on alternative substrates), the lack of radiolabelled substrates 
make this an unacceptable method to use.  Also, the inability to conveniently produce activity-
time graphs makes the determination of initial rate kinetics difficult. 
 
1.4.3 HPLC Methods 
 HPLC can also be used to analyse the metabolites from the BHMT reaction.  Betaines 
are colourless and have no useful UV absorption, however they can be conjugated with 
fluorescent molecules or ‘tags’.  The tagged betaines are relatively easy to separate on 
standard anion-exchange HPLC columns.35,80-82  Using similar conditions to those employed in 
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the radiolabelled methods for BHMT detection, the substrates can be incubated with the 
enzyme, and later analysed for methionine or betaine concentration. 
 This technique suffers from a similar problem to the radiolabelled assay.  The initial 
rate data can be difficult to determine without continuous data (also giving rise to high 
uncertainties).  There is also no guarantee that the fluorescent tags will work with all potential 
betaine analogues of interest, and these may need modification to enable quantification of 
analogues of glycine betaine.  For these reasons, this assay is unsuitable for the analysis of 
BHMT substrate specificity. 
 
1.4.4 In Vivo Bacterial Assay 
 In response to the need for a sensitive assay which could identify potential substrates 
for BHMT, Garrow et al developed an in vivo assay for BHMT, utilising bacterial growth in a 
minimal medium.  E. coli J5-3 is a methionine auxotroph; it cannot synthesise a supply of its 
own.  As a consequence, if J5-3 is provided with a plasmid encoding BHMT activity and a 
viable source of methyl donors, it will be capable of growth, and a measure of optical density 
will be a measure of the activity of the BHMT enzyme.83 
 One drawback to this assay is the dependency on bacteria: the betaine product of the 
BHMT reaction may have antibiotic properties – a property which some betaine analogues 
have, as noted by Chambers and Lever.84  However, Garrow et al used the assay to show that 
the thetins are substrates, and that proline betaine could also be a substrate. 
 The microbiological assay is also incapable of giving kinetic results, a frustrating 
setback if a potential substrate is found, and cannot be completely characterised.  Furthermore, 
it is likely that the sensitivity seen in this assay is a result of a non-linear response at low levels 
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of methionine production, making low levels of BHMT activity difficult to quantify.  This does, 
however, make the microbiological assay good for detecting trace levels of activity. 
1.4.5 Nuclear Magnetic Resonance (NMR) Assays 
 The naturally occurring betaines, broadly speaking, all contain methyl groups attached 
to a hetero-atom.  This is the functionality which gives rise to their cationic centre, and partially 
contributes to their zwitterionic and kosmotrophic properties. 
 As a direct consequence of this moiety, these methyl groups all appear as singlets in 
proton NMR spectra, often well separated from resonances arising from other functionalities.  
Glycine betaine methyl signals appear as a strong singlet at 3.22 ppm, and the BHMT products 
DMG and methionine methyl signals appear as singlets at 2.88 ppm and 2.10 ppm, 
respectively.  All three signals can be observed simultaneously so the progress of the BHMT 
reaction can be monitored by analysis of these three parameters (loss of betaine signal, and 
increase in DMG and methionine signals).  What is more, potential analogues for the BHMT 
reaction will also contain methyl groups, and are likely to generate signals in different regions 
of the NMR spectrum from glycine betaine, DMG and methionine. 
 NMR spectroscopy can be used to quantify chemicals in complex mixtures so magnetic 
resonance spectroscopy lends itself as an ideal technique for the analysis of BHMT activity.  It is 
capable of analysing multiple substrates and products, is rapid, non-destructive, can be 
automated, and it enables kinetic analysis of substrates and inhibitors. 
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1.5 Thesis Aims 
Most of the aims in this thesis involved the application of 1H-NMR spectroscopy to 
biological samples.  Specifically the aims were: 
1. To develop a reproducible method for the purification of BHMT from liver 
samples [Chapter 2]. 
2. To develop a 1H-NMR spectroscopic assay for BHMT for the purposes of 
detection of BHMT, and measurement of kinetic constants for BHMT [Chapters 
3 and 4]. 
3. To use 1H-NMR spectroscopy to investigate the substrate specificity of BHMT 
from rat liver [Chapter 5]. 
4. The observation of BHMT from alternative sources, including Agnathan liver 
samples, and to partially characterise the enzyme for comparison with rat BHMT 
[Chapter 6]. 
5. To use 1H-NMR spectroscopy to measure methylamines and related compounds 
in urine as an indirect method for the detection of BHMT activity in vivo 
[Chapter 7]. 
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It's so much easier to suggest solutions when you don't know too much about the problem. 
-     Malcolm Forbes 
An undefined problem has an infinite number of solutions. 
-     Robert A. Humphrey 
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CHAPTER 2: 
Protein Purification 
 
2.1 Introduction 
In order to study a protein properly, it is desirable to purify it first.  However, 
purification of a protein from tissue is often a laborious process, and is difficult to scale up.  If 
more protein is required, often there is a trade-off between purity and yield, a more pure 
protein often results in less activity through the denaturation of proteins from mechanical and 
chemical stresses that are involved in the purification steps. 
The type of study anticipated for the enzyme dictates the purity required.  If detection 
of activity is all that is required, then analysis of crude extracts may be sufficient to give useful 
information.  For structure-function studies, high degrees of purity may be needed to remove 
interference from other proteins.  Activity studies do not require high purity, however, all 
conflicting activities must be removed to ensure that the activity measured is the activity of 
interest.  Also, a rapid purification is desirable as prolonged purifications often yield relatively 
low activities as proteins denature. 
The amount of purified protein obtained will not only depend on the starting material, 
but also the efficiency of the purification steps.  Purification steps must be carefully selected to 
give the best yields, while providing significant enrichment and rapid throughput.  Where a 
choice exists, the starting material that will give the fewest contaminants, while allowing the 
easiest separation and greatest yields should be chosen. 
BHMT is not widely distributed in animals; it is found almost solely in the liver, which 
reduces the options for tissues to start purification.  Recombinant human and rat BHMT have 
been produced by Breska et al,1 and have proven to be useful in structure analysis (both 
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structures have been solved from X-ray crystal data),2,3 but may lack post-translational 
modifications found in the native mammalian liver enzyme. 
Specifically, for the studies described in this thesis, BHMT was purified from liver, using 
acetone precipitation, thermal stability, anionic exchange and molecular mass.  This chapter 
outlines, individually, the steps taken during each purification step, and then brings them 
together into a purification protocol [Section 2.6].  Finally, mass spectrometry and N-terminal 
sequencing of the BHMT subunit, conclusively showed the presence of BHMT in the solution. 
 
2.2 Sources of Protein 
BHMT was extracted primarily from rat and sheep liver.  These tissues were selected 
for several reasons.  Most mammals express BHMT in the liver and kidney, and BHMT makes 
up to 1.6% of total soluble liver protein.4  Rat and sheep liver is also relatively easy to obtain 
and can be easily homogenised. 
Initially rat livers were washed in 20 mM potassium phosphate buffer at pH 7.5.  This 
effectively removes much of the haemoglobin, which can complicate separation of BHMT.  The 
liver was then homogenised using a turret homogeniser (5000 rpm) at room temperature for 
20 s with two volumes of phosphate buffer.  The resulting suspension was centrifuged (10,000 
g) for 30 min at 4 ºC to remove the cellular debris.  The resulting supernatant contains BHMT 
activity, measured by adding 0.1 mL of crude homogenate with 0.1 mL of 10 mM glycine 
betaine, and 0.1 mL of 10 mM homocysteine (preparation described in Chapter 4) and 0.2 mL 
of 20 mM potassium phosphate buffer at pH 7.5.  The sample was then assayed using the 
NMR assay in Chapter 4, and activity identified by the production of methionine. 
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2.3 Heat Denaturation 
2.3.1 Introduction 
BHMT is a thermostable protein, capable of withstanding high temperatures (70 ºC) as 
initially described by Durell in 1957, when working on “thetin homocysteine methylpherase”.5  
Heat denaturation, therefore, is an effective purification step as most other proteins are 
denatured at temperatures above 50 °C for very short times.  Durell heated liver homogenate 
to 70 ºC for 5 min, BHMT is stable for up to 10 min at these temperatures without 
denaturing.5-9  Eppendorf tubes with a 1 cm bore were used to ensure rapid heating once 
plunged into a hot water bath and rapid cooling of the resulting protein solution. 
It should be noted that this procedure is favoured in the literature.5-9  Almost all BHMT 
purifications begin with this heat denaturation step, although there are no data on 
optimisation of this purification step.  
2.3.2 Method and Results 
Rat liver homogenate (1 mL) was incubated in a pre-heated water bath at 60, 70, 80 
and 90 ºC, for 2, 5, 10 and 20 min.  The homogenate was then plunged onto an ice/water 
slurry after the specified time.  To ensure that the sample is heated in an approximately 
uniform manner, the heat shock was done in 1.5 mL Eppendorf tubes.  The samples were then 
centrifuged (10 min, 4 ºC at 10,000 g) and the soluble protein was analysed for BHMT activity 
at saturating concentrations of betaine and homocysteine (5 mM) using the NMR spectroscopic 
assay described in Chapter 4.  The results are summarised in Figure 2.1 below.  Protein 
concentration was determined using an automated Bradford assay standardised against bovine 
serum albumin (BSA). 
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This experiment showed clearly that the literature preparation consisting of a 70 ºC/10 
min heat denaturation, was effective, but not optimal: heating at 90 ºC for 2 min was over five 
times as efficient as a purification step, compared with the procedures of Durell.5   
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Figure 2.1 Temperature dependence and time course of the heat denaturation step during BHMT 
purification.  Purification is expressed as specific activity versus crude homogenate. 
 
 
2.4 Anion-Exchange Chromatography 
2.4.1 Introduction 
Following heat denaturation, a range of chromatographic techniques were found to be 
available to further purify the protein mixture to homogeneity.  Anion-exchange 
chromatography is a commonly used technique, based on the competitive binding of negatively 
charged species to a cationic resin.  The resin was prepared and equilibrated with a buffer 
containing an anion, which was bound to the resin.  Upon loading the heat denatured liver 
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extract, the most highly anionic species will competitively bind to the resin, displacing the 
buffer anion, and becoming immobile.  After eluting the non-binding species from the column, 
a salt gradient (normally sodium chloride) was applied, competing with the anionic protein for 
the cationic centres on the resin and resulting in the elution of the anionic protein into the 
buffer. 
Once removed from the column, the protein solution was desalted by dialysis or 
selective filtration (gel filtration or ultra filtration were used to de-salt the mixture).  With 
respect to BHMT purification, the heat-denatured protein mixture produced was applied to the 
anion-exchange columns after adjusting the pH of the buffer towards a more basic solution 
(pH ~ 8.5-9). 
2.4.2 Method 
DEAE anion exchange resin (Pharmacea Biotech, A-50, 15 mL) was prepared by 
equilibration with TRIS buffer (50 mM, pH 9) and was loaded into a short column (30 cm x 1.7 
cm diameter).  The heat-treated liver extract (pH 9, 15 mL) was loaded onto the resin.  The 
column was eluted with a linear sodium chloride gradient in TRIS buffer to 1 M NaCl (1 
mL/min), with fractions being collected automatically every 10 mL and the UV280 absorbance 
being used as an indication of protein concentration.  BHMT activity was detected by spiking 
the fractions to 5 mM glycine betaine and homocysteine, and NMR spectroscopy was used to 
detect the production of methionine [Chapter 4]. 
2.4.3 Results 
The BHMT activity eluted as one peak, over the entire gradient as applied.  
Furthermore, the yield of BHMT was unclear, as the resulting BHMT activity appeared to be 
unstable.  The activity of fractions deteriorated and after 48 h the activity had diminished to 
undetectable levels.  There were a number of proteins that remained on the column, 
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observable from the strong discoloration of the column which remained after the salt gradient 
had been applied.  The remaining protein could be removed using 2 M NaCl, giving a brown 
solution that contained no BHMT activity.   
 
2.5 Size Exclusion Chromatography 
2.5.1 Introduction 
Size exclusion chromatography (gel filtration) is a commonly employed technique 
which separates biological molecules on the basis of size.  It is useful for de-salting protein 
mixtures and for the crude separation of proteins with disparate molecular weights. The resins 
used for gel filtration are based on sugar (cellulose) backbones (Sepharose) or synthetic 
equivalents (Sephadex, Superdex) and there are a variety of fractionation ranges available. 
Like all forms of column chromatography the basis of separation is a difference 
between the target protein and the mobile/stationary phases.  In gel filtration, the resin beads 
have well defined pores, which increase the volume of the mobile phase which is accessible to 
the proteins which are able to fit within the pores.  Effectively, this means that proteins which 
are too large to be included within the resin pass through a relatively small elution volume (Ve), 
whereas small proteins are eluted in a much larger volume by virtue of the extra eluant 
required to flush out the pores in the resin. 
The pores in the resin fall within a range of sizes, enabling fractionation of mixtures of 
proteins of varying sizes.  This also offers a technique for experimentally determining the 
molecular weight of the protein in question.  By measuring the volume of buffer required to 
elute the unknown protein and comparing this to appropriate standards, a measure of the 
approximate size of the unknown can be obtained.  This requires calibration of the column 
including a measure of V0, the void volume, the smallest possible elution volume from the 
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column.  V0 can be determined by applying a solution of blue dextran (MR ~ 2000 kDa), a dyed 
polysaccharide which gives an obvious chromatographic signal when it emerges from the 
column. 
The elution volume can also be affected by other physical properties, such as protein 
shape.  In general, long thin proteins will elute faster (in smaller volumes) than globular 
proteins.  Gel filtration media have a varying fractionation range, and for the purposes of 
separating BHMT from other proteins and macromolecules in the heat denatured liver 
homogenates, G-200 was found to be most suitable (fractionation range of 10 kDa to 800 kDa 
for globular proteins).   
2.5.2 Method 
600 mL of Sepharose CL-6B size exclusion resin (Sigma, CL-6B-200) was rinsed four 
times with 20 mM sodium phosphate buffer (800 mL at pH 7.5) and packed into a 2 m column 
under slight positive pressure using a peristaltic pump (1 mL/min).  Once packed, the resin was 
flushed with 1 L of phosphate buffer and 2 mL of 1 mg/mL blue dextran was applied to the 
column.  Phosphate buffer was applied using a peristaltic pump (flow rate 2 mL/min), and the 
eluant volume recorded until the blue dextran fraction was at its maximum concentration, as 
determined by UV absorbance (280 nm).   
Protein standards (Sigma, MW-GF-1000) were applied following the manufacturer’s 
instructions and their elution volumes recorded using UV absorbance (280 nm) under identical 
conditions to the blue dextran.  The elution volume was expressed as a fraction of the void 
volume, and found to vary linearly with log10 (protein size) [Figure 2.2]. 
To purify and estimate the molecular size of BHMT from liver, the heat denatured 
homogenate (15 mL) was applied gently to the column under gravity and then eluted with 
phosphate buffer under the same conditions as the dextran and standards.  Fractions were 
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collected every 10 mL, and 2 mM glycine betaine and homocysteine were spiked into the 
fractions before NMR spectroscopy was used to assay for methionine production [Chapter 4].  
Tubes with BHMT activity were pooled and concentrated using stirred concentration cells 
(Amersham Biosciences), and Bradford assays were used to determine the protein 
concentration of the pooled fractions. 
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Figure 2.2 Calibration of G-200 column with standard molecular weight proteins. 
 
2.5.3 Results 
The calibration line for the Sepharose column is shown in Figure 2.2.  The elution 
volume for the BHMT solutions, was 315.5 mL (Ve/Vo = 1.79) of buffer, that yielded a 
calculated size of 241.3 ± 4.8 kDa (incorporating a 2% error in measurements estimated from 
uncertainties on measurements).  There was also a notable peak of aggregated protein eluted 
at the void volume. 
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Figure 2.3 Absorbance at 280 nm indicating protein elution from a G-200 column (flow rate, 1.1 
mL/min, chart speed 0.2 mm/min).  The activity of BHMT (inset), determined by 1H-NMR spectroscopy, 
was determined indicating the presence of BHMT (two bold squares indicate 10 ‘units’ of BHMT activity 
or a DMG integral of 10 against 5 mM tBuOH by NMR spectroscopy) in the three active fractions. 
 
2.6 Combined strategy 
2.6.1 Introduction 
After studying several steps as described in the sections above, a purification strategy 
was formulated including homogenisation, heat denaturation and size exclusion 
chromatography.  Anion exchange chromatography was deliberately avoided, because the 
resulting fraction appeared to denature or lose activity slowly over a period of 48 h.  Similarly, 
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TRIS buffer was avoided, because experience from anion exchange indicated that it appeared 
to reduce the activity of the enzyme. 
2.6.2 Final Method 
2.6.2.1 Crude Homogenate 
Rat liver (24.3 g) was homogenised in 50 mL of potassium phosphate buffer (20 mM, 
pH~7.5).  The resulting suspension was centrifuged at 10000 g and 4 °C for 30 min, as 
described above (Section 2.2).  The resultant solution was assayed for protein concentration 
using the techniques described above, and a 100 μL aliquot was incubated for 24 h with 2 
mM homocysteine and 2 mM glycine betaine, in the presence of a 5 mM tert-Butanol internal 
standard, as described in Section 4.3.  The integral of methionine production (compared to the 
tert-Butanol integral) was used as an index of BHMT activity (an integral of 1 equating to one 
unit of activity).  This measurement of activity was then divided by the total protein 
concentration to give the specific activity measurement. 
 
2.6.2.2 Heat Denaturation 
The homogenate from Section 2.6.2.1 above (55 mL) was then divided into 1 mL 
Eppendorf tubes and plunged into a 90 °C water bath for 2 min.  The tubes were placed 
immediately on ice for 5 min to reduce the temperature of the solution, then centrifuged at 4 
°C for 10 min.  The resultant solution was assayed for protein concentration using the 
techniques described above, and a 100 μL aliquot was incubated for 24 h with 2 mM 
homocysteine and 2 mM glycine betaine, in the presence of a 5 mM tert-butanol internal 
standard, as described in Section 4.3.  The integral of methionine production (compared to the 
tert-Butanol integral) was used as an index of BHMT activity (an integral of 1 equating to one 
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unit of activity).  This measurement of activity was then divided by the total protein 
concentration to give the specific activity measurement. 
 
2.6.2.3 Size Exclusion Chromatography 
 The clear homogenate obtained from Section 2.6.2.2 above (31 mL) was then applied 
to a column, packed with SuperDex G200 (Sigma; ~450 mL resin, 2.6 cm x 83 cm) which had 
been washed with 1.5 L of potassium phosphate buffer (20 mM, pH~7.5).  The column was 
eluted at 1.1 mL/min, with tube changes every 12 min.  Protein concentration was monitored 
using absorbance at 280 nm.  Fractions were spiked with 2 mM glycine betaine and 
homocysteine and incubated for 24 h.  The fractions were then analysed using NMR 
spectroscopy.  Those tubes in which DMG had been produced, and which indicated a dominant 
45 kDa band by SDS-PAGE analysis were pooled and concentrated using a stirred 
concentration cell (Amersham Biosciences, 100 mL), washed through the concentration cell 
with potassium phosphate buffer (20 mM, pH~7.5) until no trace of methionine, glycine 
betaine, or DMG could be observed using NMR spectroscopy.  The sample volume was reduced 
in the concentration cell under 40 psi to 10 mL.  The resultant solution was assayed for protein 
concentration using the techniques described above [Section 2.5.2], and a 100 μL aliquot was 
incubated for 24 h with 2 mM homocysteine and 2 mM glycine betaine, in the presence of a 5 
mM tert-Butanol internal standard, as described in Section 4.3.  The integral of methionine 
production (compared to the tert-butanol integral) was used as an index of BHMT activity (an 
integral of 1 equating to one unit of activity).  This measurement of activity was then divided 
by the total protein concentration to give the specific activity measurement. 
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2.6.2.4 SDS-PAGE Analysis 
All SDS-PAGE analysis was conducted using Life Therapeutics ‘Lifegels’ (4-20% 
gradient) in Tris-HEPES-SDS buffer following the instructions provided in the kitset.  Gels were 
refrigerated at 4 °C and 150 V was applied along the gel.  Staining with Coomasie Blue and 
destaining were also performed using the instructions provided. 
 
2.6.3 Results 
Table 2.1 Purification Table: 
Purification step Protein 
Concentration 
(mg/mL) 
Volume 
obtained 
(mL) 
Activity 
(Units/ 
mL) 
 
Specific 
Activity 
(Units/mg) 
 
Percent 
Yield 
(%) 
 
Purification 
Tissue 
Homogenate 22.82 55 75.1 3.3 100 1 
Heat 
Denaturation 
1.99 31 47 23.6 62.6 7.2 
Size Exclusion 
Chromatography 0.19 35.5 20.7 108.9 27.6 33.1 
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Figure 2.4 SDS-PAGE analysis of rat liver subjected to the purification procedures described in Section 
2.6, and stained with Coomassie Brilliant Blue.  Lane 1: Crude extract, Lane 2: 90 °C heat treatment, 
Lanes 3, 4 and 5: Size Exclusion Chromatography following the three active fractions [Figure 2.3] as 
they were eluted from the column, and Lane 6: Sigma Wide SDS-PAGE markers.  The ~45 kDa subunit 
of BHMT is clearly visible after size exclusion chromatography, and the relative activity of these three 
fractions approximates the intensity of the 45 kDa band. 
 
 
 
 
2.7 Mass Spectrometry Analysis 
2.7.1 Introduction 
To verify the presence of BHMT and to confirm that the observed activity was a due to 
BHMT protein, a mass spectrum of the final purified BHMT solution was obtained.  Mass 
spectrometry gives a total mass of the subunits present in the reaction mixture, and would also 
identify if there were any post-translational modifications of BHMT, including glycosylation 
(which would increase the mass of the BHMT subunit) and cleavage of the protein (which 
would give a decreased mass). 
Chapter 2 – Protein Purification    
 
50 
 
2.7.2 Method 
A sample of the BHMT (0.8 mg/mL, 2 mL), purified as described in Section 2.6 was 
de-salted against distilled water (3 x 500 mL) using dialysis at 4 °C for 8 h each exchange.  
The resultant solution was submitted for electrospray mass spectral analysis with Professor 
Stephen Brennan in the Christchurch School of Medicine. 
Urea was added to the sample to 8 M and the sample was heated to 90 °C for 30 min 
to denature the protein.  Iodoacetamide (150 μL, 55 mM) was added to block the cysteine 
residues. 
The sample was then analysed directly by electrospray ionisation (ESI) mass 
spectrometry (MS) on a Platform II quadrupole analyser (Micromass).  Injections of 10-20 μl 
were introduced to the ion source at 5 μl/min.  The probe was charged at +3500 volts and the 
source maintained at 60 °C.  The mass range 400–1200 m/z was scanned every 3 s with a 
cone voltage ramp of 30–60 volts and up to 80 scans were averaged in acquiring the raw 
data. Calibration was made over this same m/z range using the charge series generated by 
human α globin and data was acquired and processed using MassLynx software and 
transformed onto a true molecular mass scale using maximum entropy (MaxEnt) software 
supplied with the instrument. 
 
2.7.2.1 Tryptic Digest of BHMT Subunit 
Tryptic digests were prepared from approximately 0.25 mg of the white precipitate 
BHMT as described in the mass spectral work above. The individual chains were dried under N2 
and redissolved in 50 μl of 50 mM NH4HCO3. Trypsin (1.5 μg) was added and the reaction 
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incubated for 16 h at 37 °C. After drying under vacuum with P4O10, digests were redissolved in 
100 μl of 0.1% HCOOH, 50% acetonitrile and 10 μl was analyzed by ESI MS as above. The 
m/z range 300–1900 was scanned every 4 s. 
2.7.3 Results 
Initial attempts to obtain a mass of the entire BHMT subunit were unsuccessful.  Trace 
amounts of albumin were identified in the mass spectra, but the expected BHMT subunit mass 
was not identified.  It was noted, however, that small amounts of precipitate were forming at 
the bottom of the Eppendorf tubes following dialysis.  Tryptic digest of the solution and these 
precipitates gave sufficient fragments to map 75% of the BHMT subunit, including two pairs of 
fragments which were also identified as conjoint sequences [Figure 2.4]. 
 
Figure 2.5 Predicted rat BHMT amino acid sequence showing (marked) the observed tryptic fragments 
of BHMT, as identified by electrospray mass spectrometry.  Cyan indicates the possible N-linked 
glycosylation site.  These fragments are summarised in Table 2.2 below. 
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Table 2.2 Observed fragments from tryptic digest of BHMT subunit (complete listing of tryptic 
fragments is in Appendix 1. 
 
Fragment Fragment Sequence Mass (Daltons) Observed M/Z (3 s/f) 
T5 GILER 586.34 587
T6 LNAGEVVIGDGGFVFALEK 1934.01 968
T9 AGPWTPEAAVEHPEAVR 1815.89 606, 909
T10/11 QLHREFLR 1115.62 530
T11 EFLR 563.31 564
T12/13 AGSNVMQTFTFYASEDKLENR 2425.12 803
T16 VNEAAJDIAR 1117.52 560, 1117
T16/17 
VNEAAJDIARQVADEGDALVAGGVSQTPS
YLSJK 3568.68
593
T17/18 QVADEGDALVAGGVSQTPSYLSJKSETEVK 3412.47 625, 782, 1042
T20 IFHQQLEVFMK 1418.74 710
T22 NVDFLIAEYFEHVEEAVWAVEALK 2820.4 941
T23 TSGKPIAATMJIGPEGDLHGVSPGEJAVR 2966.4 476
T25 AGAAIVGVNJHFDPSTSLQTIK 2285.15 446, 558, 743
T27 EGLEAAR 744.38 745
T29/30 
AYLMSHALAYHTPDJGKQGFIDLPEFPFGLE
PR 3794.82
756, 945
T34/35 EAYNLGVR YIGGJJGFEPYHIR 2648.04 658, 877
T35 YIGGJJGFEPYHIR 1727.75 577, 864
T36 AIAEELAPER 1097.57 550, 1098
T36/37 AIAEELAPERGFLPPASEK 2042.07 676
T41/42 KEYWQNLR 1153.59 569, 1140
T43 IASGRRPYNPSMSKPDAWGVTK 2261.13 607
T45 EATTEQQLR 1074.53 538
T48/49 FKSAQ 597.31 580
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Figure 2.6 Mass spectrum of rat BHMT after tryptic digestion.  Peaks are identified in Table 2.2 above. 
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2.8 N-terminal Sequencing 
2.8.1 Introduction 
To confirm that the detected BHMT activity was due to the rat BHMT protein, N-
terminal sequencing was conducted on the 45 kDa band seen in the SDS-PAGE gel, suspected 
to be the BHMT subunit, comparing it to the rat cDNA data available.  
2.8.2 Method 
Rat BHMT extract, obtained after size exclusion chromatography and concentrated to 
1 mg/mL was analysed using gradient SDS-PAGE electrophoresis (5-20%, Sigma) and stained 
for 1 h with Coomassie Blue stain. The stain was removed using 10% acetic acid in methanol, 
washed twice for 2 h each time.  A second SDS-PAGE was conducted using the same extract 
and markers, but was not stained. The second gel was electro-blotted at 100 mA constant 
current (voltage ~45 V) for 15 h to PVDF membrane and stained for 1 min with amido black 
stain, followed by washing twice with 10% acetic acid in water. 
The 45 kDa band was identified on the PVDF membrane and excised. The sample was 
submitted to the Protein Microchemistry Facility in the Department of Biochemistry at the 
University of Otago, Dunedin, New Zealand.  For the rat sequence only 10 amino acids were 
sequenced to identify BHMT.  The same procedures were then performed on the hagfish liver 
extract, post size-exclusion chromatography, and concentration to 1 mg/mL. Sigma wide-range 
markers (M 4038, Sigma) were used to confirm and identify the ~45 kDa band in the SDS-
PAGE and PVDF blot [Chapter 6]. 
2.8.3 Results 
The Protein Microchemistry facility obtained the predicted Rat cDNA sequence of ‘‘A P I 
A G K K A K R G I L E R’’ [Figure 2.4] together with low yields of sequences with staggered 
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starting N-termini into the chain.  Despite a clear dark 45 kDa band being excised in rat BHMT 
it gave lower yields than expected, approximately 30 pmol.  There was evidence of amino 
peptidase activity cleaving N-terminal amino acids, giving a staggered starting point and 
making interpretation of the sequence data difficult. 
 
 
2.9 Genomic Sequencing of Rat BHMT 
2.9.1 Introduction 
 As the intial N-terminal protein sequence of rat BHMT was ambiguous, genomic DNA 
was extracted from two of the Sprague-Dawley rats and the DNA sequence that encodes this 
region [Figure 2.5] was determined. 
 
2.9.2 Method 
6.5.2.1 Genomic DNA extraction 
Tissue (0.5 g) was excised from the liver of two Sprague-Dawley rat livers which had 
been stored at -80 °C.  Genomic DNA was purified using the reagents and procedures in the 
‘QIAamp DNA Mini Kit’ (Qiagen, Valencia, CA 91355).  The samples were suspended in 180 
μL of ‘ATL’ buffer with 20 μL of ‘protease K’, mixed and incubated at 56 °C for 2.5 h with 
vortex stirring every 20 min.  The sample was centrifuged briefly, then a further 200 μL ‘ATL 
buffer’ was added, the sample was mixed thoroughly and incubated for 10 min at 70 °C.  The 
sample was then briefly centrifuged, and 200 μL of 100% ethanol was added, mixed and the 
sample was loaded onto a ‘QIAamp Spin Column’ and centrifuged at 6000 g for 1 min.  The 
filtrate was discarded, and 500 μL of ‘AW1 buffer’ was applied to the column, followed by 
centrifugation at 6000 g for 1 min.  The filtrate was discarded and 500 μL of ‘AW2 buffer’ 
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applied and centrifuged at 20000 g for 1 min.  The filtrate was discarded and 200 μL of TE 
buffer was applied, left to sit for 5 min, then centrifuged through the column at 6000 g for 1 
min.  DNA concentration was determined by absorbance at 280 nm and purity determined by 
the ratio of A260/A280. 
 
6.5.2.2 PCR Amplification of Exon-1/Intron-1 Boundary 
 PCR primers were designed and ordered through Invitrogen (Auckland, New Zealand) 
to correspond to the 5’ region 40 bp upstream of Exon-1 and 120 bp downstream of the 
Exon-1/Intron-1 boundry [Figure 2.5].  The sequences selected were (forward) 
5’-GGATCGACGACATATATTT-3’ and (reverse) 5’-AGAGGATACTGAGCCACAA-3’. 
 The primers were diluted to 50 ng/mL upon arrival and used at this concentration in all 
PCR procedures.  PCR was conducted to amplify Exon-1 and the flanking region, using a 94 °C 
denaturation, followed by a 54-60 °C temperature gradient annealing and 72 °C 
polymerisation method, repeated for 32 cycles. 
 
Figure 2.7 Wistar rat BHMT genomic DNA sequence, showing the primer sequences ordered, and the 
Promotor, Exon1 and Intron1 region sequenced from the Sprague-Dawley rats. 
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2.9.2.3 Genomic Sequencing 
 Sequencing was performed using an Applied Biosystems ‘3130 XL’ automatic 
sequencer using the Applied Biosystems ‘BigDye’ v3.1 Cycle Sequencing Kit. 
2.9.3 Results 
2.9.3.1 DNA Extraction 
 DNA was obtained from both rats investigated and was of acceptable purity as 
determined by the A260/A280 ratio (379 ng/μL for rat-1 and 640 ng/μL for rat-2, A260/A280 1.93 
and 1.95, respectively).   
 
2.9.3.2 PCR Amplification 
The product of PCR amplification of the rat genomic DNA was visualised using 2% 
agarose electrophoresis.  PCR product was obtained in the PCR reactions which had been 
amplified at 54-58 °C.  Electrophoresis analysis in 2% agarose at 100 V revealed the presence 
of the expected ~260 bp DNA fragment in both rat-1 and rat-2 [Figure 2.6]. 
 
Figure 2.8 2% agarose analysis of the PCR products. Lane 3 (bottom) contains Invitrogen ‘PhiX 174 
RF DNA/HaeIII’ markers, lane 2 (middle) contains 5 μL rat-1 DNA post PCR amplification and lane 1 
(top) contains 5 μL rat-2 DNA post PCR amplification.  Each PCR product is 260 bp in size. 
 
 
2.9.3.3 Sequence obtained 
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 The sequence obtained is recorded in Figure 2.7 and aligned with the genomic 
sequence obtained from the NCBI database of Wistar Rat DNA.  There are two point mutations 
(or strain differences) in the Sprague-Dawley rat sequence at position 72 and 78, both of 
which are in the promoter sequence, not coding for any amino acids in BHMT.  Intron 1 begins 
at position 143 (‘GTGATG…’).  
 
Figure 2.9 Alignment of experimentally determined Sprague-Dawley BHMT sequences and published 
Wistar rat genomic sequence.  The experimentally determined sequences have three point mutations, or 
strain differences with the genomic Wistar rat sequence, at position 46, 72 and 78 above, but neither is 
in Exon1. 
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2.10 Discussion 
The heat denaturation step was found to be simple and efficient, and provided a 5 fold 
purification in a single step, particularly when used as the initial step of BHMT purification.  It 
was clear that prolonged exposure to high temperatures was efficient at denaturing the 
proteins in the crude liver homogenate, and that this denaturation occurs faster at higher 
temperatures.  What was unique is the durability of BHMT to temperatures as high as 90 °C 
for as long as 20 min.  Heat denatured protein was also easily separated from the active 
soluble BHMT. 
It is unclear why BHMT that was eluted from the DEAE ion-exchange was unstable.  
One explanation is that there was an essential anionic cofactor or coenzyme which is removed 
under these conditions, although there are no known cofactors (other than zinc, which is 
cationic) for BHMT activity.  The DEAE may contain some impurity which is inhibitory to BHMT 
activity, although the same loss of BHMT activity was observed after several washes of the 
column.  This loss of activity was similar to the observations of Lee et al, who noticed their 
BHMT fractions were unstable unless stored with homocysteine and DMG.7  It maybe that there 
is an inhibitor leaching from the DEAE gel, slowly affecting the stability of BHMT activity, or 
that there is an unidentified co-factor required for the stabilisation of mammalian liver BHMT. 
The instability may also reflect the change to TRIS buffer, which is known to inhibit 
some enzymes.10-12  TRIS (tris-(hydroxymethyl)aminomethane) contains a chemically active 
primary amine moiety, which is known to react in aqueous environments with common 
biological molecules.13  It is possible that mammalian BHMT is similarly inhibited by TRIS buffer, 
although Garrow et al employ TRIS buffer in their preparations without similar problems in 
their recombinant BHMT solutions.14 
Anion exchange chromatography was not used in the purification protocol for BHMT 
from liver tissue. 
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There has been controversy regarding the oligomeric state of BHMT.  Some groups 
have reported that it is a hexameric protein, 7,15 others (particularly those relying on the crystal 
structures that have been obtained from recombinant BHMT) suggest a tetrameric protein.2,3  
The work of Waditee and Incharoensakdi on BHMT from Aphanothece halophytica, showed 
evidence that, at least in this species, (not mammalian) an octomeric protein was the active 
oligomeric state.16   
The results obtained here suggest that the hexameric state is much more likely for 
purified rat liver BHMT.  However, the measurement obtained is smaller than the expected 
mass for a hexamer by 29 kDa.  There are at least two potential explanations for this result.  
First, while mass is the major factor in determining the elution volume of a protein, undergoing 
size exclusion chromatography, the protein shape also influences the result.  Second, it has 
been hypothesised that BHMT-2 could form a heterodimer with BHMT.14  If this was the case, 
then the resulting heterotetramer protein would have a lower mass (BHMT-2 subunits are 
predicted to have a lower mass than BHMT – 40.4 kDa vs 45.0 kDa, respectively, for human 
proteins).  If this was occurring, say in a 4 x BHMT- 2 x BHMT2 configuration, then the 
predicted mass of the resulting hexamer would be 260.6 kDa (based on human proteins; the 
sequence for rat BHMT-2 is unavailable).  This result is similar to the results obtained in the 
experiment, that would support this hypothesis, although no 40 kDa band was observed under 
SDS-PAGE analysis [Section 2.6]. 
 The combination of heat denaturation and size exclusion chromatography, a similar 
purification to the procedures used by Garrow in 1996.6  Garrow reports a final purification of 
47 fold over the crude homogenate obtained from porcine liver.6  The purification observed 
here was 33.1 fold.  SDS-PAGE analysis [Figure 2.3] revealed a single dominant band at ~45 
kDa size, which corresponded to the expected size of the BHMT subunit (44,970 Da).  The 
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resulting protein was of an adequate homogeneity to proceed to kinetic characterisation, as 
established by SDS-PAGE analysis. 
Approximately 75% of the BHMT subunit was mapped using the tryptic digest 
procedure.  This information, and with the ~45 kDa protein band observed in SDS-PAGE 
analysis of the BHMT active fractions and the N-terminal analysis seen in Section 6.4, allow 
the positive identification of BHMT in the rat liver extract. 
There was one possible N-linked glycosylation site, however the tryptic peptide 
containing this site was clearly identified in the mass spectrum, indicating that there was no 
glycosylation at this site. 
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2.11 Conclusion 
The purification of BHMT from rat liver was effected simply using procedures which are 
commonly employed in protein purification.  Heat denaturation was employed as an initial 
purification step, providing 7-fold purification over the crude homogenate.  Size exclusion 
chromatography of the supernatant after heat shock gave a 33-fold purification over the crude 
extract, which is comparable to the purification factors quoted by other groups.6,7 
The mass spectral data obtained also indicated the presence of BHMT subunits in the 
solution, although no data could be obtained on the BHMT unit as a whole.  The possibility 
exists that there was post-translational modification of the BHMT subunit, but the data 
obtained were unable to identify any.  However, the work done with the tryptic digest does 
suggest several locations where those modifications are unlikely. The fact that those fragments 
were observed, with the predicted mass, indicates that it is not likely that there is modification 
there.
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NMR Spectroscopic Assays 
 
 
 
Technology is dominated by two types of people: those who understand what they do not manage, and 
those who manage what they do not understand. 
- Putt’s Law 
 
Even he, to whom most things that most people would think were pretty smart were pretty dumb, 
thought it was pretty smart. 
-     Douglas Adams, ‘The Salmon of Doubt’ 
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CHAPTER 3: 
NMR Spectroscopic Assays 
 
3.1 NMR Concepts 
3.1.1 Introduction 
Current assay techniques for BHMT activity are all unsuitable for high throughput 
analysis of multiple substrates or for rapid assessment of kinetic results.  Glycine betaine does 
not contain a chromophore, and is not fluorescent.  What is more, DMG and methionine are 
also limited as indices of BHMT activity, since both compounds are also difficult to quantify. 
There is interest in the effects of betaines on BHMT activity, because these may be 
used as methyl group donors to lower homocysteine in people with heart or kidney disease.  
This has been recently called into question, following the reports on the NORVIT (Norwegian 
Vitamin) study,1 and the HOPE (Heart Outcomes Prevention Evaluation) study,2 both of which 
found that folate and vitamins B6 and B12 supplementation in CVD patients lowered plasma 
homocysteine, but was not associated with a lower risk of further cardiovascular events.  These 
studies have been used to claim that the ‘Homocysteine Hypothesis is dead’, that is that there 
is no causal link between homocysteine and CVD.3  Neither study included betaine 
supplementation in their regimes, which have been shown to be effective in lowering 
homocysteine.4-9  Despite some interpretations of the NORVIT and HOPE studies, the 
homocysteine hypothesis has not been disproved by their research.3  These two studies do not 
remove the overwhelming evidence that homocysteine is an atherogenic determinant.10  The 
possibility that excessive folate and vitamin B12 supplementation may increase the risk of CVD 
through hypermethylation has not been discussed or eliminated.11,12  The possibility remains 
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that BHMT, using glycine betaine as a methyl donor, is a much more important regulator of 
plasma homocysteine.  For this reason, research into BHMT metabolism and regulation should 
be pursued, and analogues of glycine betaine which may assist in lowering homocysteine 
through BHMT should be sought. 
 
3.1.2 Nuclear Magnetic Resonance 
Nuclear magnetic resonance (NMR) has rapidly become one of the most powerful 
techniques in chemical analysis since its inception in 1945.13  It has become such a powerful 
technique, that multiple Nobel prizes have been awarded to people in the field of NMR, 
including F. Bloch and E.M. Purcell, who won the Nobel Prize in Physics in 1954 for their work 
on NMR, and for the first experimental evidence of the NMR effect.  R.R. Ernst earned the 
Nobel Prize in Chemistry in 1991 for developing the 2-dimensional technique.14   
It is one of the few truly non-destructive analytical techniques that exists in chemistry, 
and has found wide application in fields as diverse as solid-state engineering, surface 
chemistry, protein structure analysis, medical imaging and other biological analyses.15 
 
3.1.3 Spin, and the Nuclear Magnetic Resonance Effect 
NMR is the result of a quantum effect called ‘nuclear spin’.  Nuclear spin arises from 
the subatomic particles making up the nucleus, which also have a characteristic ‘spin’ number 
associated with them.  This spin effect is attributable to all subatomic particles, however, some 
have an overall spin of zero. 
This thesis will not probe the exact nature of quantum spin or its causes, nor will it 
outline in any detail the workings of the NMR spectrometer.  However, a brief analysis of spin 
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and the NMR effect will enable a greater understanding of the information presented later in 
the chapter. 
Total nuclear spin can take only integer or half integer values (quanta) which are 
always multiples of I = ½.  Nuclei with spin of zero (I = 0) do not exhibit an NMR resonance 
and so do not feature in any NMR experiment.  Most elements contain at least one isotope 
with I > 0, enabling analysis by NMR spectroscopy.  The most abundant nucleus in the 
universe, and in most organic/biological chemistry, is the hydrogen nucleus (1H), with I = ½.  
Of note is also 13C, which gives an NMR signal (I = ½) but is only present at 1.1% natural 
abundance, and so measurements of it are not as sensitive as 1H-NMR spectroscopy. 
Possessing a nuclear spin in effect gives the nucleus an angular momentum vector, 
which, combined with the charge in the nucleus, gives them a weak magnetic field (µ – the 
nuclear magnetic dipole moment), enabling them to respond to external magnetic fields in the 
same manner as macroscopic magnets do.  Moreover, the nucleus will precess with a 
frequency known as the Lamor frequency.   
For any given proton, the nuclear magnetic dipole moment (µ) is given by Equation 
3.1, where mp is the mass of the proton, e is the charge on one electron and ħ is the Planck 
constant: 
 µ = eħ2mp = 5.051 × 10
-27 JT-1     Equation 3.1 
In the presence of a large external magnetic field (B¯), µ orients in accordance, and for 
a nucleus with spin = I, there are 2I + 1 possible orientations (for a proton, I = ½, and the 
number of orientations is 2, ±½).  The energies of these orientations (m1) are given by 
Equation 3.2: 
Em = -g1µ1B¯m1       Equation 3.2 
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Where g is the nuclear g-factor: an experimentally determined characteristic of the 
nucleus.  If g is a positive number, then the nucleus is aligned with the external field, if g is 
negative, then the nucleus is aligned against the field.  In the presence of a large external 
magnetic field, two energy levels are formed, and there is an energy gap given by the 
difference of these two levels: 
 ΔE = g1µ1B¯       Equation 3.3 
If a photon can be introduced with energy that corresponds to the energy gap, as 
determined by the external magnetic field, then the nucleus can be induced to ‘flip’ from spin 
up to spin down.  This gives rise to the resonance effect.   
In any given sample, however, there are a large number of nuclei present, and given 
the same chemical environment, they will resonate with the same frequency [Figure 3.1 (a)].  
Hence, individual μ vectors can be combined into a larger summed vector, named the ‘bulk 
magnetisation vector’, ‘M’ which is further described in the diagram Figure 3.1 (b). 
 
Figure 3.1 The combination of individual µ’s (a) to give a bulk magnetization vector M (b).   
 
The response produced and measured by the NMR spectrometer is a result of the bulk 
magnetization vector, and analysis of the pulse sequences can also be thought of as acting on 
the bulk magnetization vector.  As RF pulses are applied to the sample in the spectrometer, M 
rotates along the axis of the RF pulse, changing the direction by an angle which depends on 
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the duration of the RF pulse.  At the appropriate duration, this results in the magnetization 
lying in the x’-y’ plane, known as transverse magnetization.  As this magnetization returns to 
the ground state of M0, it undergoes relaxation, that is, it loses the energy that was added to 
the system [Figure 3.2].   
 
Figure 3.2 Bulk magnetization vector after a 90° pulse (a), and the resulting relaxation process back 
to the Z'-axis (b).  The M vector along each axis is shown. 
 
There are two ways a nucleus can ‘relax’ – or ‘lose’ that energy back to the 
environment.  The first is via longitudinal relaxation, the process by which the population of 
nuclei return to the ground energy state from which they came.  This process gives rise to the 
spiral seen in Figure 3.2 (b), and also is the process from which the NMR signal, or Free 
Induction Decay (FID) is produced.  This relaxation occurs via an exponential function, with an 
exponential constant called T1. 
The second relaxation process, called transverse relaxation, arises from magnetic field 
inhomogeneity, the proximity of other I = ½ nuclei which can interact with the nucleus, and 
the molecular dynamics of the species in solution.  This also fits an exponential decay function, 
and is given the constant T2.   
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3.1.4 Pulse Sequences 
Modern NMR spectrometers are capable of applying a number of RF signals (‘pulses’) 
to the samples during the course of NMR experiments.  These normally exploit one of the 
parameters mentioned above to enhance or reduce a signal or set of signals which is 
problematic within a spectrum.  There are several of these parameters which were used during 
the course of this thesis, and the pulse sequences are detailed within this chapter. 
In Fourier Transform NMR (FT-NMR) spectroscopy, a pulse is applied in the form of 
monochromatic RF radiation at the Lamor frequency of the protons of interest.  In practice, the 
excitation pulse (or hard pulse) is a short one, of the order of 10 µs, so the Heisenberg 
uncertainty principal describes a considerable uncertainty on that frequency; effectively the 
pulse is a polychromatic one, covering the entire window of the spectrum.  The duration of the 
pulse (Δt) is referred to as the pulse width. 
If a longer, weaker pulse is applied to a region of the spectrum (known as a selective 
excitation, or soft pulse) then the uncertainty on the frequency is lower, and the pulse excites a 
small part of the spectrum, selectively. 
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3.2 Quantitative NMR Spectroscopy 16 
3.2.1 Introduction 
The NMR experiment as it is normally conducted is not a quantitative one.  In 
principle, the integrals of peaks from the 1H-NMR experiment should reflect the number of 
nuclei which gave rise to them.  That is, a -CH3, -CH2 and CH group should give rise to relative 
integrals of 3, 2, and 1, respectively, regardless of the species in the sample tube which gave 
rise to them.  The integrals from a single pulsed Fourier Transform 1H NMR (FT-NMR) 
experiment are not normally quantitative, however, and can often have an error of 20-30%. 
 
3.2.2 T1 Relaxation 
In order for quantitative measurements to be gathered from the NMR experiment, 
several considerations must be taken into account.  First, if the nuclei are not allowed to relax 
fully to their ground state then the second 90º RF pulse will flip them past 90º.  Consequently, 
their signals will decrease from each subsequent iteration of the pulse sequence.  To avoid this, 
a delay is inserted between each iteration, enabling M to fully return to the ground state 
magnetization.  In practical terms, a value of 5 T1 is used and is easily adopted in 
1H-NMR 
spectroscopy. 
Measuring T1 values is performed by a pulse sequence known as ‘inversion recovery ’.  
Essentially, the sample is subjected to a 180º pulse, allowed to recover and then a further 90º 
pulse is followed by data acquisition [Figure 3.3].  The recovery delay is varied over a range of 
values, and as the sample relaxes, the bulk magnetisation vector returns along the z’ axis to 
zero, and then back to the ground state.  The rate at which this occurs is a direct measure of T1 
(there is no net x-y magnetisation, so there is little influence from T2).  The second 90º pulse 
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will take the bulk vector and place it along the y’ axis, which then allows a signal which can be 
acquired and Fourier transformed to give a spectrium. 
A plot of the final peak versus relaxation time will show an ‘inverted’ signal that 
passes through zero (when the bulk magnetization vector passes through the origin – no 
resulting signal along the y’ axis) and finally into a positive signal.  If the delay is sufficiently 
long enough, the 180º pulse will relax away so that it has no effect on the size of the 
spectrum.  An example is shown in Figure 3.4. 
 
 
Figure 3.3 A typical ‘inversion recovery’ experiment used for measuring T1.  The ‘p1’ pulse is a hard 
180º pulse which ‘inverts’ all the resonances along the z axis.  The ‘d2’ delay is arrayed over a rage of 
times (in s) to allow the signals to partially recover before ‘pw’, a 90º pulse, and data acquisition.   ‘D1’ 
is set high (20 s) to allow total relaxation before the next iteration of the experiment. 
 
The time required to give a zero point spectrum (τnull) can be used to gauge the value 
of T1.  This follows from the exponential nature of T1 relaxation: 
Mt = M0(1-2e
-τ/T1)      Equation 3.4 
Where Mτ is proportional to the magnitude of the signal observed after delay τ.  M0 is 
the initial magneton, seen at τ = 0, and T1 is the exponential decay constant for longitudinal 
relaxation.  It follows that: 
Chapter 3 – NMR Spectroscopic Assay 
73 
 T1 = 
τnull
ln2 = 1.443 τnull      Equation 3.5 
 
 
Figure 3.4 An example of the result from an ‘inversion recovery’ experiment, as outlined in the text.  
The delay required to give a ‘zero point’ spectrum, where no resultant NMR signal is seen, is used to 
gauge the value of T1. 
 
 
3.2.3 T2 Relaxation 
There is a second mechanism by which nuclei can release the energy imparted by the 
pulse, known as transverse relaxation, or T2.  Where T1 was the loss of magnetisation along the 
z’ axis, ultimately giving a null signal, transverse relaxation or T2 relaxation results in a 
‘blurring’ or fanning of the individual magnetisation vectors in the x’-y’ plane [Figure 3.5]. 
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Figure 3.5 T2 relaxation.  The bulk magnetisation vector along the y’ axis is lost as individual groups 
of magnetisation vectors, often isochromats, with different Lamor frequencies. 
 
In terms of observable effects on the acquired spectrum, having a rapid relaxation from 
T2 effects (a ‘short’ T2) will lead to line broadening in the post-Fourier transform spectrum. 
The field inhomogenities that give rise to T2 relaxation can arise from two distinct but 
inseparable sources.  The first is static field inhomogeneity, i.e., the magnetic field is not the 
same over the sample volume; some nuclei experience a larger field than others, and so the 
Lamor frequency is different for these nuclei.  Correctly calibrating or ‘shimming’ the NMR 
magnet prior to spectrum acquisition minimises effects resulting from an irregular magnetic 
field. 
The second major contributing factor giving rise to transverse relaxation is small local 
differences in magnetic field resulting from molecular components in solution – i.e., arising 
from solution components.  
 
3.2.4 Internal Standards for Quantification 
Another consideration for quantitative NMR spectroscopy is that there is no equivalent 
to the molar extinction coefficient (ξ) from UV spectroscopy.  That is, the peak integrals cannot 
easily be converted to absolute concentrations from the standard FT-NMR experiment.  In order 
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to quantify the concentration of substances present, an internal standard of known 
concentration must be present to give a measure of the relative intensity to the sample. 
Internal standards must be carefully chosen.  It must be non-reactive (in order to not 
interfere with the chemicals present in the sample) and ideally give rise to a singlet which is 
easily discernable from the rest of the spectrum.  For kinetic analysis, there is the extra 
requirement for the reference compound to be kinetically neutral to the enzyme.  It was found 
that tert-butanol did not affect BHMT activity, so was used for kinetic measurements of BHMT 
[Chapters 4, 5, 6].  Acetonitrile is not a normal component of mammalian urine, so was used 
for quantitative measurements in urine [Chapter 7]. 
3.2.5 Aqueous Measurements 
Water presents a problem for 1H-NMR spectroscopic measurements.  Since the water 
molecule contains two protons, and is present at 55 M concentrations, it gives rise to a 
dominating peak (110 M 1H equivalent) at about 4.7 ppm.  Furthermore, the protons on the 
water peak are in rapid exchange with any amine or hydroxyl peaks in the sample.  
There are several methods for removal of water signals from 1H-NMR spectra.  The 
simplest is the presaturation technique, which uses a selective irradiation on the water signal 
for several s prior to the 90° pulse, which effectively scrambles the magnetisation of water 
protons, giving them no signal, therefore removing them from the spectrum.  The 
consequences of this technique include the substitution of the excited protons from the solvent 
to exchangeable protons, like that on the hydroxy, or amine moiety.  However, there is little 
disturbance to the baseline when this technique is used.  A second technique used during the 
course of the work of this thesis was the double pulsed field gradient spin echo (DPFGSE) 
technique.  This technique uses field gradients to selectively excite the solvent molecules, 
scrambling their magnetisation and therefore rendering them invisible to the proton spectrum.  
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The consequences of this technique include the distortion of the baseline in ways which can be 
obstructive to the quantification of the peaks in the spectrum, particularly if the underlying 
molecules differ significantly in concentration.17  The DPFGSE, however, achieves much better 
suppression of the solvent peaks than the presaturation technique.  There are other techniques 
which were not employed in the course of this thesis, including WATR (Water Attenuation by 
Transverse Relaxation).18-20 
 
 
3.3 Relaxation Measurements of Methylamines 
3.3.1 Introduction 
In order to set appropriate delays in the pulse sequences being used in NMR 
spectroscopy, the T1 relaxation measurements must be made.  There are standard procedures 
for the measurement of T1, which have been pre-loaded into the Varian software (used for this 
work), and are evoked with the command ‘dot1’.  This automatically initiates a 180° - delay - 
90° - acquire pulse sequence (as described in Section 3.2.2) with incrementally increasing 
delays.  This sequence, however, provides no water suppression and so the ‘inversion-recovery’ 
sequence must be modified with some form of presaturation between iterations.  Fortunately, 
a 3 s presaturation pulse can be introduced before the inversion recovery.  Unfortunately, once 
significant delays are employed in the pulse sequence (i.e., in the 3-4 s range) the effects of 
the presaturation pulse begin to wane, and can swamp any nearby peaks that are being 
analysed. 
3.3.2 Method 
Aqueous solutions of glycine betaine, dimethyl glycine, methionine, acetonitrile and 
tert-Butanol were prepared at 5 mM and 100 μM.  The pulse sequence described above 
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(inversion recovery, with presaturation on the water resonance for three s) was introduced to 
the sample and d1 was arrayed over the values 0.1, 0.2, 0.4, 0.8, 1.6, 3.2, and 6.4 s. 
3.3.3 Results 
Each of the small metabolites extinguished during the 1.6 s array experiment, 
indicating that the T1 decay constant was ~ 1.6/ln2 = 2.3 s.  This measurement remained 
constant over concentrations, with the 5 mM and the 100 μM sample giving the same 2.3 s T1 
value. 
 
3.4 Validation of 1H-NMR Spectroscopy for Urine Methylamine Measurements 
3.4.1 Introduction 
Alternative methods for measuring methylamine metabolites in urine were 
investigated in response to two clinical demands.  First, there has been increasing recent 
interest in betaines and betaine metabolites because of their association with homocysteine 
metabolism8,21-24 and, hence, with vascular disease.8,25  Secondly, trimethylamine (TMA) 
excretion is increased in patients suffering from a genetic disorder known as ‘fish odour 
syndrome’.26,27  An increase in the ratio of TMA to trimethylamine N-oxide (TMAO) is diagnostic 
for this condition, and useful for diagnosing heterozygotes.  While this is not a fatal condition, 
it inflicts a characteristic odour which can be socially debilitating. 
In previous work, the Osmolyte Research group at Canterbury Health Laboratories, in 
Christchurch, have used the HPLC separation of aracyl derivatives to measure these 
metabolites.25,28-31  This is satisfactory for plasma but with urine samples there are a large 
number of peaks, and to get adequate resolution it is necessary to resort to long run-times 
(>60 min).  Even so, it is difficult to resolve all the metabolites of interest in one 
chromatogram.  Additionally, TMA and TMAO give the same derivative and are not separately 
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quantified.  In an animal study23 it was found that 1H-NMR spectroscopy could be used to 
measure all the metabolites of interest rapidly and at the same time, and subsequent 
experience32 suggested that this technique could be used to provide a clinical diagnostic 
service.  
NMR spectroscopy has been used for the identification and quantification of a 
number of metabolites in urine and plasma.  In the early 1980’s, 1H-NMR spectroscopy 
established itself as a versatile tool for the analysis of whole urine.  The early work of Bales et 
al, and Nicholson et al showed that useful clinical information could be derived from whole 
urine NMR work.33,34  More recently, sophisticated techniques have been developed to suppress 
the water and protein signals which complicated those early spectra.35  The use of NMR 
spectroscopy in clinical applications is becoming more commonplace, given its unique ability to 
identify and quantify multiple metabolites in a single run. Wide ranging clinical studies using 
NMR spectroscopy have been undertaken, including disturbed metabolism of TMA,27,36 
supplementation in athletes,37 determination of novel metabolic disorders38 and observation of 
renal clearance.39  Urine betaine and TMAO analysis by 1H-NMR spectroscopy has previously 
been problematic since they can easily be confused.40   Experiments were undertaken to 
demonstrate that, for the group of methylamine metabolites studied, these problems can be 
resolved and a rapid and versatile diagnostic assay developed. 
3.4.2 Method 
3.4.2.1 Materials 
Glycine betaine, trigonelline, dimethylglycine (DMG), trimethylamine, trimethylamine 
N-oxide, acetonitrile, deuterium oxide and HCl were purchased from Sigma-Aldrich (St Louis, 
MO, USA).  Proline betaine was synthesised using the method of Cornforth and Henry.41 
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3.4.2.2 Sample Preparation  
400 µL of urine was added to 100 µL of 1 M HCl solution containing acetonitrile at 25 
mM as an internal standard. 
 
3.4.2.3 NMR Assay 
All 1H NMR spectra were recorded on a Varian INOVA 500 instrument, at 23 °C in 5 
mm NMR tubes with a 3 mm D2O lock insert.  For the measurements, a 90° radiofrequency 
pulse, with duration of 8.1 μs was used.  The delay between pulses was 5 s, acquisition time 
was 1.982 s.  Eight transients were recorded for each sample, with 30,272 data points for 
each transient.  Spectral width was set to 8,000 Hz.  Water suppression was achieved using a 
presaturating irradiation of the water spin population of 3 s during the relaxation delay period.  
All spectra were zero filled to 128k points, and then Fourier transformed.  Phasing and 
baseline corrections were completed manually.  The software used for these procedures was 
VNMR version 6.1C (Varian), which also provides a signal-to-noise calculation facility for the 
determination of the limits of detection. 
Quantification of the metabolites was performed using an internal standard of 
acetonitrile (5 mM).  Peak integrals and peak heights were measured after baseline and drift 
correction and then expressed as a ratio to the acetonitrile integral. 
Trigonelline was subject to the same analysis as the other betaines, but its proximity to 
the suppressed water resonance led to baseline distortions.  Peak integrals proved to be 
unreliable for trigonelline, and a more reproducible measure was obtained from the peak 
height ratio to acetonitrile in a method similar to Fulton et al.42 
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3.4.2.4 Precision and Recovery Study 
 To make urine samples with elevated levels of betaines, 100 µL of aqueous standards 
of the betaines was added (spiked) into 10 mL of urine. This resulted in a urine samples with 
elevated concentrations of the methylamines in question (spikes were: 100 µM trigonelline, 
750 µM TMAO, 75 µM glycine betaine and TMA, 140 µM DMG and 2.5 mM creatinine). The 
unspiked urine sample with low betaine levels was also used in this precision study. Six 
batches with four replicates of the spiked and non-spiked urine were analysed.  
 
3.4.2.5 Linearity 
 Standard solutions, at concentrations of 50 - 700 µM,  were prepared for each of 
trigonelline, glycine betaine, proline betaine and DMG.  Because of differences in 
concentrations in samples, TMAO was prepared at 100 – 7000 µM, TMA at 10 – 700 µM and 
creatinine at 0.25 - 17.5 mM. These were prepared by serial dilution of a 10 mM aqueous 
stock standard. Samples were analysed and the linearity of the method was determined using 
linear regression analysis over six data points. 
 
3.4.3 Results 
3.4.3.1 Internal Standards  
 Acetonitrile was used as an internal standard because its resonance is well separated 
from the resonances of the compounds of interest.  The resonance positions of many 
metabolites are dependent on the solution pH, so the use of HCl was required to ensure that 
the pH of the samples was consistent between analyses.  At low pH, the TMA peak was split 
into a doublet with coupling observed to the ammonium proton,43 however, the methyl 
resonances were sufficiently removed from other metabolites for integration of both peaks to 
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be achieved.  Lowering the pH to ~1 was required for separation of TMAO and glycine 
betaine.  A typical spiked spectrum is shown in Figure 3.6.  Additionally, carnitine was 
observed at 3.07 ppm, and it did not interfere with any of the species that were measured. 
 
 
Figure 3.6 Spiked (300 µM) urine with methyl resonances for the metabolites studied. 
 
3.4.3.2 Spectrum Analysis 
 Baseline distortions, which were introduced after the water suppression was applied, 
were problematic for the methyl resonance of trigonelline, which was near the residual water 
resonance.  The use of peak height data, which can be extracted after smoothing the baseline, 
was far more reliable than peak integral data when applied to trigonelline.42 
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3.4.3.3 Precision 
 The coefficient of variation (CV) was below 10% for within batch and between batch 
variation when using the internal standard calibrated data [Table 3.1].  A brief comparison of 
peak height and peak integral data was performed.  The peak integral data were used for most 
of the metabolites presented here, because the baseline was flat and the peaks were well 
resolved. In the case of trigonelline, the residual water resonance caused a significant baseline 
distortion. Peak height proved to be more reliable, with artificial baseline correction performed 
using the Varian VNMR software. Peak heights were difficult to obtain for the other 
metabolites, as the neighbouring signals made the same baseline corrections complicated. 
Table 3.1 Results of precision and recovery study of betaines in urine with betaine spike and unspiked 
sample (four batches, n=6). (* Trigonelline results obtained from peak height data.) 
 
Analyte  Mean  
μM 
Within 
batch CV 
Between 
batch CV 
Recoveries 
% 
Trigonelline* low urine 75 4.8 4.1  
 spike 178 6.9 2.3 98 
TMAO low urine 976 4.3 2.0  
 spike 1760 2.5 8.5 105 
Proline betaine low urine 67.0 4.7 2.3  
 spike 165 2.9 2.8 98 
Glycine betaine low urine 63.1 5.8 6.2  
 spike 138 4.5 3.0 100 
Dimethylglycine low urine 60.5 6.0 5.7  
 spike 197 4.1 3.1 98 
TMA low urine 8.4 7.4 6.6  
 spike 83 4.2 5.1 100 
Creatinine low urine 3950 0.9 0.7  
 spike 6370 0.6 3.0 97 
 
3.4.3.4 Limits of Detection 
Limits of detection (S/N =3) for each compound are shown in Table 3.2. The precision 
of this NMR method was good at both low levels (unspiked sample) and high levels (100 μM).  
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3.4.3.5 Accuracy 
 Recoveries of betaines were over 95% for all betaines in urine. The recovery values 
given in Table 3.1 show that all of the betaines of interest could be measured accurately. 
Table 3.2 Chemical shift (relative to acetonitrile at 1.9 ppm) and limit of detection (LOD) for the 
metabolites analysed. (* Trigonelline results obtained from peak-height data.) 
 
Analyte Chemical Shift (ppm) LOD (µM) 
Trigonelline* 4.30 25  
TMAO 3.37 15  
Proline betaine 2.99 25  
Glycine betaine 3.19 15  
DMG 2.82 20  
TMA 2.73, 2.72 15  
Creatinine 2.97 25  
 
3.4.3.6 Linearity 
 The NMR assay was linear over the range of 50 µM - 1000 µM for trigonelline, glycine 
betaine, proline betaine and DMG, 100 – 7000 µM for TMAO, 10 – 700 µM for TMA and 
0.250 - 17.5 mM for creatinine. Standard lines for these metabolites are shown in Figure 3.7. 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Standard lines for the metabolites measured by 1H-NMR Spectroscopy.  TMAO and 
creatinine were omitted because of differences in scale, however, all methylamines were linear over the 
specified ranges. 
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3.4.3.7 TMA Analysis 
 Two patients with suspected cases of trimethylaminuria were given a load of 600 g of 
fish and had a urine sample taken 12 h later.  Their TMA and TMAO concentrations were 
determined and the percentage ratio of TMA and TMAO are given at about 5% for both 
people.  As a comparison, a normal control has about 1% ratio of TMA [Table 3.3].  
 
Table 3.3 TMA and TMAO measurements of two suspected cases of heterozygous trimethylaminuria 
and a normal control. 
 
 TMA  TMAO Ratio 
TMA/TMAO 
% TMA/ 
TMA+TMAO 
%TMAO/ 
TMA+TMAO 
Patient 1 30.01  603.8  0.05 4.7 95 
Patient 2 56.22 1102.27 0.04 4.8 95 
Control 2.09 236.05 0.009 0.9 99 
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3.5 Discussion 
The results of the first, inversion-recovery experiment placed limits on the delays set 
into the NMR experiment.  In reality, the need for consistent delays between calibration and 
sample allows for the relaxation of the samples, but delays should be well over 4 x 2.3 s to 
ensure complete relaxation.  The parameters developed in the inversion-recovery experiment 
were used in the validation of the NMR assay for clinical applications. 
Measurement of methylamine metabolites by 1H-NMR spectroscopy is a rapid, simple, 
non-destructive and effective quantitative method, involving minimal sample preparation and 
the capacity to analyse many samples in a short time (2-3 minutes per sample). As well as the 
metabolites presented here, the method could be adapted to measure other methylated 
substances, for example carnitine (which does not interfere with the urine components that 
were the subject of the present studies). Moreover, when an unknown metabolite occurs in a 
urine sample, the NMR spectrum can provide substantial information about its nature.  If 
required, 2D NMR spectroscopy can also be run on the sample with no further preparation and 
structural information gathered. 
Previously, other groups have used NMR spectroscopy for measuring these 
methylamines.  Lundberg et al quantified DMG and glycine betaine in the urine of patients 
with premature vascular disease.44  A new inborn error of metabolism giving elevated urine 
excretion of DMG was identified similarly,38 and we used this technique to observe changes in 
DMG excretion in a DMG supplementation study.45  Often water is evaporated off and replaced 
with deuterium oxide,27 however, it is shown here that the water signal can be suppressed 
without this time-consuming step.  Alternative methods that have been used for water 
suppression in 1H-NMR spectroscopy include Double Pulsed Field Gradient Spin Echo (DPFGSE), 
WATERGATE and WET pulse sequences.23,35  Presaturation was chosen here, because none of 
the signals in question were in rapid exchange with water.  It is essential to lower the pH of 
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the urine to pH~1 to correctly assign the signals. Previously the resonance caused by TMAO 
(pKa = 4.65) in the urine of renal failure patients has been incorrectly attributed to glycine 
betaine (pKa = 1.83).
40 These are resolved after acidifying the samples, and this is necessary 
since both are likely to be present in substantial amounts in normal urine. 
The methods described here are being used for studies of urinary betaines and vascular 
disease,25,32 which require simultaneous measurement of glycine betaine and its metabolite 
DMG, along with the potentially confounding dietary betaines,46,47 proline betaine and 
trigonelline. It is also being used for the diagnosis of TMAuria and an example of results with 
presumed heterozygous subjects is illustrated [Table 3.3]. However, the approach is far more 
general, for example the presence of clearly resolved carnitine peaks in normal urine samples 
suggests that carnitine and acylcarnitines could also be measured. Most groups have measured 
methylamine metabolites by combinations of chromatographic procedures with UV, 
fluorescence or mass-spectrometric detection: 1H-NMR spectroscopy is a rapid non-destructive 
alternative. 
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3.6 Conclusion 
The use of 1H-NMR spectroscopy for the measurement of methylamines is not new.  
Several groups have previously worked on the use of 1H-NMR spectroscopy to measure 
chemicals in biofluids, including urine, plasma, and cerebro-spinal fluid.48-66  These groups have 
measured various markers of disease, from trimethylamine (and its oxide) as a marker of fish-
odour syndrome, to glucose for diabetes, to creatine excretion for doping studies (in France, 
where the substance is a banned athletic supplement).  The application of 1H-NMR 
spectroscopy, to routine clinical measurements is only limited by the financial investment that 
the magnets require. 
NMR spectroscopy is a superior method of analysis of methylamines to the currently 
available methods.  Methods currently employed for methylamine analysis include HPLC and 
head-space gas chromatography - mass spectrometry (GCMS).  Methylamines tend to lack 
chomophores, and are not generally fluorescent, so are not easily detected using HPLC.  
Furthermore, the analysis times for HPLC are up to 60 min, making high-throughput analysis 
difficult.  GCMS of the headspace of a sample is only applicable to the analysis of 
trimethylamine and its oxide, and is often complicated by interfering compounds in the sample. 
The studies presented here allow for the rapid detection and quantification of 
methylamine compounds.  Furthermore, the techniques described should be applicable to most 
other compounds present in the urine, which may also be used as markers of disease.  In most 
cases, quantitative measurements were completed within 5 min, and the sample preparations 
were far simpler than the chemical manipulations necessary for HPLC analysis.  The CV’s 
presented for the methylamines in these studies are comparable to those obtained in clinical 
assays, making NMR spectroscopy an attractive alternative to the techniques available now. 
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CHAPTER 4: 
Kinetic Measurements of BHMT 
 
4.1 Introduction 
There are several methods available for the measurement of BHMT activity, but all suffer 
from various problems.  Early assay techniques used a manometric method to measure CO2 
production, as an index of BHMT activity (they were measuring “thetin-homocysteine 
transmethylase”).1  This approach was adopted when it was realised that the BHMT reaction, using 
the thetin substrates, results in lowered pH (the hydrogen ion on homocysteine is replaced with a 
methyl group, but is not absorbed by the thio-ether product).  In the presence of sodium carbonate, 
the liberated acid generates CO2, which is measured in the headspace of the reaction. 
Measuring the formation of methionine became a favoured technique when glycine betaine 
was employed as the substrate, because this reaction does not liberate hydrogen ions.2  The 
procedure involved colorimetric analysis of the solutions with nitroprusside, which generates a 
coloured complex with methionine.  This approach, however, can be hampered by a non-specific 
chromogen formation.  
Other techniques for the measurement of BHMT have included a HPLC method, based on 
the detection of the methionine product.3,4  In this method, the methionine is derivatised by 
2,4-dinitrofluorobenzene or o-phthalaldehyde, forming a coloured (or fluorescent) adduct which 
can be easily detected from absorbance readings at 360 nm.  Similar approaches are taken in the 
radiochemical assay, which uses radio labelled 14C methyl groups on the betaine, which are passed 
onto the methionine product, and separated using ion-exchange chromatography.  The tubes 
containing methionine are counted, and a measure of enzyme activity is derived from the 
radioactivity produced.  Microbiological techniques for the detection of methionine production have 
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also been employed, using the growth of methionine auxotropic bacteria on minimal media, 
supplemented with methionine produced by BHMT.5,6 
In all three methods based on methionine production the final result is the only reading 
which is obtained, that is, the reaction is stopped by the addition of trichloroacetic acid, to 
precipitate the BHMT protein, prior to the reaction which quantifies the methionine produced.  
There are several problems with this method for deriving kinetic results.  First, uncertainties in rates 
are greater if only one point is obtained – using a product-time graph reduces uncertainty in rate 
measurements.  Second, there is no good way to ensure that the reaction is complete – or indeed if 
it has even begun.  All the methods mentioned for derivatizing and separating the methionine from 
the reaction mixture take several hours of work, and problems with set-up of the experiment will 
not be apparent until the analysis is complete.  More importantly, the reaction mixture is destroyed 
in each measurement, as the addition of trichloroacetic acid denatures the BHMT so no further 
work can be done.  Third, there must be a commercially available source, or easy synthetic route, to 
obtain the required radioactive substrate.  Even if a viable synthetic route is available, radioactive 
precursors must be sourced, and this is not always a simple task.  Fourth, there is the complication 
of dealing with radioactive chemicals.  Extra precautions must be taken to ensure that there is no 
contamination with the radioactive chemicals, and with extra health and safety issues. 
There is one other method for assaying BHMT activity, developed by the Garrow group at 
the University of Illinois.  A strain of E. coli has been developed (J5-3) which lacks a functional 
methionine synthase pathway, and so is a methionine auxotroph.6  The growth of J5-3 is linearly 
dependent on methionine supplementation in their medum.  If they are supplied with a plasmid 
coding for a functional BHMT protein and grown on medium lacking methionine, then they are able 
to augment their methionine supply and grow at a rate dependent on the BHMT activity.  
Effectively, a simple measure of the optical density (or the absorbance at 450 nm) gives a measure 
of the activity of the BHMT being coded by the plasmid introduced into the E. coli.  This functional 
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complementation assay is particularly useful if assaying for mutations or for activity from novel 
substrates, but is unable to give kinetic results because the bacterial growth is slower than the rate 
of the enzyme reaction. 
 
4.2 Kinetics of BHMT with Glycine Betaine 
4.2.1 Introduction 
In vitro kinetic analysis of enzymes provides a useful insight into their mechanisms and 
biological function.  The most simple analysis of enzyme kinetics is a form of the ‘steady state 
approximation’ or, as it is applied to enzymes, the Michaelis Menten equation: Rate = 
Vmax [S]
Km + [S]
. 
This equation essentially defines the rate of the reaction (measured as either the 
appearance of products, or the loss of substrates) with two constants (Vmax and Km) and the 
concentration of substrates available to the enzyme at the time of the measurement.  Vmax is the 
maximal rate that the enzyme would be capable of if the substrate were present at effectively 
infinite concentration (not including substrate-inhibited enzymes) and Km is a combination of two 
rate constants (one for the rate of substrate binding, and the other for the rate of reaction once the 
substrate is bound).  Once these have been measured for any given substrate in the enzyme, the 
Michaelis Menten constants can give clues into the biological function of the enzyme, as well as 
inferences about the binding site(s) and active site(s) of the protein, particularly if the constants 
obtained from different substrates are compared. 
The assays described in Section 4.1 are not easily adapted to operate on alternative 
substrates (either because they interfere with nitroprusside, or are not available in radiolabelled 
form), so 1H-NMR spectroscopy was identified as a potential assay tool.  NMR spectroscopy has the 
advantage of being able to detect and quantify micromolar amounts of betaines, and produce a 
Chapter 4 – Kinetic Measurements of BHMT    
 
97 
measurement in under 2 min.  Moreover, modern NMR spectrometers are fitted with temperature 
controlled sample probes, allowing kinetic analysis at different temperatures.  
 
4.2.2 Materials and Methods 
4.2.2.1 Materials  
Glycine betaine monohydrate, its demethylated product DMG, trigonelline hydrochloride 
and homocysteine thiolactone were purchased from Sigma (St Louis, MO, U.S.A).  Superdex 200 
was purchased from Amersham Biosciences (UK).  
 
4.2.2.2 Enzyme Purification 
These procedures are all based on work described in Chapter 2.  Liver BHMT was purified 
from an inbred Lewis rat after euthanasia by CO2 asphyxiation.  12 g of liver was excised and 
homogenized with 3 volumes (w/v) of 20 mM potassium phosphate buffer containing 5 mM 
methionine and glycine betaine at pH = 7.5 (Buffer 1), in a manual glass homogenizer.  The sample 
was centrifuged at 7000 g for 5 min, the supernatant was separated into 1.5 mL Eppendorf tubes 
and heat treatment for 10 min at 70 °C, followed by cooling on ice for 5 min and then centrifuged 
at 7000 g for a further 5 min. The supernatant (5.5 mL) was applied to a 450 mL Superdex G200 
column, pre-washed and equilibrated with Buffer 1.  Proteins were eluted with Buffer 1 at 1.1 
mL/min and fractions collected every 13 mL. 
Homocysteine (100 μmole) was added to each fraction, followed by incubation for 12 h at 
4 °C.  Fractions displaying a DMG methyl-group singlet by 1H-NMR spectroscopy were collected 
and concentrated under pressure (40 psi) in a stirred concentration cell (Millipore) through a Diaflo 
ultrafiltration membrane (Amicon Corporation, MA).  The concentrated sample was mixed with 20 
mM potassium phosphate buffer (100 mL) at pH = 7.5 (Buffer 2) and reconcentrated three times 
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until no DMG, methionine or glycine betaine was found by 1H-NMR spectroscopy.  The total volume 
was decreased during the buffer replacement, from 39 mL (total volume from three fractions 
containing BHMT activity) to 12.5 mL.  Enzyme purity was assessed by SDS-PAGE electrophoresis.  
A single band at 45 kDa was observed [Chapter 2].  Total protein concentration was determined 
using the Bradford method (Bio-Rad), standardized with bovine serum albumin. 
 
4.2.2.3 Preparation of Substrates 
L-Homocysteine was prepared for the assay using the method of Duerre and Miller.7  
L-Homocysteine thiolactone (0.7 mg) was dissolved in 2 M NaOH (0.4 mL), incubated for 5 min, 
then neutralized with saturated KH2PO4 (0.6 mL). 
 
4.2.2.4  1H-NMR Spectroscopy  
All 1H-NMR spectra were recorded on a Varian INOVA 500 instrument, at 37 °C in 5 mm 
NMR tubes with a 3 mm D2O lock insert.  For the measurements, a 90° radiofrequency pulse, with 
duration of 8.1 μs was used.  The delay between pulses was 5 s, acquisition time was 1.982 s.  
Eight transients were recorded for each sample, with 30,272 data points for each transient.  Sweep 
width was set to 8,000 Hz.  Shimming was completed using the field gradient autoshim macro. 
Water suppression was achieved using the DPFGSE technique.  All spectra were zero filled to 128k 
points, and then Fourier transformed.  Phasing and baseline corrections were completed manually.  
The software used for these procedures was VNMR version 6.1C (Varian). 
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4.2.2.5 Standard Line 
A standard line for DMG and methionine was prepared, using 50, 100, 250, 500, 750 µM 
and 1 mM solutions in Buffer 2.  These were spiked with 5 mM tert-butanol (final concentration), 
and 1H-NMR spectra were obtained using the methods described in Section 4.2.2.4.  The DMG 
peak integral to tert-butanol peak integral was calculated and plotted against DMG concentration 
to form the standard line. 
 
4.2.2.6 Enzyme Assay and Kinetics  
Kinetic and endpoint assays were evaluated.  For the kinetic assay, a solution of BHMT 
extract (protein = 97 μg/mL) was prepared containing a BHMT-saturating concentration of 
homocysteine (1 mM), glycine betaine (concentration varied from 0.05 to 2 mM) and 5 mM 
tert-butanol in Buffer 1 and placed in an NMR tube.  DPFGSE water suppression was used to 
remove the solvent peak.  A pre-acquisition delay was used to automate acquisition, with delays 
between spectra acquisition set to 544 s (giving 10 min between spectra).  A total of 12 spectra 
were acquired for each assay run.  The 1H-NMR assay incorporates a short delay between mixing 
and spectrum acquisition; it took 160 s for the sample to be mixed, placed within a 5 mm NMR 
tube and the spectral parameters to be entered for each sample run.  This was not a problem for 
BHMT analysis, since its activity is slow, with only 13.5 µmol produced in one min under the assay 
conditions used.  This activity was not detectable.  Precision measurements were conducted on six 
solutions containing 2 mM glycine betaine and 1 mM homocysteine. 
4.2.3 Results 
4.2.3.1 NMR Spectra  
After autophasing, the DMG peak was clearly visible at a chemical shift of 2.88 ppm, 
flanked by smaller, broad multiplets from homocysteine and methionine.  The tert butanol signal 
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was clearly visible at 1.15 ppm, and the glycine betaine peak could be seen at 3.22 ppm [Figure 
4.1].  Methionine appeared at 2.10 ppm, however this coincided with a broad resonance, and no 
kinetic analysis was performed using this peak.  An example 10 h incubation sequence is shown in 
Figure 4.2. 
The large difference in concentration between glycine betaine, tert-butanol and DMG led 
to a deformity in the baseline of the spectra, which correlated to irregularities in the integrals 
obtained.  This was corrected using the ‘baseline correction’ macros within the Varian software.  
This was also incorporated into the standard line for DMG, which was linear over six points (DMG 
concentration: 50 μM – 2 mM, R2=0.9991). 
 
Figure 4.1 A 1H-NMR spectrum of the kinetic analysis performed on BHMT.  Glycine betaine (3.21 ppm), 
DMG (2.86 ppm) and methionine (2.09 ppm) methyl singlets are all clearly visible in the spectrum, as well as 
multiplet signals from homocysteine (2.10, 2.60 ppm) and methionine (2.22, 2.79 ppm). 
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4.2.3.2 Enzyme Reaction  
Over a 14 h period, the concentration of DMG was observed to increase in a linear fashion 
for the first 150 min, reaching a plateau after 12 h [Figure 4.3].  For kinetic measurements, the 
data obtained over the first 2 h were used to derive the initial rate.  The coefficient of variation for 
the measurement of DMG was 6.3% over six replicates (mean = 0.75 mM DMG) containing 
saturating levels of glycine betaine and homocysteine (10 mM and 2 mM, respectively – 300 
nkatals).  The limit of detection for the assay is 10 µM of DMG, representing 6 nkatals under 
identical conditions.  Activities below 6 nkatal gave signal to noise ratios lower than 3 for DMG in 
the 1H-NMR spectra.   
 
Figure 4.2 Layered sequential 1H-NMR spectra (at 1 h intervals) showing homocysteine, methionine and 
DMG.  Glycine betaine and homocysteine were initially at 2 mM, respectively (glycine betaine was off scale, 
and cut from this image).  DMG (2.87 ppm above) and methionine (2.15 ppm above) are seen to increase 
over the incubation period. 
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Figure 4.3 The BHMT reaction, as monitored by 1H-NMR spectroscopy of the DMG peak.  
 
4.2.3.3 Michaelis Menten  
The initial rate data using glycine betaine as a substrate were consistent with classical 
Michaelis Menten type kinetics, with a Vmax = 17 ± 0.7 nmol min
-1 mg-1 and a Km = 0.19 ± 0.03 mM 
[Figure 4.4].  Estimates for Vmax, Km and uncertainties were determined using ‘Enzfitter for 
Windows’ (Biosoft V2.16.0.1). 
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Figure 4.4 Lineweaver-Burk plot and Michaelis Menten plot (inset) of the BHMT reaction, as monitored 
by 1H-NMR spectroscopy.  Error bars are derived from experimental variation. 
 
4.3 The Endpoint Assay 
4.3.1 Introduction 
One of the big problems when conducting enzyme assays, is determining the concentration 
of active protein in the sample.  Normally the sample is purified as much as possible, as determined 
by specific activity, and the sample is then assumed to be 100% active protein.  This can be 
confirmed by techniques like active site titration and SDS-PAGE but neither of these techniques will 
discern active protein from inactive protein. 
BHMT is subject to feedback inhibition from DMG, assumed to be because of the formation 
of an abortive complex between BHMT, DMG and homocysteine [Chapter 1].8  Because DMG is 
produced directly as a product of the betaine reaction, and is such a potent inhibitor of the enzyme, 
it offers an alternative method for the determination of active BHMT in the sample.  This ‘Endpoint 
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Assay’ for BHMT can also be used to observe other potential substrates, and was employed in the 
work described in Chapter 5. 
 
4.3.2 Method 
Solutions containing 38.8, 29.1, 19.4, 14.6, 9.7 and 4.9 mg/mL BHMT were incubated 
with 2 mM glycine betaine and homocysteine for 24 h.  The solutions were then analysed using 1H-
NMR spectroscopy (parameters as above in Section 4.2.2, without pre-acquisition delay) for DMG 
concentration.  DMG was determined by comparing the DMG peak integral to a standard line, 
derived above in Section 4.2.2.5. 
4.3.3 Results 
The final DMG concentration was found to be dependent on the initial concentration of 
BHMT present in the solution.  The linear relationship (R2 = 0.986) was used to measure the 
concentration of BHMT in an unknown solution [Figure 4.5].  The endpoint assay used any 
incubation time above 14 h [Figure 4.3] but had a greater sensitivity than the kinetic assay alone 
(the detection limit was 2 nkatal) and gave a CV = 5.3% (n = 6).   
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Figure 4.5 Standard line showing the linear relationship between protein concentration (BHMT) and DMG 
concentration after 24 h of incubation (R2 = 0.986). 
 
4.4 Discussion 
Since homocysteine has been identified as a cardiovascular risk factor,9-11 its metabolism in 
mammals has been a subject of intense investigation. It is intimately linked with the metabolism of 
methyl groups, methionine and methyl donor availability.12 In normal metabolism, homocysteine is 
either catabolized via cystathionine or it is methylated to form methionine. Most attention has 
focused on methylation by methionine synthase, requiring folate and B12-dependent enzyme 
systems, but increasing attention is being given to the role of BHMT in regulating the circulating 
homocysteine concentrations in mammals.13,14 
The 1H-NMR spectroscopic methods described here were able to deliver kinetic results, 
reproducibly (the CV on betaine and DMG is described in Chapter 3, but is 4.5% and 4.1% 
respectively) and, unlike other assays, offers several indices of activity (the disappearance of glycine 
betaine, or the appearance of methionine or DMG).  NMR spectroscopy also offers the unique 
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ability of monitoring any potential alternate substrates, something which was explored for Chapter 
5.   
 The kinetic constants obtained using these new techniques were comparable to those 
obtained using radiolabelled betaine, and the HPLC method.  Various studies have reported Km for 
glycine betaine to be 23,15 48 16 and 100 μM17.  The Km for glycine betaine presented here (190 μM) 
is higher than these estimates, but the other methods for estimating BHMT activity have all suffered 
from an inability to trace the reaction as it progresses.  Figure 4.3 shows how slow the BHMT 
reaction is, when operating at Vmax.  Using saturating levels of glycine betaine (5 mM) the turnover 
rate for the enzyme was 0.8 /min. 
The endpoint assay is a new application of the feedback inhibition by DMG to detect and 
measure the concentration of BHMT in an unknown sample.  Similar techniques, applied to 
methionine, have been used by Ericson and others to identify the protein in crude homogenates.18  
These techniques will not give an accurate estimate of the BHMT concentration because there are 
other enzymes within the crude homogenate which are capable of using methionine as substrates.19  
It is likely, at least in the initial period, that those crude homogenates were using some of the 
produced methionine in secondary reactions.  Furthermore, there are other methods for the 
production of methionine from homocysteine, via methionine synthase (E.C. 2.1.1.13, MS) 
[Chapter 1].  For these reasons, the production of methionine cannot be relied on as an accurate 
gauge of BHMT concentration or activity in crude homogenates. 
The chance of interference in the DMG measurement is much lower than on methionine.  
There are only two known fates for DMG, demethylation by dimethylglycine dehydrogenase 
(DMGDH, E.C. 1.5.99.2) to form methylene-tetrahydrofolate [Chapter 1],20 or excreted in the urine 
(impossible in crude samples).  In mammals, the only known enzyme which uses DMG is DMGDH, 
localised on the inner membrane of the mitochondrion.  In samples which have been homogenised 
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and solid material removed by centrifugation, it is unlikely that there are significant amounts of 
DMGDH present in the sample to interfere with the DMG production. 
DMG was the best index of BHMT activity in crude and partially purified samples.  In 
purified BHMT samples, there was no possibility of conflicting activity, so either methionine or DMG 
production, or betaine consumption could be used as a measure of relative activity.  In crude 
extracts, it was unlikely that there would be any interfering enzyme activity which could confuse the 
interpretation of the results.  Incubation times of 14 h were required, because of the slow turnover 
number of BHMT (0.8 min-1). 
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4.5 Conclusion 
 The techniques described in this chapter were shown to be capable of reproducible kinetic 
results, with similar results to the already existing assays for BHMT.  The NMR spectroscopic assay 
features all the benefits of the other assays, in a single analysis (kinetic results, on multiple 
substrates, with the ability to distinguish between alternative products, without the need for 
radiolabelled substrates) as well as, for the first time, being able to plot the activity of the enzyme 
over a time-course. 
 Furthermore, the endpoint assay described here could be useful in the analysis of multiple 
substrates and may find application clinically in the analysis of kidney or liver failure.  When the 
kidney or liver is damaged, either through chemical or mechanical stress, often proteins which are 
normally found in the cytoplasm of the liver/kidney cells are leaked through the cell membrane into 
the plasma.  The analysis of BHMT using this endpoint assay may establish another marker for this 
process, since BHMT is only found in the liver and kidney (in up to 1.6% of the soluble protein).15  
The endpoint assay would be a useful index for this process, given the ease of preparation and 
rapidity of NMR analysis.  Unfortunately the >14 h incubation would make these measurements 
too cumbersome for routine clinical use. 
Chapter 4 – Kinetic Measurements of BHMT    
 
109 
References 
(1) Maw, G. A. Biochemical Journal 1959, Thetin-homocysteine transmethylase. The 
distribution of the enzyme, studied with the aid of trimethylsulfonium chloride as substrate, 
72, 602-608. 
(2) Borsook, H.; Dubnoff, J. W. Journal of Biological Chemistry 1947, Methionine formation by 
transmethylation in vitro, 169, 247-258. 
(3) Goeger, D. E.; Ganther, H. E. Archives of Biochemistry and Biophysics 1993, Homocysteine-
dependent demethylation of trimethylselenonium ion and selenobetaine with methionine 
formation., 302, 222-227. 
(4) Lee, K. H.; Cava, M.; Amiri, P.; Ottoboni, T.; Lindquist, R. N. Archives of Biochemistry and 
Biophysics 1992, Betaine:homocysteine methyltransferase from rat liver:  purification and 
inhibition by a boronic acid substrate analog, 292, 77-86. 
(5) Ericson, L. E. Acta Chemica Scandinavica 1960, Betaine-homocysteine methyltransferases. 
III. The methyl-donor specificity of the transferase isolated from pig liver, 14, 2127-2134. 
(6) Mulligan, J. D.; Laurie, T. J.; Garrow, T. A. Journal of Nutritional Biochemistry 1998, An 
assay for betaine-homocysteine methyltransferase activity based on the microbiological 
detection of methionine, 9, 351-354. 
(7) Duerre, J. A.; Miller, C. H. Analytical Biochemistry 1966, Preparation of L-homocysteine 
from L-homocysteine thiolactone, 17, 310-315. 
(8) Castro, C.; Gratson, A. A.; Evans, J. C.; Jiracek, J.; Collinsova, M.; Ludwig, M. L.; Garrow, 
T. A. Biochemistry 2004, Dissecting the Catalytic Mechanism of Betaine-Homocysteine S-
Methyltransferase by Use of Intrinsic Tryptophan Fluorescence and Site-Directed 
Mutagenesis, 43, 5341-5351. 
(9) Boushey, C. J.; Beresford, S. A.; Omenn, G. S.; Motulsky, A. G. Journal of the American 
Medical Association 1995, A quantitative assessment of plasma homocysteine as a risk 
factor for vascular disease. Probable benefits of increasing folic acid intakes, 274, 1049-
1057. 
(10) Nygörd, O.; Nodrehaug, J. E.; Refsum, H.; Ueland, P. M.; Farstad, M.; Vollset, S. E. New 
England Journal of Medicine 1997, Plasma homocysteine levels and mortality in patients 
with coronary artery disease, 337, 230-236. 
(11) Welch, G. N.; Loscalzo, J. New England Journal of Medicine 1998, Homocysteine and 
atherothrombosis, 338, 1042-1050. 
Chapter 4 – Kinetic Measurements of BHMT    
 
110 
(12) Park, E. I.; Garrow, T. A. Journal of Biological Chemistry 1999, Interaction between dietary 
methionine and methyl donor intake on rat liver betaine-homocysteine methyltransferase 
gene expression and organization of the human gene., 274, 7816-7824. 
(13) Lundberg, P.; Dudman, N. P. B.; Kuchel, P. W.; Wilcken, D. E. L. Clinical Chemistry 1995, 
1H NMR determination of urinary betaine in patients with premature vascular disease and 
mild homocysteinemia, 41, 275-283. 
(14) Slow, S.; Lever, M.; Lee, M. B.; George, P. M.; Chambers, S. T. International Journal of 
Biochemistry & Cell Biology 2004, Betaine analogues alter homocysteine metabolism in 
rats, 36, 870-880. 
(15) Garrow, T. A. Journal of Biological Chemistry 1996, Purification, kinetic properties, and 
cDNA cloning of mammalian betaine-homocysteine methyltransferase, 271, 22831-22838. 
(16) Finkelstein, J. D.; Harris, B. J.; Kyle, W. E. Archives of Biochemistry and Biophysics 1972, 
Methionine metabolism in mammals: kinetic study of betaine-homocysteine 
methyltransferase., 153, 320-324. 
(17) Skiba, W. E.; Taylor, M. P.; Wells, M. S.; Mangum, J. H.; Awad, W. M., Jr. Journal of 
Biological Chemistry 1982, Human hepatic methionine biosynthesis. Purification and 
characterization of betaine:homocysteine S-methyltransferase, 257, 14944-14948. 
(18) Ericson, L. E. Acta Chemica Scandinavica 1960, Betaine-homocysteine methyltransferases. 
I. Distribution in nature, 14, 2102-2112. 
(19) Tallan, H. H.; Cohen, P. A. Biochemical Medicine 1976, Methionine adenosyltransferase: 
kinetic properties of human and rat liver enzymes, 16, 234-250. 
(20) Meskys, R.; Harris, R. J.; Casaite, V.; Basran, J.; Scrutton, N. S. European Journal of 
Biochemistry 2001, Organization of the genes involved in dimethylglycine and sarcosine 
degradation in Artherobacter spp. Implications for glycine betaine catabolism, 268, 3390-
3398. 
  
Chapter 5 
 
Alternative Methyl Donors with BHMT 
 
 
 
That which has always been accepted by everyone, everywhere, is almost certain to be false. 
- Paul Valery 
 
It is a very sad thing that nowadays there is so little useless information. 
-     Oscar Wilde 
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CHAPTER 5: 
Alternative Methyl Donors with BHMT 
 
 
5.1 Methyl Donors in BHMT 
The role of betaines in homocysteine metabolism is well described, but their 
mechanism of action is poorly understood.  BHMT is the only known enzyme which is capable 
of demethylating glycine betaine.  The fate of the DMG produced in this reaction is also well 
known in mammals; it is either excreted in the urine, or it is further demethylated to sarcosine, 
producing methylene-tetrahydrofolate (THF).1  The sarcosine has a similar metabolic fate, being 
excreted, or further demethylated into glycine, forming another molecule of THF.2  THF can also 
be used as a methyl donor, remethylating homocysteine into methionine via the enzyme 
methionine synthase. 
It is known that the same transporter proteins that control glycine betaine 
concentration are also capable of transporting betaine analogues, such as arsenobetaine,3 
DMSP,4 DMT,5 trigonelline and proline betaine6-8 (albeit in micro-organisms).  The role of 
betaine analogues in BHMT activity and control has not been fully explored, except for a short 
paper by Ericson in 1960, in which he uses partially purified porcine liver BHMT, and exposes it 
to D,L-homocysteine and a variety of betaine analogues.9 
Exposing enzymes to a number of substrate analogues and inhibitors is a powerful 
technique for getting information about the binding site of the enzyme.  Ericson’s experiment 
showed that a wide array of glycine betaine analogues were capable of transferring a methyl 
group to homocysteine, using microbiological detection of methionine to quantify the activity, 
after incubation for several hours.10  The nitroprusside reaction was unsuitable for these 
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experiments, because it was found to give false positive measurements; some of the betaines 
would interfere with the formation of the coloured complex.  The microbiological technique 
described by Ericson is not generally suitable, because it is not necessarily selective for 
methionine production and also because the growth of bacteria in the presence of trace, or 
low levels, of methionine is not linear.  This means that any low levels of activity seen by 
Ericson are likely to actually reflect a much lower BHMT activity than reported.  Furthermore, 
there is no guarantee that Ericson actually measures methionine, as there is no way of 
ensuring that some bacterial enzyme is not breaking down the substrates present in the 
reaction mixture and producing the results he records. 
Ericson’s results shows that porcine liver BHMT is sensitive to α-substitution, increased 
chain length in the betaine (between the tert-amine moiety and the carboxylic acid) and 
substitution on the cationic centre.  Substitution of the carboxylic acid moiety on glycine 
betaine for a carboxy-methyl ester, a carboxy-ethyl ester, or nitrile moeity retained some 
function (while lowering activity), but substitution of an amide moiety gave no activity at all.  
He did get traces of activity (13% vs glycine betaine) when the α-methyl glycine betaine 
(alanine betaine) was incubated with BHMT. 
Ericson’s explanation for the decreased activity of alanine betaine was steric 
hindrance.  He retested the same betaine in a ‘swan mussel’ (Anodonta cygnea, a freshwater 
bivalve mollusc which is relatively common in Britain) methyl transferase, and obtained a 45% 
activity following the same incubation period and conditions as before.  He could not exclude 
the possibility that there were multiple methyltransferases in the mussel, which were 
contributing to a much higher activity with alanine betaine compared with porcine liver BHMT.  
However, the activity in the mussel was still significantly less than for glycine betaine alone.  
He did exclude the possibility of different BHMT/betaine ratios giving the anomalous results by 
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adding more alanine betaine to the porcine liver and getting no appreciable increase in 
activity. 
Ericson also found that several betaines were inhibitors, including ergothionine (2-(2-
mercapto-1H-imidazol-5-yl)-2-(trimethylammonio) acetate, structure shown below in Section 
5.1.3) which was the first time this had been described.  Ergothionine is a metabolite which is 
accumulated in the mammalian liver and red blood cells, but is of unknown function.  He 
proposed that the three methyl groups located on the quaternary amine moeity in ergothionine 
might be good alkylating agents for homocysteine in BHMT, instead finding ergothionine to be 
a potent inhibitor, obtaining no activity when a ½ molar equivalent of glycine betaine was 
added to the reaction mixture. 
Ericson’s results for chain length indicated that, when an amine moeity was acting as 
the alkylating agent in BHMT, any increase in chain length (from glycine betaine to 
propiobetaine, butyrobetaine, and valerobetaine; structure shown below in Section 5.1.3) 
would yield no methionine. DMT was highly active, as was DMSP, and S-methyl methionine, 
each increasing in chain length by one carbon, respectively, DMT being the most active (1300 
‘units’) versus 850 ‘units’ for DMSP, 1200 ‘units’ for S-methyl methionine and 100 ‘units’ 
glycine betaine.  In each case, the transfer of methyl groups from the thetins was inhibited by 
glycine betaine. 
While these results are useful indicators of activity for further investigation, the use of 
microbiological assays should be treated with caution, because the rate of bacterial growth 
may not be linear at extremely low levels of activity, bacterial metabolism may lead to 
methionine production from a reaction which is not BHMT and the activity is not directly 
measured (except in the case of BHMT transformed methionine auxotrophs such as J5-3).11  
Nakajima, while working on fish analogues of BHMT from fish species, and using the 
nitroprusside reaction to quantify BHMT activity, found that DMSP gave more activity than 
Chapter 5 – Alternative Methyl Donors in BHMT 
114 
DMT and glycine betaine, in contrast to all other reported findings.12  Furthermore, he reported 
activity from choline, dimethylsulfoxide and dimethylsulfone, which have been otherwise 
reported to be inactive in mammalian BHMT.12  He also repeated these experiments on bovine, 
rat and chicken liver extracts, finding activity in all these samples, in comparable levels to the 
fish livers.  All of Nakajima’s experiments are conducted on crude extracts from livers, and 
there is likely to be metabolites present in the enzyme reactions which may give false positive 
readings.  It is also possible that the BHMT activity Nakajima reported was actually a result of 
choline oxidation in the liver extracts he was using. 
There have been other attempts to explore and describe the binding site of BHMT.  
Awad et al described a sulfur-alkylated homocysteine analogue (S-carboxybutyl L-
homocysteine, CBH) which they suggest mimics the transition state of the BHMT reaction.13  
This model was the first to actually describe the reaction mechanism of BHMT, as one of direct 
methyl transfer between glycine betaine and zinc-bound homocysteine.  The assays Awad and 
Skiba et al used for the CBH work were human liver BHMT extracts, and they used the 
radiochemical assay with 13C-labelled glycine betaine; an assay technique which is much more 
specific for BHMT activity.13,14  More recent work by Jiracek et al in synthesising BHMT inhibitors 
revealed structures similar to CBH as potent inhibitors, with IC50 values in the low μM 
concentration range.15  Their work has been conducted on recombinant human BHMT, which 
may have a different quaternary structure to purified liver BHMT [Chapter 2], but they also 
used the radiochemical assay.  The only other inhibitor which has been described is a boronic 
acid derivative of glycine betaine, which was tested on a rat liver BHMT using an HPLC 
technique, and which uses o-phthalaldehyde to derivatise methionine to detect it.16 
The only technique developed which is able to accurately measure the levels of activity 
unambiguously over all these betaine analogues, is the NMR spectroscopic assay described in 
Chapter 4.  The microbiological assay will detect low levels of activity, but might not be linear 
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at low levels of BHMT activity, and so will not accurately quantify the initial velocity.  
Radiochemical assays require significant chemical research to develop synthetic strategies 
which will introduce radioactive methyl groups to the betaine analogues.  Furthermore, the 
risks involved when handling radioactive substrates lead to them being avoided wherever 
possible.  Inhibition studies would still be possible, using radioactive glycine betaine.  The 
HPLC assay would require the development of fluorescent tags which would allow detection of 
the betaine analogues after the assay is completed, and the colorimetric assay may give false 
positive results, if the betaine analogue (particularly the sulfur analogues) reacts with 
nitroprusside.  The NMR spectroscopic assay does not suffer from any of these problems.  
Furthermore, the NMR spectroscopic assay is the only assay technique that can continuously 
monitor the kinetics of the BHMT catalysed reaction. 
The only research which has probed the binding of glycine betaine has been the IF 
work by Castro et al.17  In this important paper, Castro and co-workers showed that there is no 
betaine binding to BHMT without the presence of homocysteine, that betaine and DMG did 
not bind to BHMT if methionine is present, and discovered two residues which appear to report 
the binding of glycine betaine (Trp-342 and 352 from the neighbouring BHMT subunit).  These 
findings imply that there is a binding pocket for glycine betaine, but that this pocket is not 
available to glycine betaine until homocysteine has bound, perhaps through a conformational 
change.  Trp-44 is known to be involved in betaine binding to BHMT from crystal structure 
observations of CBH-BHMT complexes.18  It is also possible that the zinc-bound homocysteine 
forms a distinct part of the betaine binding site, and that the electron rich zinc-bound sulfur of 
homocysteine stabilises the partial positive charge on the methyl groups of glycine betaine. 
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5.1.1 Introduction 
 The potential for CVD drugs which use BHMT to lower circulating homocysteine (in the 
same way as folic acid, vitamin B12 and glycine betaine are prescribed now) makes the 
investigation of methyl donors in BHMT an attractive prospect.  Glycine betaine is limited in its 
capacity to lower homocysteine, partially because the BHMT gene is controlled by betaine and 
methionine concentrations,19-23 because glycine betaine is subject to strong homeostasis,8,24-26 
self regulation by product inhibition via DMG,17,27 and creates more methionine, which is 
converted via methylation reactions back into homocysteine.28,29  These concepts are more fully 
explored in Chapter 7, Section 7.1.2.  Alternative betaines may further reduce circulating 
homocysteine by not affecting the BHMT gene, and not producing DMG to inhibit BHMT 
activity.  However, as Ericson discovered in 1960, mammalian liver BHMT is not active with all 
betaine analogues.9  His experiments revealed that the active site of BHMT may be more 
discriminating than first thought (after it was found to work on DMT, DMSP and glycine 
betaine).  A large library of betaine analogues was produced by Kelly Randal, a previous Ph.D. 
student in the Osmolyte Research group at Canterbury Health Laboratories, which provides a 
useful start to explore possible substrates and inhibitors of rat liver BHMT.  Furthermore, the 
NMR spectroscopic assay is an ideal tool for the analysis of these betaine analogues, because 
the assay is simply adapted for use on these analogues and requires no special synthesis of 13C 
labelled betaine analogues.  Furthermore, it provides quantitative measurements quickly and 
simply which are directly related to BHMT activity, unlike the microbiological assay. 
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5.1.2 Method 
5.1.2.1 Materials  
Glycine betaine monohydrate, its demethylated product DMG, trigonelline 
hydrochloride and homocysteine thiolactone were purchased from Sigma (St Louis, U.S.A).   
 
5.1.2.2 Synthesis of Betaines 
 Arsenobetaine ((carboxymethyl)trimethylarsonium bromide): 
Trimethylarsine (0.5 mL, 1.124 g/mL, 4.68 x10-3 moles) was dissolved under an inert 
argon atmosphere in toluene (5 mL).  The solution was stirred and cooled on ice.  Bromoacetic 
acid was recrystalised from a hot solution in hexanes and was dried in vacuo.  One mole 
equivalent of the recrystalised bromoacetic acid (0.66 g, 4.54 x10-3 moles) was dissolved in a 
further 5 mL of toluene and added dropwise to the stirred solution of trimethylarsine.  A white 
precipitate was formed over the period of one minute, and the reaction was allowed to stir at 
room temperature for 16 h.  The white solid was collected and dried in vacuo.  
Yield: 0.965 g, 82%. 
1H-NMR (500 MHz, D2O): δ 1.77 (s, 9H, (CH3)3-As+), 3.21 (s, 2H, CH2-As+) 
 
Phosphoniobetaine ((carboxymethyl)trimethylphosphonium bromide): 
Bromoacetic acid (1.365 g, 9.84 x10-3 moles) was dissolved in dichloromethane 
(10 mL), under an inert argon atmosphere and cooled with stirring over ice.  
Trimethylphosphine (1 g, 0.748 g/mL, 9.83 x10-3 moles) was added drop-wise to the stirred 
solution and stirred at room temperature for 16 h.  A white precipitate was formed and 
purified by washing with dichloromethane, and dried in vacuo. 
Yield: 0.604 g, 28.6%. 
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1H-NMR (500 MHz, D2O): δ 1.87 (s, 9H, (CH3)3-P+), 3.44 (s, 2H, CH2-P+) 
 
Selenobetaine ((carboxymethyl)dimethylselenonium bromide): 
Bromoacetic acid (1.806 g, 0.0130 moles) was dissolved in dichloromethane (10 mL) 
and cooled on ice under an inert argon atmosphere. Dimethylselenide (1 mL, 1.4077 g, 
0.013 moles) was dissolved in a further 10 mL dichloromethane and added drop-wise to the 
bromoacetic acid solution, with constant stirring.  The reaction mixture was allowed to warm 
to room temperature, and stirred for 15 h.  The white precipitate was separated, washed with 
10 mL dichloromethane and dried in vacuuo. 
Yield: 2.374 g, 73% 
1H-NMR (500 MHz, D2O): δ 2.66 (s, 6H, (CH3)3-Se+), 4.10 (s, 2H, CH2- Se +) 
 
Dimethylselenopropanoate ((2-carboxyethyl)dimethylselenonium bromide)30: 
Acrylic acid (5 mL, 5.255 g, 0.073 moles) was dissolved in ice cooled dichloromethane 
(50 mL).  HCl gas was generated by the reaction of sulfuric acid and ammonium chloride, and 
bubbled into the solution.  Dimethylselenide (5.6 mL, 7.951 g, 0.073 moles) was dissolved in 
ice cooled dichloromethane (20 mL) and introduced to the acrylic acid solution drop-wise, with 
the bubbling HCl gas.  A white solid was formed almost instantly, and the solution was 
allowed to stir for 24 h at room temperature.  The white solid was collected, washed with 10 
mL dichloromethane and dried in vacuo. 
Yield: 7.565 g, 47,6% 
1H-NMR (500 MHz, D2O): δ 2.68 (s, 6H, (CH3)3-Se+), 3.97 (t, 2H, CH2-Se +), 3.45 (t, 2H, 
CH2-COO
-) 
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5.1.2.3 Preparation of Substrates 
Homocysteine was prepared for the assay using the method of Duerre and Miller.31  
Homocysteine thiolactone (0.7 mg) was dissolved in 2 M NaOH (0.4 mL), incubated for 5 min, 
then neutralized with saturated KH2PO4 (0.6 mL). 
 Betaine solutions were prepared to 10 mM in potassium phosphate buffer (20 mM, 
pH= 7.5).  When mixed with the final incubation mixture, the betaine concentration was 
2 mM. 
 
5.1.2.4 1H-NMR Spectroscopic Assay 
All 1H-NMR spectra were recorded on a Varian INOVA 500 spectrometer, at 23 °C in 
5 mm NMR tubes with a 3 mm D2O lock insert.  Spectra were recorded as previously described, 
using presaturation to suppress the water resonance. 
 
5.1.2.5 Enzyme Assay 
 For each alternative substrate, three separate tubes were prepared.  Each tube 
contained 100 μL of homocysteine solution, 100 μL of potassium phosphate buffer (20 mM, 
pH = 7.5), 100 μL of potassium phosphate buffer (20 mM, pH = 7.5) containing tert-butanol 
at 25 mM.  One tube contained 100 μL of 10 mM alternative betaine solution and 100 μL of 
potassium phosphate buffer (20 mM, pH = 7.5), the second tube contained 100 μL of 10 mM 
alternative betaine and 100 μL of 10 mM glycine betaine, the third tube contained 100 μL of 
10 mM glycine betaine and 100 μL of potassium phosphate buffer (20 mM, pH = 7.5).  
Activity was expressed as a ratio of integrals to tert-butanol (integral = 100), which had been 
shown to not inhibit BHMT. 
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5.1.3 Results 
 The results are reported as an average of the three replicates.  For the activity, the 
initial integral of the betaine analogue is reported and the integral of the predicted 
demethylated product and methionine at 24 h also reported.   
 For inhibition, the DMG and methionine integrals are given as an index of methyl 
transfer from glycine betaine to homocysteine in the presence of the betaine analogue, 
recorded at t = 1 h (data not shown below) and t = 24 h. 
5.1.3.1 Activity Studies 
 The results from this section reflect the tubes which contained either glycine betaine 
alone, or betaine analogue alone, and were designed to show any production of methionine in 
the absence of glycine betaine as a methyl donor.  There were two measurements used to 
determine activity, being the production of methionine, and the production of the 
demethylated betaine analogue.  Betaines which, when incubated with homocysteine and 
BHMT, produced methionine and a dimethylglycine analogue were assumed to be substrates of 
BHMT.  The tables below show the methionine and demethylated betaine analogue integrals 
(where present) after 24 h incubation at 37 °C. 
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5.1.3.1.1 Chain Length 
Table 5.1 The effect of chain length on activity in rat liver BHMT.  Activity is measured by the 
production of methionine and any demethylated betaine analogue after 24 h of incubation at 37 °C. 
 
Betaine Analogue 
Name 
Betaine Structure Betaine 
Analogue 
Integral  
(t = 0 h) 
Demethylated 
Product Integral 
(t = 24 h) 
Methionine 
Integral 
(t = 24 h) 
Glycine Betaine 
N+ CO2-
 
46.8 7.5 5.2 
Propiobetaine 
N+
CO2-
 
40.7 0 0 
Butyrobetaine 
N+ CO2-
 
49.4 0 0 
Valerobetaine 
N+
CO2-
 
50.2 0 0 
Caprobetaine 
N+ CO2-
 
54.1 0 0 
Trimethylsulfonium S
 
32.3 0 5.7 
Dimethylthetin S+ CO2-
 
29.4 19.3 11.4 
Dimethylsulfonio- 
propionate S
+
CO2-
 
26.7 16.7 3.8 
Dimethylseleno- 
betaine 
Se+ CO2-
 
15.7 11.0 19.4 
Dimethylseleno- 
propionate Se
+
CO2-
 
13.8 7.7 16. 7 
 
In accordance with Ericson’s analysis,9 when nitrogen was the heteroatom in the 
methyl donor, any increase in chain length resulted in no activity, while seleno- and sulfonio- 
betaines retained activity from aceto-thetins to propio-thetins (it is important to note that the 
thetin demethylated products measured above are likely to be complicated by the presence of 
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methionine peaks below them one of the methylene multiplets from methionine co-resonates 
with both methylthioacetate and methylthiopropiobetaine). 
 Trimethylsulfonium presented an interesting problem, in that there was no identifiable 
demethylated product of dimethylsulfide, or dimethylsulfoxide, only methionine and unreacted 
trimethylsulfonium.  While it is unknown why no discernable demethylated product was 
observed, it is clear that trimethylsulfonium were capable of acting as a substrate of BHMT. 
 
5.1.3.1.2 Heteroatom Moiety 
Table 5.2 The effect of substitution of the nitrogen cationic centre in glycine betaine with another 
heteroatom on activity in rat liver BHMT.  Activity was measured by the production of methionine and 
any demethylated betaine analogue after 24 h of incubation at 37 °C. 
 
Betaine Analogue 
Name 
Betaine Structure Betaine 
Analogue 
Integral  
(t = 0 h) 
Demethylated 
Product Integral 
(t = 24 h) 
Methionine 
Integral 
(t = 24 h) 
Glycine Betaine 
N+ CO2-
 
46.9 7.4 5.5 
Phosphoniobetaine 
P+ CO2-
 
48.0 0 0 
Arsenobetaine 
As+ CO2-
 
52.8 0 0 
Dimethylthetin S+ CO2-
 
36.5 19.3 11.4 
Selenobetaine Se+ CO2-
 
15.7 11.0 19.4 
 
 There was a clear difference in activity when the heteroatom moiety was changed.  
The group V heteroatom betaines did not transfer methyl groups if they were heavier than 
nitrogen, however the group VI heteroatoms did.  It is worth noting that oxonium compounds 
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are used in organic synthesis and are powerful alkylating agents.  There was no ‘oxonium’ 
betaine made, however, because it would not be stable in an aqueous environment. 
 
5.1.3.1.3 α-Substitution 
Out of the five α substituted glycine betaine analogues (L-Alanine Betaine, D-Serine 
Betaine, D-Alanine Betaine, D,L-Valine Betaine, and D,L-Phenylalanine Betaine), none showed 
any methionine production, or formation of demethylated products.  These 1H-NMR 
spectroscopic results confirmed Ericson’s results, in that any α-substitution in the betaine 
results in no activity.  The work of Ericson was expanded to include stereospecific substitutions, 
but neither D or L alanine betaine, or D,L-valine betaine retained any activity with rat liver 
BHMT. 
 
5.1.3.1.4 N-Substitution 
 Substitution on the quaternary amine moiety gave a loss of activity, possibly from steric 
interference, blocking the attack of homocysteine onto the methyl group.  This is in contrast to 
Ericson’s finding, in which there was some methyl transfer from N-ethyl, N,N-dimethyl betaine.  
The seven betaines tested were N-phenyl, N,N-dimethyl glycine; diethanol-thetin; triethanol 
betaine; tri-ethyl betaine; N,N-diethyl, N-methyl glycine; N-ethyl, N,N-dimethyl glycine; N,N-
dimethyl, N-isopropyl glycine. 
 
5.1.3.1.5 Naturally Occurring Betaine Analogues 
 In accordance with Ericson’s results,9 no activity was obtained from six of the other 
naturally occurring betaines which could potentially be found within the liver and could act as 
substrates (trigonelline, proline betaine, ectoine, betonicine, ergothionine and L-carnitine), 
although Ericson obtained traces of activity of methylation from ergothionine and L-carnitine 
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while the NMR spectroscopic assay detected none.  There was activity from 10 mM S-methyl 
methionine, which produced 2.0 units of methionine in the absence of glycine betaine.   Also, 
Garrow et al have detected traces of methylation from proline betaine in their in vivo bacterial 
assay.11  There is no detectable methyl transfer from any of these betaines in the NMR 
spectroscopic assay. 
 
5.1.3.1.6 Substitution of Carboxylic Acid  
Table 5.3 The effect of substitution of the carboxylate moiety in glycine betaine for activity with 
rat liver BHMT.  Activity was measured by the production of methionine and any demethylated betaine 
analogue after 24 h of incubation at 37 °C. 
 
Betaine Analogue 
Name 
Betaine Structure Betaine 
Analogue 
Integral  
(t = 0 h) 
Demethylated 
Product Integral 
(t = 24 h) 
Methionine 
Integral 
(t = 24 h) 
Glycine Betaine 
N+ CO2-
 
46.8 7.5 5.2 
Phosphonic Acid 
Betaine N+ PO3H-
 
298 1.2 2.0 
Sulfonic Acid 
Betaine N+ SO3-
 
448 0 2.2 
 
 As a consequence of the small quantities of sample available, only one experiment 
could be completed, and the necessary precursors for the synthesis of more analogues were 
not available.  For these reasons, 10 mM phosphonic acid betaine and 15 mM sulfonic acid 
betaine were incubated with the BHMT solution, to ensure that any potential activity would be 
observed (all other conditions: homocysteine concentration, pH, etc, remained the same). 
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5.1.3.2 Inhibition/Allosteric Effects 
 These results compare the tubes which contained the betaine analogue of interest and 
glycine betaine after incubation.  For these tubes, the levels of glycine betaine activity were 
compared.  The results below reflect the glycine betaine integral at 24 h, as well as the 
methionine and DMG produced after 24 h.  These were then compared to the integrals 
resulting from glycine betaine incubated in the absence of betaine analogue. 
 
5.1.3.2.1 Chain Length 
Table 5.4 The effect of chain length on glycine betaine activity in rat liver BHMT.  Inhibition was 
measured by the production of DMG and methionine, compared to glycine betaine control after 24 h of 
incubation at 37 °C. 
 
Betaine 
Analogue Name 
Glycine 
Betaine 
Integral  
(t = 24 h) 
DMG Integral  
(t = 24 h) 
Methionine 
Integral 
(t = 24 h) 
% Inhibition 
Glycine Betaine 45.9 3.6 1.8 0 
Propiobetaine 43.7 3.8 2.0 0 
Butyrobetaine 44.2 3.7 1.9 0 
Valerobetaine 44.3 3.3 2.1 0 
Caprobetaine 44.8 3.1 2.0 0 
Dimethylthetin 43.3 Uncertain; DMT 
and DMG co-
resonant 
8.3 Competitive 
Substrate 
Dimethylsulfonio- 
propionate 
45.5 Uncertain; DMSP 
and DMG co-
resonant 
4.0 Competitive 
Substrate 
Dimethylseleno- 
betaine 
47.8 0 24.9 100 
 
Dimethylseleno- 
propionate 
49.3 Uncertain; 
DMSeP and DMG 
co-resonant 
16.6 Competitive 
Substrate 
 
 The analyses presented here support and expand the findings given in Section 5.1.3.1 
(the activity studies), that these betaines were not binding or fitting into the active site of 
BHMT.  There was no apparent inhibition from any of the nitrogenous betaines with extended 
chain length.  Furthermore, the betaines which showed rapid reaction led to greater production 
Chapter 5 – Alternative Methyl Donors in BHMT 
126 
of methionine.  While these studies are not able to provide kinetic results, it is clear that the 
BHMT-active betaine analogues are competing for the same active site as glycine betaine.  
Furthermore, the seleno-betaine was so efficient at methylation that it did not allow for any 
methylation from glycine betaine, as it kinetically out-competed glycine betaine for BHMT. 
 
5.1.3.2.2 Heteroatom Moiety 
Table 5.5 The effect of substitution of the nitrogenous cationic centre of glycine betaine with an 
alternative heteroatom on glycine betaine activity in rat liver BHMT.  Inhibition was measured by the 
production of DMG and methionine (compared to glycine betaine control) after 24 h of incubation at 37 
°C. 
 
Betaine Analogue 
Name 
Glycine 
Betaine 
Integral  
(t = 24 h) 
DMG Integral  
(t = 24 h) 
Methionine 
Integral 
(t = 24 h) 
% Inhibition 
Glycine betaine 46.8 7.5 5.2  
Phosphoniobetaine 48.4 7.4 5.0 0 
Arsenobetaine 52.8 7.8 4.8 0 
Dimethylthetin 43.3 Uncertain; DMT 
and DMG co-
resonant 
8.3 Competitive 
Substrate 
Selenobetaine 47.8 0 24.9 100 
 
 The results for hetero-atom substitution corroborated the results from the activity 
studies in that the betaines that were not substrates were not acting as significant inhibitors.  
This implied that they were not binding in the active site, or that if they were binding, they 
were being easily displaced by glycine betaine. 
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5.1.3.2.3 α-Substitution 
Table 5.6 The effect of substitution on the α-carbon of glycine betaine with larger side-chains on 
glycine betaine activity in rat liver BHMT.  Inhibition was measured by the production of DMG and 
methionine, compared to glycine betaine control, after 24 h of incubation at 37 °C. (* = Statistically 
significant difference compared to glycine betaine, p<0.05). 
 
Betaine Analogue 
Name 
Betaine Structure Glycine 
Betaine 
Integral  
(t = 24) 
DMG Integral 
(t = 24 h) 
Methionine 
Integral 
(t = 24 h) 
% 
Inhibition 
Glycine Betaine 
N+ CO2-
 
42.9 7.3 4.9  
L-Alanine Betaine 
N+ CO2-
 
40.2 6.3 4.4 0 
D-Alanine Betaine 
N+ CO2-
 
38.8 6.9 5.1 0 
D-Serine Betaine 
N+ CO2-
OH
 
40.2 7.2 5.2 0 
D,L-Valine Betaine 
N+ CO2-
 
42.2 6.9 4.9 0 
D,L-Phenylalanine 
Betaine 
N+ CO2-
 
42.3 8.8* 6.3* 0 
 
Evidence of 
Allosteric 
Affector 
 
 The results for α-substituted betaines imply that alanine, serine and valine betaine 
were not acting as inhibitors, potentially because they were not binding to the enzyme.  
Phenylalanine betaine did provide an interesting result, in that it was not active as a 
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methylating agent (see section 5.1.3.1.3, above) but appeared to produce elevated 
methionine and DMG from glycine betaine. 
 
5.1.3.2.3 N-substitution 
Table 5.7 The effect of substitution of the methyl groups on the nitrogenous cationic centre of glycine 
betaine with larger side-chains on glycine betaine activity in rat liver BHMT.  Inhibition was measured 
by the production of DMG and methionine, compared to glycine betaine control, after 24 h of 
incubation at 37 °C. 
 
Betaine 
Analogue Name 
Betaine Structure Glycine 
Betaine 
Integral  
(t = 24 h) 
DMG 
Integral  
(t = 24 
h) 
Methionine 
Integral 
(t = 24 h) 
% 
Inhibition
Glycine Betaine 
N+ CO2-
 
46.8 7.4 5.0  
N-Phenyl, N,N-
dimethyl glycine 
N+ CO2-
 
19.5 7.0 4.9 0 
Diethanol-thetin S+HO
HO
CO2-
 
15.7 (CH2) 7.5 5.2 0 
Tri-ethanol 
betaine 
N+ CO2-
HO
HO
HO
 
22.4  
(N-CH2-) 
7.0 5.2 0 
Tri-ethyl betaine 
N+ CO2-
 
37.5 (CH3) 7.3 4.9 0 
N,N-diethyl, N-
methyl glycine 
N+ CO2-
 
13.3 
(N-CH3) 
7.7 5.0 0 
N-ethyl, N,N-
dimethyl glycine 
N+ CO2-
 
24.7  
(N-CH3) 
7.4 4.9 0 
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N,N-dimethyl, 
N-isopropyl 
glycine N+ CO2-
 
14.7  
(N-CH3) 
7.6 4.8 0 
 
 Substitution of methyl groups on nitrogen with other, larger groups resulted in betaine 
analogues which did not appear to inhibit BHMT.  This was in contrast to Ericson’s findings,9 
which reveal some inhibition from triethyl-betaine and N,N-dimethyl, N-ethyl glycine betaine, 
although Ericson did not have the wide range of betaines available in the present work. 
 
5.1.3.2.4 Naturally occurring betaine analogues 
Table 5.8 The effect of naturally occurring betaine analogues on glycine betaine activity in rat liver 
BHMT.  Inhibition was measured by the production of DMG and methionine (compared to glycine 
betaine control) after 24 h of incubation at 37 °C. (* = statistically significant difference compared to 
glycine betaine, p<0.05, §S-methyl-methionine was at 10 mM, glycine betaine and homocysteine were 
both at 2 mM). 
 
Betaine 
Analogue Name 
Betaine Structure Glycine 
Betaine 
Integral 
(t = 24) 
DMG 
Integral  
(t = 24 h) 
Methionine 
Integral 
(t = 24 h) 
% 
Inhibition
Glycine Betaine 
N+ CO2-
 
46.7 6.4 4.4  
Trigonelline 
N+
CO2-
 
44.3 5.7 3.9 0 
Proline Betaine 
N+
CO2-
 
42.6 6.1 4.5 0 
Ectoine +HN
N
H CO2
-
 
45.2 7.3* 6.0* 0 
Evidence 
of 
Allosteric 
Affector 
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Betonicine 
N+
HO
CO2-
 
44.4 6.7 4.0 0 
Ergothionine CO2-
NHN
H
N
S
45.6 5.7 4.2 0 
L-Carnitine 
CO2-
OH
N+
 
44.0 5.9 3.8 0 
S-methyl-
methionine§ CO2-S+
NH3+  
45.1 5.8 4.4 0 
 
 There appears to be no evidence that any of the naturally occurring betaines 
investigated above were acting as inhibitors of rat liver BHMT.  The same effect that was 
observed with phenylalanine betaine was seen with ectoine.  It did not act as a substrate, but 
appeared to activate methylation from glycine betaine, giving elevated DMG and methionine (p 
< 0.05, n = 3).   
 Oligomerisation is required for mammalian BHMT activity.  Garrow et al have shown, 
using site-directed mutagenesis, that oligomerisation is required for stability of BHMT and also 
for catalytic activity.32  Furthermore, a crystal structure resolved by Gonzalez et al established 
conformational changes upon substrate binding and release from the enzyme.33  The binding of 
ectoine and phenylalanine betaine to the active site of one BHMT subunit may induce 
conformational changes in BHMT, resulting in more efficient methylation in the other active 
site(s).  This hypothesis could be explored further with solution-state NMR studies, 
investigating diffusion of substrates into and out of the active site, and their effect on the large 
scale conformation on the BHMT structure.   
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5.2 Discussion 
 The initial integrals for glycine betaine and the betaine analogues varied between 
experiments for several reasons.  In the case of the sulfonic acid and phosphonic acid 
analogues, there was so little available that accurate weight measurements were difficult.  
There is some inter-batch variation in the concentration of glycine betaine from the volume of 
samples investigated, which was minimised through replication of the experiments.  Thetins, 
seleno-betaines and some of the other analogues also have reduced numbers of methyl 
groups, leading to reduced integral figures.  Also, the solution behaviour of the betaines is 
likely to differ, and betaines are known to be excellent kosmotropes, which is likely to alter 
their hydration and also their NMR behaviour.34,35 
 The heteroatom substitution result was initially confusing, in that substitution of 
heavier hetero-atoms would result in an inactive betaine when in the group V elements, but 
would result in faster kinetics when in the group VI elements.  To explain this result, molecular 
modelling of the nitrogen, arsenic, phosphorus, sulfur and selenium betaines was carried out 
by Dr Robert Maclagan in the Department of Chemistry, University of Canterbury. 
 To model the thermodynamics of the methyl transfer, ab initio electronic structure 
calculations of the N-CH3 and N-H bonds in the gas phase were compiled.  The same 
calculations were repeated with substitution of the nitrogen with phosphorus, arsenic, sulfur 
and selenium to compare the expected thermodynamics of the reactions. 
 Three separate methylation reactions were modelled at B3LYP/6-31G*, MP2(FU) and 
G2/(MP2) levels of theory, incorporating vibrational and thermal corrections, scaled using 
scaling factors from the CCBDB database36 and the GUASSIAN program.  The reactions 
modelled were (where Z = heteroatom in the betaine being studied): 
 CH3Z  +  H  →  HZ  +  CH3  Equation 5.1 
 CH3Z  +  CH4  →  HZ  +  C2H6  Equation 5.2 
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 CH3Z + HS(CH3)  →  HZ  +  S(CH3)2  Equation 5.3 
 CH3Z  +  H
+  →  HZ  + CH3
+  Equation 5.4 
  
 Equations 5.1 and 5.2 are designed to model a simple radical type of transfer 
between the betaine in question and the homocysteine; essentially a concerted attack from 
homocysteine resulting in a bond breakage between the methyl group and the heteroatom.  
Equation 5.3 is designed to better model the transfer to a thiol species.  Equation 5.4 is 
designed to model the methyl group leaving the betaine as a carbocation, resulting in a free 
methyl cation which the homocysteine sulfur can then attack.  The reaction energies are 
calculated for Internal Energy (ΔU, O K, kJ mol-1) and Enthalpy Change (ΔH, 298 K, kJ mol-1).  
The results of these calculations are summarised in Tables 5.9, 5.10, 5.11 and 5.12 below. 
 
Table 5.9: Equation 5.1 calculation results, ΔU and ΔH for various betaines as they transfer a methyl 
radical group to a hydrogen atom. 
 ΔU (kJ mol-1) ΔH (kJ mol-1 
Betaine (CH3Z) B3LYP/6-31G* MP2=FU/6-31G* G2 (MP2) G2 (MP2) 
(CH3)3N
+CH2CO2
- -68.1 -8.6 -51.8 -49.5 
(CH3)3P
+CH2CO2
- -40.3 +25.2 -15.5 -15.3 
(CH3)3As
+CH2CO2
- -25.3 +38.3 -16.7 -16.8 
(CH3)2S
+CH2CO2
- -203.7 -158.5 -183.9 -182.7 
(CH3)2S
+CH2 CH2CO2
- -204.2 -151.9   
(CH3)2Se
+CH2CO2
- -177.1 -133.2 -191.2 -190.3 
(CH3)4N
+ -58.1 +0.4 -42.5 -40.0 
(CH3)3S
+ -8.2 +45.7 +1.8 +2.9 
 
Table 5.10: Equation 5.2 calculation results, ΔU and ΔH for various betaines as they transfer a 
methyl radical group to a methane group. 
 ΔU (kJ mol-1) ΔH (kJ mol-1 
Betaine (CH3Z) B3LYP/6-31G* MP2=FU/6-31G* G2 (MP2) G2 (MP2) 
(CH3)3N
+CH2CO2
- +0.6 +14.5 +21.9 +11.8 
(CH3)3P
+CH2CO2
- +28.4 +48.2 +49.2 +46.0 
(CH3)3As
+CH2CO2
- +43.4 +38.3 +48.0 +44.5 
(CH3)2S
+CH2CO2
- -135.0 -158.5 -119.2 -121.4 
(CH3)2S
+CH2 CH2CO2
- -135.5 -151.9   
(CH3)2Se
+CH2CO2
- -108.4 -133.1 -126.5 -128.9 
(CH3)4N
+ +10.6 +0.5 +22.2 +21.3 
(CH3)3S
+ +60.5 +45.7 +66.5 +64.2 
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Table 5.11: Equation 5.2 calculation results, ΔU and ΔH for various betaines as they transfer a 
methyl radical group to a methane group. 
 ΔU (kJ mol-1) ΔH (kJ mol-1 
Betaine (CH3Z) B3LYP/6-31G* MP2=FU/6-31G* G2 (MP2) G2 (MP2) 
(CH3)3N
+CH2CO2
- -8.6 -2.8 +3.8 +4.4 
(CH3)3P
+CH2CO2
- +19.1 +30.9 +40.1 +38.6 
(CH3)3As
+CH2CO2
- +34.1 +44.0 +38.9 +37.1 
(CH3)2S
+CH2CO2
- -144.3 -152.7 -128.3 -128.6 
(CH3)2S
+CH2 CH2CO2
- -144.8 -146.2   
(CH3)2Se
+CH2CO2
- -177.7 -127.4 -135.6 -136.3 
(CH3)4N
+ +1.3 +6.3 +13.1 +13.9 
(CH3)3S
+ +51.2 +51.5 +57.4 +56.8 
 
Table 5.12: Equation 5.3 calculation results, ΔU and ΔH for various betaines as they transfer a 
methyl carbocation group. 
 ΔU (kJ mol-1) ΔH (kJ mol-1 
Betaine (CH3Z) B3LYP/6-31G* MP2=FU/6-31G* G2 (MP2) G2 (MP2) 
(CH3)4N
+ -427.4 -395.7 -362.9 -361.5 
(CH3)3S
+ -377.5 -350.5 -318.6 -318.6 
 
 The results of these modelling studies reveal that there is a possible thermodynamic 
argument underpinning the results seen experimentally.  The G2(MP2) is the most accurate 
calculation available, with an accuracy of ~10 kJ/mol-1.  Tables 5.9, 5.10 and 5.11 all show 
an energy gap between the nitrogen betaines and the phosphorus/arsenic betaines (both in 
internal energy and enthalpy) which would explain why there is no activity observed for the 
heavier heteroatom betaines (phosponio-, and arsenio- betaines).  While the models suggest 
that there is still an exothermic reaction taking place at G2(MP2) level, the models are only 
approximations, involving gas-phase reactions.  It is likely that in the aqueous phase these 
approximations would be complicated by hydration (betaines are known to be powerful 
kosmotropic agents35) as well as the contribution of BHMT on their activity. 
 More striking is the absence of the same energy ‘jumps’ in the group VI compounds 
(sulfur and selenium).  The calculations reveal that they are expected, under these 
approximations, to give highly exothermic reactions, over three times more exothermic than 
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the glycine betaine reaction.  These results partially explain the increased kinetics seen in the 
enzyme reactions.  
It is important to note initially that tertiary oxonium compounds are exceptional 
alkylating agents, and although there was no ‘oxonium betaine’ tested in the sequences 
above, oxonium ions are well described as powerful agents used in synthetic organic 
chemistry.37  The oxonium betaine could not be tested because it would not be stable in the 
aqueous environment. 
The effect of size on the active site in the enzyme can be explored by calculating the 
molecular dimensions of some of the active and inactive betaines and analogues tested in 
these experiments.  For these calculations, basic MM2 (molecular mechanics 2) calculations 
were used to approximate the betaines size in X, Y and Z components.  This approximate 
calculation was performed on glycine betaine, DMT, DMSP, propiobetaine, alanine betaine, 
phenylalanine betaine and ergothionine [Table 5.13]. 
These results show a clear size and shape difference between the nitrogenous and 
sulfonio betaines, as well as the inactive α-substituted and naturally occurring ergothionine.  
Glycine betaine and DMT are approximately the same size (although glycine betaine is larger: a 
result of an extra methyl group), but DMSP and propiobetaine are quite different in dimensions 
(propiobetaine being larger in two dimensions) while phenylalanine betaine and ergothionine 
are substantially larger again. 
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Table 5.13: Results of MM2 calculations on selected betaines, revealing the approximate size of 
betaines compared. 
Longest Distance (Ǻ) Betaine 
X Y Z 
Glycine betaine 5.5 3.9 3.9 
DMT 5.7 3.9 3.2 
Propiobetaine 7.0 4.1 3.9 
DMSP 7.4 3.5 3.5 
Alanine betaine 4.9 4.9 3.9 
Phenylalanine betaine 5.4 7.7 5.7 
Ergothionine 9.5 4.6 6.0 
 
Combining the size and thermodynamic analyses reveals that both are likely to be 
influencing the substrate specificity of rat-liver BHMT.  Larger betaines are not acting as 
substrates for BHMT because of some steric effect in the active site of the enzyme, revealed by 
the drop in activity from glycine betaine to propiobetaine, and mirrored in the DMT-DMSP 
activities.  These facts also support the hypothesis that some of the larger betaines, particularly 
the naturally occurring betaines like ergothionine and L-carnitine, should not act as substrates 
in the enzyme. 
 When alternative heteroatoms are introduced into the betaine, the thermodynamics, 
and probably the reaction dynamics of the methyl transfer reaction are altered.  The 
thermodynamic calculations above imply that there may well be an alternate mechanism for 
the transfer of methyl groups from glycine betaine and from DMT.  Although these calculations 
hinge on a number of approximations, they strongly suggest the transfer of two electrons from 
the heteroatom-methyl bond to the heteroatom, resulting in a neutral heteroatom moeity.  To 
infer kinetic results would be stretching the model beyond intended limits, since the modelling 
conducted did not predict reaction co-ordinates, but initial and final thermodynamic energies. 
 Arsenobetaine presents an interesting dilemma in that the models suggests it should 
not transfer a methyl group to homocysteine thermodynamically, yet Rhizobium and 
Pseudomonas sp. show clear evidence of methyl transfer.5,38,39  There may be some coupling of 
another thermodynamically favourable reaction to drive this transfer in the species which can 
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demethylate arsenobetaine.  It is also possible that there is some different mechanism for the 
demethylation of arsenobetaine in these species.   
 It is not immediately clear why propiobetaine is not a substrate for BHMT, while DMSP, 
and DMSeP are.  While nitrogen based betaines are not good substrates for BHMT, 
thermodynamically, the sulfur and selenium betaines have much more favourable enthalpies, 
leading to much greater concentrations of methionine after incubation with BHMT and 
homocysteine.  Increasing the chain length from a glycine betaine to a propiobetaine reduces 
activity in nitrogenous betaines to undetectable levels, while the same change in chain length 
decreases both the endpoint activities and the rates for DMSP and DMSeP.  Because of their 
much greater alkylating strength, DMSP and DMSeP still act as substrates, giving higher 
concentrations of methionine.  Propiobetaine does not act as a substrate, possibly because it 
does not form a favourable conformation within the enzyme, which adds to its low 
thermodynamic enthalpy and prevents it being a substrate.   
From these results, a new model of betaine binding might be proposed.  Castro et al 
proposed that there was no betaine binding site for BHMT before homocysteine is bound.17  
This concept developed from the observation of intrinsic tryptophan fluorescence (IF) in the 
presence, and absence of homocysteine, methionine, DMG and glycine betaine and 
combinations thereof, to investigate the mechanism of BHMT.  The observation that there was 
no change in IF spectroscopy from the addition of DMG until homocysteine was previously 
bound lead to the proposal that the homocysteine was critical to the binding of betaine, 
possibly from conformational changes in the protein upon binding of homocysteine.   
This hypothesis might be slightly modified to incorporate the data presented here. The 
methyl donor substrate might be binding only as a transition state.  This would make 
homocysteine a crucial part of betaine binding (incorporating the data presented by Castro et 
al).  Moreover, it allows for the observation that the carboxylate moiety is not required for 
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activity, and why there is activity also reported from thetins and other group VI heteroatom 
substitution.  It might also explain why substitution on the heteroatom from three methyl 
groups would interfere with activity, since this substitution would also interfere with the 
formation of the transition state. 
This reasoning might explain why trimethylsulfonium is a substrate, while 
tetramethylammonium is not; trimethylsulfonium is better stabilised by this homocysteine-zinc 
complex, forming an intermediate which will transfer a methyl group, while 
tetramethylammonium does not.  The betaines all have carboxylate moieties, which will electro 
statically bind to BHMT and then be stabilised by the homocysteine-zinc complex.  It was 
demonstrated by Castro et al that DMG binds poorly to homocysteine saturated BHMT, 
probably because it is not stabilised by the homocysteine-zinc complex.17  This complex 
formation would also be affected by steric crowding at the homocysteine-betaine interface, 
which may explain why some of the betaines presented in Tables 5.4, 5.5, 5.10, and 5.11 
are neither substrates nor inhibitors – they cannot form complexes with the homocysteine-zinc 
complex, and so have weak binding to BHMT. 
This might be explored further by repeating the IF work of Castro et al, but including 
some of the alternative betaines presented in the results above.17  BHMT is a slow enzyme, 
with a turnover rate of 0.8/min, so changes in IF as some of the betaine analogues which lack 
carboxylate functionality, but still are active in BHMT, are incubated with BHMT should give 
clues about the binding of betaines in BHMT. 
This betaine-transition state binding model still allows for some betaines, such as 
ergothionine, to be inactive because of unfavourable steric interference, preventing it from 
reaching the active site of BHMT, although thermodynamic analysis would predict that there 
should be a reaction.  It is still not clear why tetramethylammonium ions are not substrates, 
while trimethylsulfonium ions are able to transfer to homocysteine. 
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The enhanced betaine methylation from glycine betaine in the presence of ectoine and 
phenylalanine betaine was a surprise.  No allosteric affector of BHMT has been described 
previously, and this finding suggests the presence of a possible cofactor for BHMT which has 
not been identified yet.  This hypothesis might also explain the loss of activity from purified rat 
liver BHMT which was observed after anion-exchange chromatography, and also described by 
Lee et al.16  If there is an unidentified cofactor for BHMT, this may be removed during 
purification, leading to an unstable protein.  There is no added cofactor required for the 
recombinant BHMT activity, which would counter this hypothesis, unless it is a naturally 
occurring cofactor, produced in the E. coli, and tightly bound in the recombinant protein 
although, it would be expected that this cofactor would be present during x-ray crystallography 
studies.  The absence of an unresolved region of electron density in the crystal structures 
implies there is no cofactor present.18,33,40,41  There are several potential metabolites which are 
structurally related to ectoine and phenylalanine betaine: the nucleotides.  It is possible that 
BHMT is activated by one or more of the nucleotides, perhaps adenosine, which is released by 
S-adenosyl-homocysteine as it is hydrolysed to free homocysteine.  Perhaps this is evidence of 
an allosteric control system in BHMT which increases turnover in vivo.  It is clear, however, that 
this requires further exploration. 
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5.3 Conclusion 
The investigation of substrate specificity was greatly enhanced by the use of 1H-NMR 
spectroscopy.  Unlike any previously existing methods, it provided multiple indices of activity, 
could independently measure most products and reactants in a single analysis and did not 
require specialist substrate preparation.  Using the new assay, several naturally occurring 
betaines were rapidly assayed for activity in rat liver BHMT.  Selenonio-betaine, dimethyl-
selenoniopropionate, and trimethyltelluronium were all explored in the NMR spectrometer, and 
contrasted with Ericson’s results from the 1960’s, where he found traces of activity and 
inhibition from a number of betaines, including alanine betaine (activity) and carnitine, 
propiobetaine and N-substituted glycine betaine analogues (inhibition). 
Sensitivity could be a complicating factor with the 1H-NMR spectroscopic assay as 
described, given the detection limits of 5 μM methionine and DMG.  Proline betaine has been 
described as a substrate by Mulligan et al, but their detection technique was bacterial growth 
after supplementation with a methionine produced via BHMT.  It is possible that their assay is 
more sensitive at lower concentrations than the 1H-NMR spectroscopic method, giving non-
linear results at extremely low concentrations.  Given the apparent sensitivity rat liver BHMT 
has to substitution in the methyl donor, it is likely that proline betaine is not a substrate for 
BHMT.  It is possible that the E. coli used in the bacterial assay was capable of utilising the 
methyl groups on the proline betaine via some other pathway, giving a false-positive analysis.  
These complications were all resolved using the NMR spectroscopic assay.   
The 1H-NMR assay for the first time allowed the direct observation of methyl transfer 
between betaines and homocysteine.  The results presented by Ericson and Nakajima as they 
explored the role of betaine analogues in BHMT from mammals, fish and chickens all relied on 
indirect observation of activity (reactions allowing the observation of methionine were 
undertaken to measure BHMT activity, using either microbiological or nitroprusside 
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detection).9,12  Any further exploration of the interactions between betaines and BHMT should 
include this 1H-NMR assay. 
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Chapter 6 
 
Comparative Studies of BHMT from 
Mammals, Aganthans and Other Species 
 
 
Humans are not proud of their ancestors, and rarely invite them round to dinner. 
-     Douglas Adams 
 
The capacity of human beings to bore one another seems to be vastly greater than that of any other 
animal. 
-     H. L. Mencken 
 
 
 
Chapter 6 – Comparative Studies of BHMT from Mammals and Agnathans 
145 
 
CHAPTER 6: 
Comparative Studies of BHMT from 
 Mammals, Agnathans and Other Species 
 
 
6.1 Introduction 
Methionine (in the form of SAM) as a methyl donor is widely used in most organisms.  
In terms of evolutionary theory, it is logical to hypothesise that those enzyme systems that are 
associated with one-carbon metabolism, and the recycling of homocysteine back to 
methionine, would have evolved early in biological history.  There is a common active site to a 
number of the methyltransferases associated with methionine synthesis, being two small motifs 
which contain a triad of cysteine residues.  These cysteine residues all bind zinc in BHMT and 
cobalamin dependent methionine synthase enzymes.1,2  Furthermore, the crystal structures of 
recombinant human BHMT and cobalamin-dependent MS from Thermotoga maritime have 
both been solved, and show remarkable similarities in N-terminal structure, a part of both 
proteins responsible for homocysteine binding.3,4  BHMT and MS belong to the pfam 02574 
family of thiol/selenol methyltransferases because of structural similarities. 
 BHMT is highly conserved in mammals; the human BHMT cDNA shares 88% identity 
with the porcine cDNA, and 94% amino acid identity with the porcine protein.5  BHMT activity 
has been purified from horse, rat, pig and cow liver,6-8 and has been detected in rhesus monkey 
lens tissue, human and chicken liver and in several other vertebrates.8-13  BHMT activity has also 
been reported in several other kingdoms.14-17  Notably, there is one report of BHMT activity 
from Aspergillus nidulans, a fungi, and appears to be the product of a single gene.14 
 Given this wide distribution of BHMT activity, and the highly conserved nature of the 
mammalian protein and gene, it can be hypothesised that other vertebrates will also have a 
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protein with BHMT activity.  It could also be hypothesised that the BHMT protein from other 
vertebrates will be highly conserved. The most distant vertebrate from mammals is the 
Agnathan superclass of jawless fish, making them a logical point for investigation of these 
hypotheses. 
The Agnathans, or ‘jawless fish’ are an ancient superclass which has two 
representative subclasses. The lamprey and hagfish are the two remaining representatives of 
the Cyclostomata class, and fall into the subclasses, Hypoartii and Hyperotreti respectively. 
Hagfish are salt water dwellers and have remained essentially unchanged morphologically for 
over 330 million years, and there are over 60 species. The lampreys are found within 
temperate coastal waters and brackish rivers, and are parasitic. Unlike hagfish, lampreys 
possess rudimentary vertebrae, which enable them to be classified as true vertebrates.  There is 
still an active debate about the evolutionary relationship between hagfish, lampreys and other 
vertebrates. 
BHMT is a zinc metalloenzyme10 which comprises up to 2% of the soluble protein in 
the mammalian liver.3 It has been found to be expressed in many mammalian kidney and livers 
including pig and human, and rat.10,18,19 BHMT activity has also been described in Alfalfa sprouts 
(Medicago marina), 20 the fungus Aspergillus nidulans,14 the cyanobacterium Aphanothece 
halophytica,21 Pseudomonads,15,22 and several extremophiles23, although there is recent 
discussion about the accuracy of the Aspergillus activity reports.24 The BHMT protein appears to 
be highly conserved in mammals, having a 94% amino acid identity, with the human BHMT 
gene sharing 88% identity to the porcine gene.5 BHMT has been purified to homogeneity from 
horse and rat liver.6  Although BHMT activity is found in the liver and kidneys of most 
mammals, its distribution within other tissues seems to be species specific.8,25,26  The BHMT 
protein has been identified as a lens crystallin in rhesus monkeys,12 and in the pancreas of 
sheep.27  In rats, there appears to be little or no activity in the kidney.25  Mammalian BHMT also 
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shares similarities to N-terminal sequences of bacterial and eukaryotic methionine synthases.9 
Based on this sequence similarity, BHMT was allocated to the pfam 02574 family of 
thiol/selenol methyltransferases.9  
This work was expanded slightly (and indirectly) by Nakajima in 1993, who explored 
the activities of thetin-homocysteine methyltransferase (THMT, shown in mammals to be 
BHMT) in rat, bovine and fish species (particularly carp, tuna and trout -- but shark and other 
cartilaginous species were not included).28  Nakajima found that each species tested possessed 
some form of THMT activity, which, when explored also displayed BHMT activity, and activity 
with S-methylmethionine (‘vitamin U’), dimethylsulfone, dimethylsulfoxide and, in the case of 
yellowtail, rainbow trout and flounder, choline as well.  Nakajima used the nitroprusside 
colorimetric assay for his BHMT activity measurements, which may be complicated by other 
metabolites remaining after the preparation of acetone powders.  Ericson found no activity 
with choline in his BHMT assays,29 however, Nakajima’s experiments were performed using 
crude acetone-powder extracts of livers (and hepatopancreas where appropriate), so there 
could be some residual oxidation of the choline to betaine taking place.28 
In a first step for a study of the evolution of BHMT,  extraction, semi-purification and 
characterisation of substrate specificity of BHMT from lamprey and hagfish livers was 
undertaken, comparing this data to that obtained for rat BHMT [Chapter 5].30 
 
6.2 Activity Studies 
6.2.1 BHMT Activity in Lampreys 
Ericson had reported BHMT activity in lamprey liver in 1960,8 but did not further 
characterise the substrate specificity of the enzyme he reported. In order to confirm the 
presence of BHMT activity in agnathan liver, and to explore the activity in other classes of 
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marine organism (Cartilaginous fish), the NMR spectroscopic endpoint assay [Chapter 4] was 
used, with glycine betaine as a methyl donor to identify tissues for further analysis. 
6.2.2 Method 
6.2.2.1 Sources of BHMT 
Active BHMT has been extracted from liver tissue directly,9,12,30-33 as well as from liver 
acetone powders sourced commercially.25 Hagfish are a common catch on commercial fishing 
boats, but are normally cast back because of their tendency to contaminate the deck of the 
boats with copious amounts of ‘slime’.§  Hagfish (Eptatretus cirrhatus) samples were obtained 
from a commercial fishing boat which had caught the fish in the Chatham Island area, 
immediately freezing the fish. The hagfish were partially defrosted, at room temperature under 
water, and the livers dissected as soon as defrosting allowed. The livers were then plunged 
into liquid nitrogen (-170 °C) until used in experiments. 
Lamprey liver was sourced from a liver sample which had been stored at -80 °C for 
two years.  No further lamprey liver samples could be obtained, so although BHMT activity was 
confirmed in the lamprey liver, analysis was restricted to hagfish liver. 
Several commercial liver and kidney acetone powders were obtained and assayed for 
activity. In these experiments, rat liver BHMT was analysed from commercial liver acetone 
powder (Sigma, L-1380), along with bovine liver (Sigma, L-7751) and kidney (Sigma, K-4752), 
lemon-shark liver (Sigma, L-1130) and snail acetone powder (Helix pomatia, Sigma, S-9764).  
 
6.2.2.2 Preparation of Samples 
Acetone powders (100 mg) were suspended in 20 mM potassium phosphate buffer 
(1 mL, pH = 7.5). The samples were vortexed for 10 s, and then allowed to sit for 15 min at 4 
                                                 
§ a defensive adaptation in hagfish, the mucous glands are a prominent feature along the lateral line of the 
hagfish body, and have earned them the common name of ‘snot-fish’. 
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°C, before being centrifuged at 7000 g for 10 min. The supernatant was removed, and 100 μL 
assayed for BHMT activity. A further 100 μL was assayed for protein concentration using the 
Bradford method (Bio-Rad), standardized with bovine serum albumin [Chapter 2]. 
For the hagfish and lamprey liver samples, 100 mg of Liver was homogenised using a 
turret homogeniser in 10 mL of 20 mM phosphate buffer (pH = 7.5) for 30 s. The samples 
were centrifuged at 7000 g for 10 min. The supernatant was removed and 100 μL assayed for 
activity. A further 100 μL was assayed for protein concentration as above. 
 
6.2.2.3 Preparation of Substrates 
L-Homocysteine was prepared for the assay using the method of Duerre and Miller.34 L-
Homocysteine  thiolactone (0.7 mg) was dissolved in 2 M NaOH (0.4 mL), incubated for 5 min, 
then neutralized with saturated KH2PO4 (0.6 mL). 
 
6.2.2.4 Activity Assay 
Hagfish liver extract (100 μL), was incubated with 2 mM L-homocysteine, 2 mM 
glycine betaine and 5 mM tert-butanol. The final volume of the sample was 0.5 mL, which was 
placed in a sealed 5 mm NMR spectroscopy tube, and incubated in a 37 °C water bath for 
24 h. 
All 1H-NMR spectra were recorded on a Varian INOVA 500 instrument, at 23 °C in 
5 mm NMR tubes with a 3 mm D2O lock insert. For the measurements, a 90° radiofrequency 
pulse, with duration of 8.1 μs was used. The delay between pulses was 5 s, acquisition time 
was 1.982 s. Eight transients were recorded for each sample, with 30,272 data points for each 
transient. Sweep width was set to 8,000 Hz. Shimming was completed using field gradient 
autoshim macros. Water suppression was achieved using a selective presaturating pulse on the 
water resonance for 3 s prior to the 90° pulse. All spectra were zero filled to 128k points, and 
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then Fourier transformed. Phasing and baseline corrections were completed manually. The 
software used for these procedures was VNMR version 6.1C (Varian). 
The ratio of methionine produced to tert-butanol integrals was used as an index of 
activity.  Specific activity was calculated by dividing the activity measured by the protein 
concentration. 
 
6.2.3 Results  
The mammalian liver samples all had BHMT activity [Table 6.1], while the bovine 
kidney, snail and shark liver acetone powders all failed to exhibit BHMT activity. The crude liver 
tissue extracts clearly have a higher specific activity than the acetone powders, which is likely 
to reflect some denaturing of BHMT in the acetone powders. 
Table 6.1 Results of BHMT activity studies.  Hagfish and Lamprey results are from 
homogenised liver tissue. 
 
Sample Protein Concentration 
(mg/mL) 
Met Integral (24 
h) 
Specific Activity 
 
Rat Liver Acetone 
Powder 
1.42 2.91 2.0 
Rat Liver homogenate 22.8 75.1 3.3 
Bovine Liver Acetone 
Powder 
1.72 
 
1.08 0.63 
Bovine Kidney 
Acetone 
Powder 
1.83 0 0 
Lemon Shark Liver 
Acetone Powder 
0.29 0 0 
Snail ‘Visceral Hump’ 
Acetone Powder 
3.00 0 0 
Lamprey Liver 0.83 3.01 3.6 
Hagfish Liver 2.12  7.19 3.4 
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6.3 Purification of Hagfish BHMT 
6.3.1 Introduction 
To characterise the hagfish BHMT, and compare it to rat BHMT, the hagfish extract 
was partially purified.  The purification methods used were deliberately chosen to match the 
steps used for purification of the rat BHMT experiments and purification [Chapter 2], because 
these were known to be effective at purifying the rat protein, and to investigate similarities 
between the physical properties of the two proteins. Homogenisation and extraction into 
potassium phosphate buffer followed by heat shock treatment, size exclusion chromatography 
and concentration in a stirred concentration cell forms the basis of both schemes. 
6.3.2 Method 
Hagfish liver (12 g) of was excised and homogenized with 3 volumes (w/v) of 20 mM 
potassium phosphate buffer at pH = 7.5 (Buffer 1), in a mechanical turret homogenizer (20 s, 
5000 rpm). The sample was centrifuged at 7000 g for 5 min, the supernatant was separated 
into 1.5 mL Eppendorf tubes and heat shock treated for 2 min at 90 °C, followed by cooling on 
an ice slurry for 5 min and then centrifuging at 7000 g for a further 5 min. The supernatant 
(5.5 mL) was applied to a 450 mL Superdex G200 column, pre-washed and equilibrated with 
Buffer 1. Proteins were eluted with Buffer 1 at 1.1 mL/min and fractions collected every 13 mL. 
The samples tubes had 100 μM added to each one prior to fraction collection, and 
they were incubated for 12 hrs, before activity was determined using the 1H-NMR spectroscopic 
assay [Chapter 4].  All other procedures followed those set out in Chapter 2 for rat 
purification. 
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6.3.2 Results  
Purification Table: 
Purification type Protein 
Concentration 
(mg/mL) 
Volume 
obtained 
(mL) 
Activity 
(Units/ 
mL) 
 
Specific 
Activity 
(Units/mg) 
 
Percent 
Yield 
(%) 
 
Purification 
Crude 
homogenate 
20.6 48 70.1 3.4 100 1 
Heat 
Denaturation 
2.07 28.5 43 20.8 61.3 6.1 
Size Exclusion 
Chromatography 
0.230 37.5 23 100 0.1 29.4 
 
 
6.4 N-terminal Sequencing 
6.4.1 Introduction 
In an attempt to confirm that the hagfish BHMT activity seen was due to a protein that 
is homologous to BHMT, N-terminal sequencing was conducted on the 45 kDa band seen in 
the SDS-PAGE gel, suspected to be the BHMT subunit.  There is no known hagfish BHMT 
cDNA, but it could be expected that, given the conserved nature of mammalian, chicken and 
zebra-fish BHMT sequence (from cDNA data), the hagfish BHMT sequence could be expected 
to have some conserved nature around the N-terminal protein sequence [Figure 6.2]. 
6.4.2 Method 
Purified hagfish BHMT (concentrated to 1 mg/mL) was analysed using gradient 
SDS-PAGE electrophoresis (5-20 %, Sigma) and stained for 1 h with Coomassie Blue stain. The 
gel was destained using 10% acetic acid in methanol, washed twice for 2 h each time.  A 
second SDS-PAGE was conducted using the same hagfish BHMT extract and Sigma Wide 
markers then electro-blotted at 100 mA constant current (voltage ~45 V) for 15 h to PVDF 
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membrane, and stained for one minute with amido black stain, followed by washing twice with 
10% acetic acid in water. 
The 45 kDa band was identified by comparison with Sigma wide-range markers (M 
4038, Sigma) and the ~45 kDa band on the PVDF blot was excised. The sample was submitted 
to the Protein Microchemistry Facility in the Department of Biochemistry at the University of 
Otago [Figure 6.1].  
6.4.3 Results 
Despite an intense 45 kDa band being excised in the hagfish extract, no sequence was 
obtained despite two attempts.  This is possibly because the N-terminal amino acid is blocked 
by acetylation, which is preventing Edmann degradation.  Attempts to deblock the hagfish 
sequence using an Acid-Alcohol-Heat process in situ (an in-house method used in the Protein 
Microchemistry Facility) did not result in any improved sequence data. 
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Figure 6.1 Hagfish BHMT PVDF blot showing hagfish extract, post size-exclusion chromatography 
(lanes 1-4), Sigma Wide-Range markers (lane 5). 
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Figure 6.2 Alignment of mouse, rat, bovine, human, porcine and zebra-fish BHMT amino acid 
sequences, as predicted from cDNA data (obtained via the NCBI databases).  Consensus sequences and 
a graphical representation of the sequence is included below the alignment.  Alignment was performed 
using the CLC Gene Workbench package (Version 1.0.2). 
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 Initially, a band of ~20 kDa was excised and sequenced, giving “D S L S K E Q V E S 
A V D E A L D K L N K Q Q V S T R K L A L A E E”.  Blast searching for this sequence gave a 
positive (p = 6.8 x10-10) ID for “Hematopoietic antimicrobial peptide-37 precursor”, or 
“Hematopoietic antimicrobial peptide-29 precursor”.35 
 
 
6.5 Comparison of Rat and Hagfish BHMT Activity 
6.5.1 Background to Comparison Studies 
 Ericson explored the distribution of BHMT across various classes of animal.8  Using the 
production of methionine as a measure of BHMT activity, he showed that extracts from all of 
the vertebrates he tested remethylated homocysteine using glycine betaine.  In two papers that 
followed, he then explored the properties of the mammalian (pig) enzyme, including the 
substrate specificity (presented in Chapter 5).  He noted that the only non vertebrate animal 
which had BHMT activity was the fresh-water mussel Anodonta cygnea, insects and arachnids 
having no activity in his crude extracts. 
 In Section 6.2 above, activity was found in mammalian (rat) liver acetone powders, 
but was absent in shark acetone powder, a species which was absent from Ericson’s research.  
Snail acetone powder also lacked BHMT activity.  There has been little characterisation of 
BHMT activity in animals beyond the class of mammals.  Ericson briefly attempted to show 
that, in some of the BHMT activities he observed, DMSP would replace glycine betaine as a 
methyl donor, and choline would not.  Furthermore, he showed that DMG inhibited the 
reactions, but choline did not affect the methyl transfer. 
 To expand this data and make a brief comparison of BHMT from hagfish and rats, the 
substrate specificity of partially purified hagfish BHMT was explored.  Substrates with activity in 
rat extracts were incubated with purified hagfish extract, and compared to glycine betaine.  
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Arsenobetaine was included in this experiment, because it is known to be a naturally occurring 
marine betaine analogue and is reportedly a substrate for Paenibacillus sp.22,36-40 
6.5.2 Method 
Potential substrates were evaluated for activity and inhibition in two separate 
experiments.  Purified hagfish BHMT (100 μL) was incubated at 37 °C for 24 h with 2 mM 
homocysteine and either 10 mM trigonelline, L-proline betaine, DMT, DMSP, selenobetaine or 
arsenobetaine.  These solutions were prepared containing an additional 10 mM glycine 
betaine, incubated identically to the tubes containing no glycine betaine and compared with 
control solutions, containing glycine betaine (10 mM) and homocysteine (2 mM) but no 
betaine analogues.  The relative activity in each solution was evaluated by monitoring 
production of DMG (for solutions containing glycine betaine), and methionine at 1 and 24 h 
using the 1H-NMR spectroscopic assay [Chapter 4]. 
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6.5.3 Results 
6.6.3.1 Activity Studies 
Table 6.3 Results of the activity studies in hagfish BHMT extract.  
 
Betaine Name Betaine Structure Betaine 
Integral  
(t = 0) 
Demethylated 
Product 
Integral 
(t = 24 h) 
Methionine 
Integral 
(t = 24 h) 
Glycine Betaine 
N+ CO2-
 
42.85 5.53 4.94 
Trigonelline 
N+
CO2-
 
18.98 0 0 
Dimethylthetin S+ CO2-
 
21.06 15.57 10.04 
DMSP 
S+
CO2-
 
19.99 12.85 5.09 
Selenobetaine Se+ CO2-
 
17.70 13.89 9.76 
Arsenobetaine 
As+ CO2-
 
45.77 0 0 
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6.6.3.2 Inhibition Studies 
Table 6.4 Results of the inhibiton studies.  Data was also recorded at t = 1 h, but did not show any 
signs of inhibition, and so is not recorded below. 
 
Betaine Name Betaine Structure Betaine 
Integral  
(t = 24) 
DMG Integral 
(t = 24 h) 
Methionine 
Integral 
(t = 24 h) 
% 
Inhibition 
Glycine Betaine 
N+ CO2-
 
42.09 5.53 4.94  
Trigonelline 
N+
CO2-
 
19.17 5.69 4.53 0 
Dimethylthetin S+ CO2-
 
19.75 Uncertain; 
DMT and 
DMG co-
resonant 
9.01 Competitive 
Inhibition 
DMSP 
S+
CO2-
 
18.03 Uncertain; 
DMSP and 
DMG co-
resonant 
4.60 Competitive 
Inhibition 
Selenobetaine Se+ CO2-
 
10.03 0 17.05 100 
Competitive 
Inhibition 
Arsenobetaine 
As+ CO2-
 
45.51 5.40 4.97 0 
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Table 6.5 Comparison of rat and hagfish activity 
Betaine Name Betaine Structure Rat 
demethylated 
product 
integral 
Hagfish 
demethylated 
product Integral 
Glycine Betaine 
N+ CO2-
 
7.51 5.53 
Trigonelline 
N+
CO2-
 
0 0 
Dimethylthetin S+ CO2-
 
19.31 15.57 
DMSP 
S+
CO2-
 
16.74 12.85 
Selenobetaine Se+ CO2-
 
10.97 13.89 
Arsenobetaine 
As+ CO2-
 
0 0 
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6.6 Discussion 
Acetone powders can provide a convenient source of protein for studies of BHMT. The 
results presented here show that BHMT can be obtained from acetone extraction.  Acetone 
powders are frequently stored for extended periods with little further degradation of proteins, 
so acetone powders may become the commercial source of choice for BHMT research. Several 
companies provide a range of mammalian liver acetone powders, as well as the snail and 
shark samples available from Sigma. 
There are some reports of unstable BHMT extracts in the literature, notablya report by 
Lee et al report a rat-liver extract which was unstable, unless in the presence of homocysteine 
and DMG.31  The rat-liver extracts which were obtained after anion-exchange chromatography 
and discussed in Chapter 2 were also found to be unstable, although the recombinant enzyme 
which is reported by the Garrow research group is quite stable, and can be stored for some 
time without loss of activity.1,9,10,41  While no activity was detected in butter-shark liver acetone 
powder, it is possible that the shark BHMT is unstable which prevents its detection in acetone 
powder. 
Hagfish BHMT can be partially purified using a scheme similar to that used for rat liver. 
The resulting hagfish BHMT also has similar properties to rat BHMT, in that its activity is 
remarkably heat stable, withstanding a 90 °C heat shock for 2 min -- a treatment which 
denatures most other proteins.  This implies some degree of similarity chemical structure 
between the two proteins. 
The size exclusion chromatography showed BHMT activity the hagfish in fractions 21-
24, the same fractions which exhibit BHMT activity when rat liver extracts are analysed. This 
result implies that the hagfish BHMT quaternary structure (based on the assumption of a 
similar ~45 kDa subunit to the rat BHMT subunit) is comparable to rat BHMT. Similar percent 
purifications are seen between the rat extraction and the hagfish extraction [Chapter 2, 
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Section 2.6.3], although these produce solutions which are much less pure than the rat liver 
purification. 
N-terminal protein sequencing on the ~45 kDa band identified in the SDS-PAGE 
analysis of BHMT active hagfish extracts did not give any results, despite two attempts at 
sequencing, and an in situ acid/alcohol/heat cycle to attempt deacetylation of the N-terminal 
amino acid.  Initially, the wrong band was excised and submitted for analysis, revealing the 
first experimental evidence for the ‘Hematopoietic antimicrobial peptide-37 precursor’ protein.  
This confirms that hagfish protein was efficiently transferred during the PVDF blot, and further 
work is required to isolate, and sequence the hagfish BHMT protein. 
There is one predicted BHMT alternate transcription site known in mice, one of which 
is anecdotally known as ‘mega-BHMT’, because it would encode a protein of 52 kDa; 
substantially bigger than BHMT. 41   It is unlikely that we are observing the product of ‘mega-
BHMT’ in the kinetic and characterisation studies because the band excised from the PVDF 
membrane is conclusively placed along side a 45 kDa marker (Ovalbumin, Sigma). 
 The hagfish BHMT activity appeared to have similar specificity for methyl donor as the 
rat BHMT [Tables 6.3, 6.4, 6.5], in that group VI heteroatom betaines are good substrates for 
both hagfish and rat BHMT, and the inclusion of an extra CH2 in the thetin series appears to 
decrease activity.  Furthermore, the betaines which are substrates also appear to have 
competitive inhibitor properties, implying that they are all reacting at a common active site.  
This implies that the mechanism of BHMT action in hagfish is similar to that of rat BHMT, and 
that the binding of betaines to rat BHMT is likely to be the same for the hagfish enzyme. 
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6.7 Conclusion 
 Agnathans were selected for comparison to mammals for several reasons.  Ericson had 
briefly reported BHMT activity in lamprey livers in 1960, and hagfish are easily sourced from 
commercial fisheries, being common as an off-catch of normal fishing activity, and are normally 
rapidly discarded.  They are the only existent members of our most distant vertebrate relatives, 
and the presence of BHMT in their livers makes them an attractive prospect for study. 
 The BHMT purification used here relies on two critical physical properties, heat 
stability, and mass, both of which offer clues about the structure of the tertiary and quaternary 
structure of the protein.  Hagfish BHMT behaved largely in the same way as rat BHMT during 
heat treatment and the size exclusion chromatography, implying a similar structure. 
 The solutions obtained from the hagfish purification were of unsuitable purity to 
conduct mass spectrometry or tryptic digests to confirm the presence of a BHMT like protein.  
Furthermore, it is difficult to predict what masses are expected, given that there is no existing 
data on the hagfish BHMT protein sequence. 
No N-terminal sequence was obtained for the hagfish BHMT subunit.  The most likely 
reason for this is N-terminal acetylation of the first residue in the hagfish. Alanine is highly 
conserved in the first amino acid position of BHMT, and is a known site for acetylation.  In situ 
attempts at un-blocking the sequence using an in-house acid-alcohol-heat procedure were not 
successful.  Further work will need to be done to confirm that there is sufficient protein on the 
PVDF blot and that the N-terminal is blocked.  In situ cyanogen bromide cleavage at 
methionine residues would (if a subunit similar to rat BHMT is present) cleave the protein into 
nine fragments, eight of which will not have a blocked N-terminal.  It may also be possible to 
elute the 45 kDa band and determine internal protein sequences after appropriate cleavage, 
using preparative HPLC. 
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 The substrate specificity work observed also implies that hagfish BHMT and rat BHMT 
have a similar betaine binding site, although it should be noted that further assays using a 
wider range of betaines, in a similar way to that performed in Chapter 5, would be required to 
conclusively probe betaine binding in hagfish BHMT.  This work, however, is a good step 
towards the full characterisation of hagfish BHMT. 
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CHAPTER 7: 
In Vivo Studies of Mammalian Betaine Metabolism 
 
7.1 Introduction 
In vitro data on enzyme properties may not reflect what happens in vivo, where there is a 
high level of cellular organization.  In vitro, all parameters are essentially under the control of the 
researcher, with temperature, pH, and the concentrations of the substrates being known and 
regulated.  In vivo there is cellular and organ compartmentalisation, active transportation of 
betaines and the excretion of betaines which can all complicate measurement of BHMT activity.  
The effect of betaines on the whole organism must be investigated separately from the in vitro 
measurements of enzyme kinetics and substrate specificity. 
NMR spectroscopy can provide a useful tool for the measurement of betaines and 
methylamines in biological fluids.  The assays used for kinetic measurements in the earlier chapters 
of this thesis were adapted and applied to the study of betaine metabolism in four separate 
studies. 
7.1.1 Methylation in Vivo 
Methyl group cycles are crucial to most organisms.  It is estimated that up to 75% of all 
the SAM generated in the body is used to synthesise creatine, but there are many other reactions 
which are linked through SAM to homocysteine metabolism.1,2  Notably, DNA is methylated within 
the cell to regulate the expression of many genes, forming an important epigenetic trigger which 
can be used to control the functions of the cell.1,3 
As a consequence of each of these methylations SAM is produced, which is directly 
hydrolysed to homocysteine.  The link between CVD and homocysteine is now well established 
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(discussed in Chapter 1).  Additionally, increased homocysteine concentrations have flow-on 
effects on other pathways present in the organism.4  Many of the methylation reactions use 
homocysteine, in the form of S-adenosyl homocysteine (SAH) as a feedback inhibitor.1 
It is known that homocysteine levels rise after a methionine load in humans,5 and also in 
rats.6  A good example of how homocysteine levels can be affected by alterations to the 
environment is in patients with Parkinson’s disease.  Treatment with L-DOPA results in the drug 
being transported to the brain, where it is decarboxylated, relieving the deficiency of dopamine, 
and reducing the symptoms.  Plasma homocysteine levels in these patients are commonly 50% 
higher than in untreated healthy controls.7  It has been shown in rats that the homocysteine 
elevating effect of L-DOPA is accompanied by a lowering of SAM levels, and was a consequence of 
methylation of the L-DOPA via catchetol-O-methyl transferase (COMT, E.C. 2.1.1.6).7 
Stead et al showed that an increased dietary creatine intake decreases the plasma 
homocysteine presumably by reducing the demand for creatine synthesis,8 and thus reducing the 
methylation flux via that pathway.  Creatine biosynthesis is known to account for up to 75% of 
S-adenosyl methionine in vivo although this is the subject of debate.1,8  Creatine synthesis is, in 
turn, also affected by a number of different factors.  Phosphate levels in plasma, ATP 
concentrations within the cell, hormonal regulation (notably thyroid hormones, although 
hydrocortisone up regulates creatine synthesis) and plasma pH have all been shown to be 
regulating factors in creatine synthesis, and might therefore have an influence on the homocysteine 
flux in the whole animal.  While these factors are influencing creatine synthesis, they may not have 
an effect on homocysteine levels within the plasma (methionine synthase, BHMT and cystathionine 
β-synthase may remove homocysteine as fast as it is made) it would alter the demands placed on 
the various enzymes in the methionine-homocysteine pathway and, therefore, on betaine as a 
methyl donor. 
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7.1.2 Whole Animal Studies 
Given the complications in vivo discussed in Section 7.1.1, it was important to look at 
how the betaines studied in this thesis affect the animal as a whole.  The ultimate aim of these four 
projects was to determine the suitability of betaines for use as therapeutic agents for the lowering 
of homocysteine in subjects with hyperhomocysteinemia. 
Glycine betaine has been used for many years to reduce high plasma homocysteine 
levels.9,10  While it is effective against extremely high homocysteine concentrations (for example in 
cystathionine β-synthase or vitamin B6 deficiency), it does not have much effect against lower 
homocysteine concentrations resulting from errors involving defects in methionine synthase.11  
Olthof et al have shown that daily betaine supplementation as low as 1.5 g is effective at lowering 
homocysteine in a post-methionine load situation (a test where the subjects are given a load of 
methionine which is converted into homocysteine).9 
There are three reasons why these betaine treatments may not be as successful as hoped.  
Firstly, the BHMT gene is regulated strongly by factors such as betaine and methionine levels.  
Secondly, as BHMT produces DMG, a feedback inhibitor of BHMT, and so regulates its own activity.  
Thirdly, as methionine is reformed by the action of BHMT, it is likely to simply re-enter the SAM 
cycle and regenerate homocysteine.12 
There is little that can be done about the first of these factors.  The control exerted by 
methionine on BHMT is at the genetic level (see Chapter 1).13-15  It is unlikely that there would be a 
simple way of altering the regulation these molecules have on the BHMT protein.  The third factor 
is also, unfortunately, not possible to adjust.  Diversion of plasma homocysteine out of the SAM-
SAH cycle is not easily achieved.  Methionine must be produced by the action of BHMT, and so, will 
logically re-enter the SAM-SAH cycle.  However, each time that cycle is returned, 50% of the 
homocysteine will enter the CBS pathway and be removed permanently.16 
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It is possible that the feedback inhibition of BHMT by DMG is externally controllable.  
BHMT is able to process methyl groups from a number of different substrates, notably 
dimethylthetin (DMT) and dimethylsulfoniopropionate (DMSP).  Both of these sulfur analogues of 
glycine betaine are more rapidly used by BHMT to convert homocysteine to methionine, but 
produce demethylated products which will then further inhibit the enzyme.  The utilization of these 
thetins should increase BHMT’s capacity to remove homocysteine. 
It is likely that the thetins will also, however, interact with the other facets of betaine 
homeostasis and transport.  In order to investigate the effect these betaines have on the 
homocysteine system, including some of the betaines not known to interact with BHMT, four 
experiments were proposed and carried out. 
The experiments which make up this chapter were all done in collaboration with other 
researchers in the betaine research group at Canterbury Health Laboratories.  Animal work was 
largely conducted by Dr Sandy Slow and the sheep study also involved Madhusudan 
Vasudevamurthy.  The DMG and coffee studies were also largely conducted by Dr Sandy Slow, with 
the assistance of Wendy Miller. 
All studies conducted here used 1H-NMR spectroscopy to locate and quantify a betaine as a 
product of the in vivo study – normally in the urine.  The methods developed in earlier chapters of 
this thesis were applied and I have been involved in the planning, methodology and execution of 
the analyses involving NMR spectroscopy presented.  
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7.2 Rat Models of Betaine Metabolism 
7.2.1 Betaine Homeostasis 
Glycine betaine therapy is successful in lowering plasma homocysteine levels in 
homocysteinuria, and also in patients with chronic renal failure,17,18 it is likely that betaines are 
capable of using BHMT to lower homocysteine.  There are a number of betaines which are known 
to interact with BHMT, notably DMT and DMSP, but proline betaine (PB) and trigonelline could also 
potentially act as substrates and inhibitors of BHMT and affect homocysteine metabolism.  At the 
time of this study, porcine BHMT had been shown to have low activity with proline betaine, about 
20% of the activity of glycine betaine.19  In vivo this could lead to a competitive inhibition of BHMT 
or assisting glycine betaine to lower homocysteine.  Trigonelline is known to be transported by the 
same betaine transporter proteins as glycine betaine and also potentially interact with the active 
site of BHMT.20  BHMT has shown activity with DMT and DMSP, with relative Km of 30 and 7 times 
those of glycine betaine, so they would be expected to assist in the removal of homocysteine.21 
7.2.2 Study design  
Six groups of 8 inbred Lewis rats were given a low betaine diet for a period of one week 
prior to the application of experimental procedures.  In five of the groups of 8 animals, six animals 
were given a betaine subcutaneous injection and the remaining two animals acted as controls.  
Additionally, one group were injected with isotonic 5% glucose solution.  Each betaine injection 
contained 1.5 mM of the betaine (one of glycine betaine, DMG, proline betaine, trigonelline, DMT 
or DMSP) and the control animals received a NaCl treatment of the same volume.  The injections 
were hypertonic at 500 mosmols/L.   
Injections were chosen to prevent uncertainties that may have been introduced if the 
betaines were administered via the food supply, providing less stress to the animals than gastric 
tube administration.  Also, microbial metabolism of the betaines in the digestive tract was avoided. 
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The rats were housed individually in metabolism cages to collect urine for 48 hours.  Urine was 
collected for the 0-8 hours and 8-24 hours pre-treatment, then the injections given, and another 
set of urine for the 0-8 hours and 8-24 hours post treatment.  The rats were given their respective 
treatments twice, with a week’s interval between them.  On the second treatment day, the rats had 
200 µL blood samples taken at 0, 0.5, 2, 4, 8 hours respectively, and finally, a 24 hour sample was 
taken after sacrifice of the rat via cardiac puncture. 
The blood samples were all analyzed for plasma homocysteine concentration (separated 
and stored at -20 ºC).  Betaine analysis for glycine betaine, DMG, proline betaine, trigonelline, DMT 
and DMSP in both the plasma and the urine was conducted using the HPLC method described in 
Chapter 1.22 
1H-NMR spectroscopy was used to identify the expected demethylated products of the 
BHMT reaction (DMT and DMSP).  The methods were the same as those described in Chapter 3.  
Metabolites were quantified by reference to an internal acetonitrile spike of 5 mM which also 
served as a chemical shift reference at 1.9 ppm.  Standard lines for the demethylated products 
(methylthioacetate and methylthioproprionate) as well as the betaines, were prepared over six 
points (0.05, 0.1, 0.5, 1, 3, 5 mM), and the ratios of the peak integrals to the acetonitrile were 
calculated. 
7.2.3 Results 
Plasma homocysteine results were expressed as an increase or decrease compared to 
baseline levels, as determined for the first (t = 0 hrs) blood sample.  The mean baseline 
homocysteine for the 48 rats was 8.5 ± 0.2 µM (four rats did not give data).  All rats experienced 
an initial drop in plasma homocysteine over the first 4 hrs, maybe a consequence of stress which is 
known to cause a rapid drop in plasma homocysteine.23  The plasma homocysteine concentration 
between the two control groups (saline and 5% glucose) was not statistically different.  Proline 
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betaine and trigonelline both caused an increase in plasma homocysteine (the effect of proline 
betaine was still significant after 8 hours) while glycine betaine, DMT and DMSP all caused 
homocysteine to drop [Figure 7.1]. 
 
Figure 7.1 Plasma homocysteine after betaine treatment. Data is expressed as mean change (µM/L) 
±S.E.M.; glycine betaine (?); proline betaine (?); trigonelline (?); DMSP (?); dimethylthetin (?); glucose 
(?); controls (?). **Highly significant difference compared to controls, P = 0.01. *Significant difference 
compared to controls P = 0.05. 
 
The plasma samples were also analyzed for glycine betaine – evidence that the injected 
betaines were interacting with betaine transport, or inhibiting metabolism of glycine betaine by 
competitively inhibiting BHMT.  Plasma from the rats given glycine betaine were also analysed for 
DMG to see if there was increased methyl transfer as a consequence of increased betaine levels, 
and the decrease in homocysteine. 
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It was clear that the betaines were rapidly absorbed, with maximum plasma concentrations 
being achieved after 30 min.  DMT achieved a maximum concentration at 8.9 ± 0.5 mM, and the 
other betaines were also equilibrated after 30 min achieving concentrations of 7.7 ± 0.7 mM 
(DMSP), 5.8 ± 0.6 mM (proline betaine), 5.4 ± 0.3 mM (glycine betaine), and 5.0 ± 0.2 mM 
(trigonelline).  
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Figure 7.2 Plasma concentrations of the administered betaines, showing the rapid absorption and 
equilibration of the betaines into the plasma.  All samples had achieved their peak plasma concentration 
within 30 min of administration.   Proline betaine (?), Proline betaine controls (?), trigonelline (?), 
trigonelline controls (?), glycine betaine (?), glycine betaine controls (?). 
 
The control rats, and the glucose injection group had no significant difference in plasma 
glycine betaine concentration, and the trigonelline and proline betaine injections also had no 
significant effect on the plasma glycine betaine concentration [Figure 7.1 (A)]. DMT and DMSP 
both caused a significant increase in plasma glycine betaine levels, which was highly significant at 
2, 4, and 8 hours after injection of DMT. 
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Given that glycine betaine can be demethylated by BHMT to form DMG, it followed that 
after injection of glycine betaine, there was an initial rise in plasma glycine betaine (peaking after 
30 min) which decayed exponentially to baseline over the 24 hour period.  This was accompanied 
by an increase in plasma DMG concentration, which was observed over the first 8 hours, but had 
returned essentially to baseline after 24 hours [Figure 7.3 (B)]. 
DMT significantly decreased the concentration of DMG in the plasma between one and 8 
hours following the injection.  At the point of greatest difference (four hours after injection) this 
was 4.5 ± 1.2 µM (p < 0.001).  This was contrasted by an increase in DMG between 8 and 24 
hours following the injection.  Methylthioacetate (MTA) was observed by HPLC analysis in the 
plasma of the DMT treated rats, and reached a maximum of 230 ± 24 µM at 8 hours after 
injection.  It is important to note that MTA is not known to occur naturally, and can only have been 
produced by demethylation of DMT.  Furthermore, the peak assigned to MTA was not observed in 
samples from baseline samples, or from any other rat urines. 
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Figure 7.3 Changes in plasma glycine betaine and DMG after injection of betaine during the rat study.  
(A), the mean change (µM/L) ±S.E.M in plasma glycine betaine after injection of proline betaine (?); 
trigonelline (?); DMSP (?); dimethylthetin (?); glucose (?); controls (?).Initial concentrations are: 
proline betaine (104 μM), trigonelline (102 μM), DMSP (99 μM), DMT (106 μM), glucose (78 μM), control 
(88 μM)  (B) Mean change (µM/L) ±S.E.M in plasma glycine betaine (?, initial concentration = 69 μM) and 
DMG (?•  ,initial concentration = 69 μM). **Highly significant difference compared to controls, P = 0.01. 
*Significant difference compared to controls P = 0.05.  
 
Each treated rat received 1.5 mM of betaine following which 41 ± 3.5% of the glycine 
betaine, 72 ± 8.7% proline betaine, 79 ± 5.1% trigonelline, 66 ± 2.5% DMSP and 7.7 ± 0.9% 
DMT was excreted into the urine after 24 hours.  Glycine betaine excretion was elevated in the rats 
which received betaine injections and saline injections, but not in the glucose control group.   
After injection with DMT and DMSP, glycine betaine excretion was significantly elevated for 
the first 8 hours, and significantly lowered for the 8-24 hour period post injection.  NMR analysis 
was used to investigate the urine of the DMT and DMSP treated rats as HPLC could not accurately 
identify the demethylated products of these two metabolites, methylthioacetate (MTA) and 
methylthiopropionate (MTP) respectively.   
MTA was identified as a singlet appearing at 1.97 ppm in the urine NMR spectrum, and 
verified by spiking of the samples.  Using the NMR methods described in Chapter 3, it was 
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quantified as 0.41 ± 0.03 µmoles and 0.57 ± 0.08 µmoles for the 0-8 hour and 8-24 hour periods 
respectively post-injection.  As this represents <0.1% of the 1.5 mmole DMT injection, it was 
hypothesised that the MTA was being further metabolised, possibly by oxidation to the sulfoxide.   
A sample of the sulfoxide of MTA was prepared by addition of one molar equivalent of 
30% H2O2 to a sample of MTA in methanol.  The sulfoxide of MTA has a pair of enantiotopic 
protons, giving rise to a unique set of doublets which were easily recognisable as evidence of the 
sulfoxide in rat urine [Figure 7.4].  
The presence of this compound was then confirmed in the urine of the DMT treated rats, 
and quantified at 138.4 ± 15.8 µmole between 0-8 hours and 33 ± 3.2 µmole between 8-24 
hours.  The sulfoxide of MTA decarboxylates to give dimethylsulfoxide (DMSO) and carbon dioxide 
over time, and so these figures are likely to be a minimum excretion estimate.  Despite confirming 
the presence of DMSO in aqueous standards of the sulfoxide, there was no observed DMSO in the 
rat urine.  The sulfoxide of MTA accounted for a further 11% of the DMT injection. 
There was no observed MTP or N-methyl proline in the DMSP or proline betaine treatment 
groups. 
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Figure 7.4 1H-NMR spectrum of acidified rat urine following DMT treatment.  The presence of the 
methylthioacetate sulfoxide is clearly seen at 2.63 ppm. 
 
7.2.4 Discussion 
It is clear that glycine betaine, DMT and DMSP are all capable of lowering circulating levels 
of homocysteine in a whole animal model.  Although all three compounds are known to be 
substrates of BHMT, the circulating concentration of homocysteine did not drop more than 30% of 
the original baseline levels. 
It is thought that this may have been a consequence of the futile methylation cycle 
mentioned in Section 7.1.2.  After homocysteine is remethylated by BHMT, it is either incorporated 
into proteins as the protein-amino acid, or it is converted into SAM, to be used in another 
methylation reaction.12 
The glycine betaine treated rats may have also experienced a significant suppression of 
BHMT activity, as a consequence of the DMG being produced.  It is, however, impossible to dissect 
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that information out of the data collected.  The significant portion of injected glycine betaine which 
was recovered from the urine may also be evidence that the glycine betaine was not being utilised 
and was being excreted. 
The absence of MTP, the demethylated product of the DMSP reaction, does not in itself 
exclude the possibility that it was produced.  The sulfoxide of this compound would be similarly 
unstable, and could decarboxylate as the MTA sulfoxide did.  The slight increase in plasma glycine 
betaine and the lower homocysteine concentration imply that the DMSP was being metabolised by 
BHMT.  It is clear from the presence of MTA and its sulfoxide in the urine, however, that DMT was 
being demethylated, and is responsible for the significant drop in plasma homocysteine, and the 
increase in glycine betaine excretion. 
In contrast, trigonelline and proline betaine were not demethylated and were excreted 
unchanged in the urine.  Notably, all the betaines gave an increase in glycine betaine excretion, 
consistent with the findings of Lever et al who showed that proline betaine increased glycine 
betaine in the urine, possibly by blocking transportation in the proximal tubules of the kidney.24  It 
is not unreasonable to hypothesise that the same mechanism could account for the elevated 
excretion in the rats. 
NMR spectroscopy was a rapid and simple method for the verification of the two unknown 
compounds in rat urine (methylthioacetate and its sulfoxide).  Each measurement was complete, 
offering the identification and quantification of each unknown within 2 min. 
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7.3 Chronic Renal Failure in Sheep 
7.3.1 Renal Failure and Homocysteine 
Human patients who are suffering chronic renal failure (CRF) experience a dramatic 
increase in plasma homocysteine level.25  Moreover, they can also experience 10-20 times the 
incidence of CVD compared with normal people.  The mechanism responsible for this increase in 
CVD in CRF is unknown, but glycine betaine depletion may play a part in the condition.  During 
CRF, glycine betaine is cleared at an elevated rate by the kidneys, giving a lower concentration in 
the plasma, and if left without replacement, this may lead to a chronic increase in plasma 
homocysteine, and therefore, an increased risk of CVD. 
A model of CRF was set up by Dr Sandy Slow to investigate the addition of DMT to dialysis 
fluid being used in Continuous Ambulatory Peritoneal Dialysis (CAPD).  DMT was chosen for its 
efficient methyl transfer in BHMT, which should result in the greatest drop in homocysteine.  The 
analysis was conducted in a similar way to the rat study [Section 7.2], with most betaine analyses 
being conducted by HPLC, and 1H-NMR spectroscopy being used to analyse betaines that could not 
be easily be discerned by HPLC. 
7.3.2 Study Design 
Four Coopworth sheep (wether hoggets) weighing between 36 kg and 52.5 kg were 
housed in metabolism cages, fed a diet consisting of lucerne chaff, crushed barley and all-purpose 
ruminant pellets, and were given 4 L of tap water each day.  The animals were adjusted to this for 
1-2 weeks before experimental procedures were initiated.   
A standard (47 cm universal) double-cuff Tenckhoff peritoneal dialysis silicone rubber 
catheter was inserted into the peritoneum of each animal using appropriate analgesia and 
anaesthetic and the surgery site was allowed to heal for up to two weeks.  The catheters were 
flushed daily with 1 L of 1.36% glucose solution and were treated with concentrated heparin 
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(10,000 units) and corticosteroid (Depo-medrol®, 20 mg prednisolone) in a 10 mL volume to ensure 
they were not blocked. 
Following healing of the catheter insertion site a full bilateral nephrectomy was conducted 
using appropriate analgesia and anaesthetic on three animals, to generate acute renal failure.  
Water was restricted to 1 L/day for the nephrectomised animals.  Peritoneal dialysis commenced 
within 2 hours of recovery from nephrectomy surgery using a standard human dialysis regime 
consisting of 4 exchanges per 24 hours using either 1.5 L or 2 L of dialysis fluid per exchange and 
was employed for up to 14 days. 
Blood samples (5 mL) were collected daily from each animal via jugular venipuncture into 
lithium heparin vacutainer tubes. An aliquot of whole blood was removed for haematocrit 
measurement and plasma was separated from the remaining blood by centrifugation at 2000 g for 
10 min. Heart rate, respiration rate, rectal temperature, food and water intake and behaviour of all 
animals were monitored daily, both pre and post nephrectomy. 
Plasma concentrations of electrolytes (sodium, chloride, potassium, calcium, magnesium 
and phosphate), creatinine, glucose, albumin, bilirubin, urea and urate were measured daily for all 
animals both pre and post nephrectomy. 
DMT was added to the dialysis fluid at 10 g per exchange except in the case of one animal 
which received 5 g per exchange.  Dialysis fluid samples were assayed for methylthioacetate (the 
expected demethylated product of DMT) and methylthioacetate sulfoxide by 1H-NMR as previously 
described [Section 7.2.2]. 
7.3.3 Results 
The first two nephrectomised animals which were treated with DMT died within 48 hours 
of exposure to DMT.  Attention was then turned to two other subjects, one of which had been 
nephrectomised but had no exposure to DMT and another which had intact kidneys and was 
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placed onto dialysis.  After exchanges with DMT were given, both showed rapid signs of DMT 
toxicity.  The conclusion was that DMT was toxic regardless of dosage (the non-nephrectomized 
sheep received 5 g DMT per exchange, compared to 10 g per exchange for the other animals), and 
kidney function.  All sheep died within 48 hours of exposure, although the onset of symptoms was 
subject to individual variation. 
DMT toxicity resulted in a high heart rate, laboured breathing, salivation and lethargy.  
Animals became non-responsive, lost appetite and stopped drinking.  One animal was withdrawn 
from DMT treatment after initial signs of respiratory distress, but still continued to decline until 
euthanized. 
Plasma concentrations of DMT at death ranged from 0.5-7.8 mM, and were undetectable 
before exposure to DMT.  The expected demethylated product, methylthioacetate, and its sulfoxide 
were not detected in plasma or dialysis fluid by NMR spectroscopy, or by HPLC.   
Post mortem analysis of the DMT treated sheep revealed significant differences in the 
lungs.  The DMT caused a consolidation of the lungs, resulting in an abnormal red-purple 
colouration and the lungs sank when placed in water.  It was concluded that the sheep had died 
from lung failure.  The lung was examined histologically, and it was concluded that the damage 
was consistent with Diffuse Alveolar Damage (DAD), consisting of hyaline membranes and 
proteinaceous exudates.  When exhibited by adult patients, the condition is known as Adult 
Respiratory Distress Syndrome (ARDS).   
7.3.4 Discussion 
Given the success of DMT in the rat study [Section 7.2], the toxicity of DMT in sheep was 
unexpected.  The rats showed no signs of adverse reaction, and experienced rapid drops in plasma 
homocysteine.  More importantly, two sheep in a pilot study which were given acute sub-cutaneous 
injections of 10 g of DMT showed no effects of DMT toxicity. 
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There are several potential explanations for the differences in metabolism observed.  Firstly, 
sheep may have a species-specific response to DMT.  They certainly have differences in BHMT 
distribution: rats express BHMT in the liver and have extremely low activity in the kidney 26-28, sheep 
express BHMT in the pancreas to levels which exceed those in the liver, as well as having 
significant activity in the kidney.29  This may lead to differences in DMT metabolism between the 
species. 
In rats the demethylated product (methylthioacetate) was observed as well as the sulfoxide 
of methylthioacetate.  Both compounds were absent from the sheep samples, indicating that there 
may be a difference in metabolism between them.  It should also be noted that sheep have a 
rumen, containing microbes which may take DMT and alter its metabolism significantly, producing 
toxic chemicals which led to the lung failure observed. 
The rats were exposed to only two doses of DMT at approximately 460 mg/kg, whereas the 
sheep were receiving approximately 500-800 mg/kg DMT daily, over four exchanges.  While the 
rapid failure of the lungs in sheep indicates that the onset of toxicity was rapid, the constant 
exposure to relatively high levels of DMT, in addition to any metabolic differences, may lead to a 
greater effect than that seen in the rats.  In rats, the DMT concentrations after 24 hours were 20-
fold lower than those observed in the sheep, (0.5-7.8 mM), showing that the exposure in rats may 
have been insufficient to show toxic effects. 
Finally, while unlikely, the route of administration was different for the animals which 
experienced DMT toxicity, indicating that route may be significant for toxicity.  The rapid absorption 
and distribution of thetins, however, would indicate that this is unlikely to be a significant factor. 
As with the rat metabolism study, NMR spectroscopy was a rapid method for the detection 
and quantification of DMT and its demethylated product MTA.  Measurements were conducted on 
urine or dialysis fluid and were obtained much faster than by HPLC (2 min for NMR spectroscopy, 
versus 45-60 min for HPLC). 
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7.4 Coffee and Trigonelline  
7.4.1 Coffee Consumption and Homocysteine 
It has been shown that coffee consumption is correlated with plasma homocysteine 
levels.30,31 This correlation appears to be independent of the preparation of the coffee, with filtered 
and unfiltered coffee both increasing plasma homocysteine by as much as 10%.32,33  A total 
abstention from coffee leads to a reduction in total homocysteine.34  It is known that caffeine 
interacts with homocysteine concentration, but there are other components of coffee which are 
glycine betaine analogues, and may affect BHMT in vivo. 
Trigonelline is a naturally occurring betaine found in high concentrations in coffee up to 
1% of the dry material in roasted coffee beans.  At the time of the study, the effects of trigonelline 
on BHMT extracts were not known, and it was suspected from the rat study [Section 7.2] that 
trigonelline may have a homocysteine raising effect in vivo.  It is important to note that this 
homocysteine elevating effect could be caused directly through interactions with BHMT, or through 
interactions in betaine transportation. 
7.4.2 Study Design 
After approval from the Canterbury Medical Ethics Committee, 8 males (18-38 years) were 
recruited and were tested for normal homocysteine, folate, vitamin B12 and haemoglobin 
concentration.  None of the subjects were taking B vitamin supplements, all were non-smokers and 
had no abnormal medical history.   
All were judged to be healthy after a physical examination.  Latin-square design was used 
to randomise the three treatments consisting of 100 mL water, 50 mg trigonelline in 100 mL water, 
and 5 g instant coffee (containing ~50 mg trigonelline) dissolved in 100 mL water.  Each treatment 
was separated by a one week wash-out period.  Subjects were asked to abstain from foods which 
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were known to be high in trigonelline, including coffee, for 48 hours prior to the study days,35 and 
they fasted for 12 hours prior to study commencement.   
Indwelling catheters were inserted, and fasting base-line blood samples (10 mL) were 
withdrawn into EDTA vacutaners.  After treatment, blood samples were withdrawn every hour, and 
urine samples were collected every second hour for 8 hours. After each blood sample, subjects 
were given 150 mL water.  After 8 hours, subjects collected an 8-24 hour urine sample overnight, 
and returned the next morning for a final blood sample.  Standardised breakfasts and lunches were 
prepared from foods known to be low in glycine betaine and trigonelline.35   
Plasma was prepared by centrifugation of the blood samples at 2000 g for 10 min.  Urine 
volume was recorded, and a 10 mL aliquot was removed and frozen at -20 °C until required for 
analysis.  Samples were analysed using standard Canterbury Health Laboratories clinical tests, with 
the exception of DMG and trigonelline, which were measured using the 1H-NMR spectroscopy assay 
described in Chapter 3 of this thesis. 
The effect of the treatments on plasma homocysteine was expressed as a function of 
difference compared with baseline levels. 
7.4.3 Results 
Mean baseline plasma homocysteine concentrations for days 1, 2 and 3 were 8.0 ± 0.2, 
7.8 ± 0.2 and 7.8 ± 0.2 μM respectively.  Plasma homocysteine was significantly elevated after 
coffee consumption compared with water and trigonelline between one and 8 hours after 
treatment (P = 0.019, Figure 7.5).  Water and trigonelline did not differ significantly during the 
study (P = 0.789).  The mean difference in plasma homocysteine was significantly elevated for 
coffee consumption at 4 hours (P = 0.0006), 5 hours (P = 0.0013) and 7 hours (P = 0.0024). 
Mean baseline plasma glycine betaine was 41.2 ± 4.4, 41.9 ± 3.7 and 43.1 ± 5.7 mM 
over the three study days respectively.  It was significantly elevated at 1 hour following trigonelline, 
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when compared with the water and coffee consumption (P = 0.0035 and 0.0040 respectively).  
This effect had gone after 2 hours.  There was no significant difference between coffee and water 
for plasma glycine betaine. 
Baseline glycine betaine excretions were measured as ratios to creatinine [Figure 7.6].  
They were 3.8 ± 0.7, 7.1 ± 1.0 and 5.0 ± 0.7 mmol/mol creatinine.  Coffee consumption lead to an 
increase in glycine betaine excretion at two hours by 7.3 ± 0.9 mmol/mol creatinine and by 8.8 ± 
0.9 mmol/mol creatinine at four hours.  This was significantly elevated when compared to 
trigonelline and water.  Trigonelline lead to a lowered excretion of urine glycine betaine at four 
hours which was significant, although only at that time point.  Trigonelline excretion in the urine 
was clearly elevated post-trigonelline and coffee consumption, and these two treatments did not 
have any significant differences over any of the time points.  The average baseline trigonelline 
concentrations were 6.5 ± 1.8, 5.2 ± 0.8 and 6.0 ± 0.8 mmol/mol creatinine for the study days 
respectively. 
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Figure 7.5 Plasma homocysteine as a function of time over the three treatments.  Coffee (?) was 
significantly different (*) at the 4, 5 and 7 hour time point compared to trigonelline (?) and water (?). 
 
 
Figure 7.6 Urine excretion of glycine betaine, and trigonelline following Coffee ( ), trigonelline (?) and 
water (?).   All y-axis values are in units of mmol/mol creatinine. 
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7.4.4 Discussion 
Coffee consumption gave rise to rapid increases in plasma homocysteine concentration by 
approximately 10%.  Given the previous studies which indicated that chronic coffee consumption 
led to a higher plasma homocysteine,30,32,33 this result is important, confirming those results and 
showing the effect acutely.   
The trigonelline treatment did not result in any significant increased homocysteine 
concentration in the plasma, indicating that it is unlikely to be the active compound giving the 
results noted in the chronic consumption studies.30,32,33  No direct evidence for the inhibition of 
BHMT activity in vivo could be obtained by this study, although the elevated glycine betaine 
excretion at two and four hour time points, combined with lowered plasma glycine betaine 
concentrations, indicate that coffee consumption may have an effect on the transportation and 
homeostasis of glycine betaine.  Curiously, trigonelline alone did not have this effect, showing that 
there may be some other active compound in coffee leading to this observation. 
There was an increase in plasma homocysteine after the consumption of coffee, which may 
have been caused by the inhibition of BHMT activity.  If coffee consumption lowers the glycine 
betaine pool available to BHMT (by increasing the excretion of betaine) then the observed increase 
in plasma homocysteine may be explained. 
Roughly 50% of the increase in homocysteine was attributed to caffeine from the coffee36  
and chlorogenic acid, also present in high levels in coffee, is known to increase homocysteine.37 The 
exact reason for the increase in homocysteine is likely to be complex, and involve a number of the 
compounds present in the coffee.  This experiment has excluded trigonelline from the likely list of 
active compounds which can increase homocysteine. 
NMR spectroscopy showed it ability to identify and quantify methylamine compounds with 
no chemical manipulation and with rapid turnover.  There was no clinical assay for trigonelline 
available at Canterbury Health Laboratories, and NMR spectroscopy was able to obtain results with 
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a 2 minute turnover of samples.  DMG measurements by HPLC are complicated by co-elution with 
other compounds.  NMR spectroscopy was employed to quantify the urine excretion in the subjects, 
as the DMG methyl-singlet signal is clear and separate from other peaks in the spectrum. 
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7.5 Dimethylglycine (DMG) Supplementation 
7.5.1 Dimethylglycine and Methylation 
Like glycine betaine and choline, DMG is an important source of methyl groups, which can 
be catabolised and used to form folate.  However, the role of DMG in the regulation of plasma 
homocysteine is not clear.  DMG is a potent feedback inhibitor of BHMT activity38 and BHMT makes 
up as much as 50% of the remethylation of homocysteine to methionine in the body.16  These 
interactions would lead to the prediction that high DMG would lead to a high homocysteine 
concentration. 
DMG, however, can donate both of its remaining methyl groups to form 5’-methyl- 
tetrahydrofolate (mTHF).  The two equivalents of mTHF formed from the metabolism of DMG can 
then go on via methionine synthase to remove homocysteine.  Methionine synthase is responsible 
for the remaining 50% of the homocysteine which is recycled back to methionine.16  This 
information leads to the assumption that high DMG decreases plasma homocysteine: the opposite 
prediction to the interaction with BHMT. 
Choline metabolism leads to the production of DMG in most mammalian cells, however, 
DMG can be purchased over the counter in health food stores (known as ‘pangamic acid’, or 
‘vitamin B15’) as a supplement for the enhancement of athletic abilities, improvement of epileptic 
symptoms, alleviation of autism and the stimulation of the immune system.39 
There have been a few clinical studies of DMG supplementation, and none have any 
evidence to support most of the claims made by the health food industry.  None of the studies 
performed to date, however, have looked specifically at the effect of DMG on homocysteine 
metabolism.  Given the potential for DMG to effect plasma homocysteine, a study was designed to 
investigate the interaction of DMG in patients with Chronic Renal Failure (CRF).  CRF patients have 
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elevated plasma homocysteine levels and should show any effects of DMG supplementation more 
readily than the normal population. 
7.5.2 Study Design 
After approval from the Canterbury Medical Ethics Committee, 8 pre-dialysis male CRF 
patients (44-75 years) were recruited from the Christchurch Hospital Nephrology Database.  One of 
the patients, due to unrelated health complications, did not complete the course of the study. 
Of the remaining seven subjects, all had normal red blood cell folate concentrations and 
were replete in vitamin B12.  The cause of CRF in the seven subjects was hypertension (2), chronic 
glomerulonephritis (2), polycystic disease (1), reflux nephropathy (1) and obstructive uropathy (1).  
All had stable renal function as measured by plasma creatinine levels for three months before the 
trial began and they remained stable during the study. 
The trial had a randomised, crossover, blinded study design, with the two treatments being 
400 mg of DMG solution (Health World Limited, Queensland, Australia; Liquid preparation 
containing 50 mg/mL DMG in 20% ethanol by analysis) or placebo (20% ethanol) for 28 days.  
After 28 days, the subjects changed treatments without a wash-out period. 
Fasting venous blood samples were drawn into EDTA tubes, and 12 hour urine samples 
were collected prior to treatment and at the end of treatment, on days 28 and 56.  Blood samples 
were placed on ice until separated at 2000 g for 10 min, within an hour of collection.  Urine 
volume was recorded and a 10 mL aliquot was taken for analysis.  All samples were frozen at -20 
°C until analysis. 
Plasma homocysteine analysis was performed using standard clinical assays in Canterbury 
Health Laboratories.  Plasma and urine glycine betaine, as well as plasma DMG, were measured by 
HPLC.  The urine DMG was analysed using the 1H-NMR assay described in this thesis, and as used 
for the rat and coffee study.40  Plasma methionine was measured using a ninhydrin based amino 
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acid analyser.  Urine creatinine was measured under standard clinical procedures based on the Jaffé 
reaction.  Urine concentrations were converted to units of mmol/mol creatinine. 
 
7.5.3 Results 
There was no significant difference from baseline plasma glycine betaine (P = 0.452), 
homocysteine (P = 0.624) and methionine (P = 0.457) after either the placebo or the DMG 
treatment.  Plasma DMG concentration was significantly elevated after the DMG treatment, when 
compared to baseline (P = 0.021) and the placebo had no effect on plasma DMG concentration (P 
= 0.997) [Table 7.1]. 
Urine glycine betaine was not significantly altered after either of the treatments.  Urine 
DMG was significantly elevated after the DMG treatment compared to the baseline (P = 0.014) and 
the placebo (P = 0.008).  The placebo and baseline were not significantly different [Table 7.1]. 
 Baseline DMG (mean ± SE) Placebo 
Plasma (μM) 
Homocysteine 17.7 ± 1.7 18.3 ± 1.3 17.9 ± 1.4 
DMG 9.7 ± 1.1 71.9 ± 24.5 * 11.2 ± 1.7 
Glycine betaine 40.0 ± 4.7 34.8 ± 3.0 37.0 ± 4.0 
Methionine 27.8 ± 2.0 28.9 ± 2.1 26.6 ± 3.3 
Creatinine 310 ± 40 330 ± 40 320 ± 40 
Urine (mmol/mol creatinine) 
DMG 9.6 ± 3.0 34.5 ± 10.2 * 8.9 ± 2.1 
Glycine betaine 79.6 ± 17.1 60.2 ± 13.5 66.7 ± 12.6 
 
Table 7.1 DMG trial results.  Baseline, DMG treatment, and Placebo plasma and Urine concentrations for 
all the measured biochemicals.  * Significant difference to placebo and baseline (P < 0.05). 
 
7.5.4 Discussion 
Plasma DMG concentrations were elevated in the patients at baseline and placebo, 
consistent with previous observations of CRF patients.41  The normal range for DMG in plasma is 
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1.4-5.3 μM.38  Supplementation of 400 mg DMG over four weeks significantly elevated DMG in 
both the plasma and urine, but had no effect on glycine betaine, homocysteine, methionine or 
creatinine, compared with placebo. 
Glycine betaine excretion was elevated in the baseline urine results, but this was 
unaffected by the supplementation with DMG.  It was expected that plasma glycine betaine would 
increase, as a result of BHMT feedback inhibition by DMG, but this was not seen.   
It is unlikely that these results would be any different in other population groups, where 
homeostasis of betaines is not disturbed as it is in CRF.  It is possible that the two effects 
mentioned in the introduction, the inhibition of BHMT and the formation of mTHF are both 
occurring, and neutralising each other. 
DMG supplementation in patients with CRF has no effect on plasma homocysteine or 
betaine homeostasis, resulting only in an increased plasma DMG and elevated DMG excretion. 
Chapter 7 – In Vivo Studies of Mammalian Betaine Metabolism    
 
 
197 
References 
 
(1) Brosnan, J. T.; Jacobs, R. L.; Stead, L. M.; Brosnan, M. E. Acta Biochimica Polonica 2004, 
Methylation demand: A key determinant of homocysteine metabolism, 51, 405-413. 
(2) Stead, L. M.; Jacobs, R. L.; Brosnan, M. E.; Brosnan, J. T. Advances in Enzyme Regulation 
2004, Methylation demand and homocysteine metabolism, 44, 321-333. 
(3) Ulrey, C. L.; Liu, L.; Andrews, L. G.; Tollefsbol, T. O. Human Molecular Genetics 2005, The 
impact of metabolism on DNA methylation, 14, R139-R147. 
(4) Finkelstein, J. D.; Martin, J. J. Journal of Biological Chemistry 1986, Methionine 
metabolism in mammals. Adaptation to methionine excess, 261, 1582-1587. 
(5) Silberberg, J.; Crooks, R.; Wlodarczyk, J.; Nair, B.; Finucane, P.; Guo, X. W.; Xie, L. J.; 
Dudman, N. Australian and New Zealand Journal of Medicine 1997, Reference range for % 
rise in homocysteine after oral methionine load, 27, 717. 
(6) Miller, J. W.; Nadeau, M. R.; Smith, D.; Selhub, J. American Journal of Clinical Nutrition 
1994, Vitamin B-6 deficiency vs folate deficiency: comparison of responses to methionine 
loading in rats, 59, 1033-1039. 
(7) Muller, T.; Woitalla, D.; Hauptmann, B.; Fowler, B.; Kuhn, W. Neuroscience Letters 2001, 
Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated 
patients with Parkinson's disease, 308, 54-56. 
(8) Stead, L. M.; Au, K. P.; Jacobs, R. L.; Brosnan, M. E.; Brosnan, J. T. American Journal of 
Physiology. Endocrinology and Metabolism 2001, Methylation demand and homocysteine 
metabolism: effects of dietary provision of creatine and guanidinoacetate, 281, E1095-
1100. 
(9) Olthof, M. R.; van Vliet, T.; Boelsma, E.; Verhoef, P. Journal of Nutrition 2003, Low dose 
betaine supplementation leads to immediate and long term lowering of plasma 
homocysteine in healthy men and women, 133, 4135-4138. 
(10) Olthof, M. R.; Verhoef, P. Current Drug Metabolism 2005, Effects of betaine intake on 
plasma homocysteine concentrations and consequences for health, 6, 15-22. 
(11) Singh, R. H.; Kruger, W. D.; Wang, L.; Pasquali, M.; Elsas, L. J., II Genetics in Medicine 
2004, Cystathionine b-synthase deficiency: effects of betaine supplementation after 
methionine restriction in B6-nonresponsive homocystinuria, 6, 90-95. 
(12) Essen, A. v. In Mathematics and Statistics; University of Canterbury: Christchurch, New 
Zealand, 2003, p 34. 
Chapter 7 – In Vivo Studies of Mammalian Betaine Metabolism    
 
 
198 
(13) Dinning, J. S.; Neatrour, R.; Day, P. L. Proceedings of the Society for Experimental Biology 
and Medicine 1953, Effect of diet on rat-liver betaine transmethylase, 84, 499-501. 
(14) Ericson, L. E.; Harper, A. E. Journal of Biological Chemistry 1956, Effect of diet on the 
betaine-homocysteine transmethylase activity of rat liver. I. Amino acids and protein, 219, 
49-58. 
(15) Finkelstein, J. D.; Kyle, W.; Harris, B. J. Archives of Biochemistry and Biophysics 1971, 
Methionine metabolism in mammals. Regulation of homocysteine methyltransferases in rat 
tissue, 146, 84-92. 
(16) Finkelstein, J. D.; Martin, J. J. Journal of Biological Chemistry 1984, Methionine 
metabolism in mammals.  Distribution of homocysteine between competing pathways, 259, 
9508-9513. 
(17) Wilcken, D. E. L.; Wilcken, B.; Dudman, N. P. B.; Tyrrell, P. A. New England Journal of 
Medicine 1983, Homocystinuria-the effects of betaine in the treatment of patients not 
responsive to pyridoxine, 309, 448-453. 
(18) McGregor, D. O.; Dellow, W. J.; Robson, R. A.; Lever, M.; George, P. M.; Chambers, S. T. 
Kidney International 2002, Betaine supplementation decreases post-methionine 
hyperhomocysteinemia in chronic renal failure, 61, 1040-1046. 
(19) Mulligan, J. D.; Laurie, T. J.; Garrow, T. A. Journal of Nutritional Biochemistry 1998, An 
assay for betaine-homocysteine methyltransferase activity based on the microbiological 
detection of methionine, 9, 351-354. 
(20) Mendum, M. L.; Smith, L. T. Applied and Environmental Microbiology 2002, 
Characterization of glycine betaine porter I from Listeria monocytogenes and its roles in salt 
and chill tolerance, 68, 813-819. 
(21) Goeger, D. E.; Ganther, H. E. Archives of Biochemistry and Biophysics 1993, Homocysteine-
dependent demethylation of trimethylselenonium ion and selenobetaine with methionine 
formation., 302, 222-227. 
(22) Lever, M.; Bason, L.; Leaver, C.; Hayman, C. M.; Chambers, S. T. Analytical Biochemistry 
1992, Same-day batch measurement of glycine betaine, carnitine, and other betaines in 
biological material, 205, 14-21. 
(23) De Oliveira, A. C.; D'Almeida, V.; Hipolide, D. C.; Nobrega, J. N.; Tufik, S. Canadian Journal 
of Physiology and Pharmacology 2002, Sleep deprivation reduces total plasma 
homocysteine levels in rats, 80, 193-197. 
Chapter 7 – In Vivo Studies of Mammalian Betaine Metabolism    
 
 
199 
(24) Lever, M.; Sizeland, P. C. B.; Bason, L. M.; Hayman, C. M.; Chambers, S. T. Biochimica et 
Biophysica Acta 1994, Glycine betaine and proline betaine in human blood and urine, 
1200, 259-264. 
(25) Bostom, A. G.; Lathrop, L. Kidney International 1997, Hyperhomocysteinemia in end-stage 
renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes, 
52, 10-20. 
(26) Ericson, L. E. Acta Chemica Scandinavica 1960, Betaine-homocysteine methyltransferases. 
I. Distribution in nature, 14, 2102-2112. 
(27) Maw, G. A. Biochemical Journal 1959, Thetin-homocysteine transmethylase. The 
distribution of the enzyme, studied with the aid of trimethylsulfonium chloride as substrate, 
72, 602-608. 
(28) McKeever, M. P.; Weir, D. G.; Molloy, A.; Scott, J. M. Clinical Science 1991, Betaine-
homocysteine methyltransferase: organ distribution in man, pig and rat and subcellular 
distribution in the rat, 81, 551-556. 
(29) Xue, G. P.; Snoswell, A. M. Comparative Biochemistry and Physiology, Part B: Biochemistry 
& Molecular Biology 1986, Developmental changes in the activities of enzymes related to 
methyl group metabolism in sheep tissues, 83B, 115-120. 
(30) Stolzenberg-Solomon, R. Z.; Miller, E. R., III; Maguire, M. G.; Selhub, J.; Appel, L. J. 
American Journal of Clinical Nutrition 1999, Association of dietary protein intake and 
coffee consumption with serum homocysteine concentrations in an older population, 69, 
467-475. 
(31) Nygård, O.; Refsum, H.; Ueland, P. M.; Vollset, S. E. American Journal of Clinical Nutrition 
1998, Major lifestyle determinants of plasma total homocysteine distribution: the 
Hordaland homocysteine study, 67, 263-270. 
(32) Urgert, R.; van Vliet, T.; Zock, P. L.; Katan, M. B. American Journal of Clinical Nutrition 
2000, Heavy coffee consumption and plasma homocysteine: a randomized controlled trial 
in healthy volunteers, 72, 1107-1110. 
(33) Grubben, M. J.; Boers, G. H.; Blom, H. J.; Broekhuizen, R.; de Jong, R.; van Rijt, L.; de 
Ruijter, E.; Swinkels, D. W.; Nagengast, F. M.; Katan, M. B. American Journal of Clinical 
Nutrition 2000, Unfiltered coffee increases plasma homocysteine concentrations in healthy 
volunteers: a randomized trial, 71, 480-484. 
Chapter 7 – In Vivo Studies of Mammalian Betaine Metabolism    
 
 
200 
(34) Christensen, B.; Mosdol, A.; Retterstol, L.; Landaas, S.; Thelle, D. S. American Journal of 
Clinical Nutrition 2001, Abstention from filtered coffee reduces the concentrations of 
plasma homocysteine and serum cholesterol--a randomized controlled trial, 74, 302-307. 
(35) de Zwart, F. J.; Slow, S.; Payne, R. J.; Lever, M.; George, P. M.; Gerrard, J. A.; Chambers, S. 
T. Food Chemistry 2003, Glycine betaine and glycine betaine analogues in common foods, 
83, 197-204. 
(36) Verhoef, P.; Pasman, W. J.; Van Vliet, T.; Urgert, R.; Katan, M. B. American Journal of 
Clinical Nutrition 2002, Contribution of caffeine to the homocysteine-raising effect of 
coffee: a randomized controlled trial in humans, 76, 1244-1248. 
(37) Olthof, M. R.; Hollman, P. C.; Zock, P. L.; Katan, M. B. American Journal of Clinical 
Nutrition 2001, Consumption of high doses of chlorogenic acid, present in coffee, or of 
black tea increases plasma total homocysteine concentrations in humans, 73, 532-538. 
(38) Allen, R. H.; Stabler, S. P.; Lindenbaum, J. Metabolism: Clinical and Experimental 1993, 
Serum betaine, N,N-dimethylglycine and N-methylglycine levels in patients with cobalamin 
and folate deficiency and related inborn errors of metabolism, 42, 1448-1460. 
(39) Graber, C. D.; Goust, J. M.; Glassman, A. D.; Kendall, R.; Loadholt, C. B. Journal of 
Infectious Diseases 1981, Immunomodulating properties of dimethylglycine in humans, 
143, 101-105. 
(40) Slow, S.; Lever, M.; Lee, M. B.; George, P. M.; Chambers, S. T. International Journal of 
Biochemistry & Cell Biology 2004, Betaine analogues alter homocysteine metabolism in 
rats, 36, 870-880. 
(41) McGregor, D. O.; Dellow, W. J.; Lever, M.; George, P. M.; Robson, R. A.; Chambers, S. T. 
Kidney International 2001, Dimethylglycine accumulates in uremia and predicts elevated 
plasma homocysteine concentrations, 59, 2267-2272. 
  
Chapter 8 
 
Conclusions and Future Work 
 
 
 
Alice: Will you tell me which way I ought to go from here? 
Cheshire Cat: That depends a good deal on where you want to go.  
Alice: I don't much care ... 
Cheshire Cat: Then it doesn't matter which way you go.  
- Alice in Wonderland, Lewis Carroll 
 
Sometimes I lie awake at night, and I ask, "Where have I gone wrong?" 
Then a voice says to me, "This is going to take more than one night." 
-     Charles M. Schulz, Charlie Brown in ‘Peanuts’ 
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CHAPTER 8: 
Conclusions and Future Work 
 
8.1 Thesis Aims 
 Most of the aims of this thesis involved the application of 1H-NMR spectroscopy to 
biological samples.  Specifically the aims were: 
1. To develop a method for the purification of BHMT from liver samples [Chapter 2]. 
2. To develop a 1H-NMR spectroscopic assay for BHMT for the purposes of detection of 
BHMT, and the measurement of kinetic constants for BHMT [Chapters 3 and 4]. 
3. To use 1H-NMR spectroscopy to investigate the substrate specificity of BHMT from 
rat liver [Chapter 5]. 
4. To make observations of BHMT from alternative sources, including Agnathan liver 
samples, and to partially characterise the enzyme for comparison with rat BHMT 
[Chapter 6]. 
5. To use 1H-NMR spectroscopy to measure methylamines and related compounds in 
urine as an indirect method for the detection of BHMT activity in vivo [Chapter 7]. 
 
8.2 Reproducible BHMT Purification 
In Chapter 2, the purification of BHMT from rat liver was described, using several elements 
of previously reported preparations.  In short, purification was based on tissue homogenisation, 
followed by heat treatment and then size exclusion chromatography.  The methods were further 
developed and it was found that BHMT can survive at higher temperatures, although for much 
shorter times than had previously been described.  This enabled the initial purification step to be 
greatly improved from a ~1.5 fold purification (70 °C for 5 min) step to a ~5 fold one (90 °C for 2 
min).  These steps were used in all rat liver extractions. The purified BHMT was not homogeneous, 
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but SDS-PAGE analysis showed considerable enrichment of BHMT activity.  It was estimated by 
visual inspection of SDS-PAGE results that BHMT accounted for approximately 80 % of the total 
protein in the final product. 
Further work to determine the BHMT concentration could be performed and used to 
“correct” the concentration of active BHMT in the kinetic calculations.  For example, an ELISA 
technique, based on antibodies raised against rat liver BHMT, would be a suitable method for 
analysis of total BHMT concentration.  Active site titration, to determine the concentration of active 
BHMT in the solution, might also be worth doing.1  This procedure uses an interaction between a 
known competitive inhibitor of the enzyme and some method of detecting its interaction with the 
protein.  The method may have to be adapted to include kinetic techniques, as described by 
Brocklehurst et al.1  A suitable inhibitor might be S-(γ-carboxybutyl)-L-homocysteine (CBH) which 
was described in Chapter 1.  Brocklehurst et al related the number of active sites with the catalytic 
activity of the enzyme, showing that a mathematical relationship can be drawn between the two 
and that this can be used to determine the number of active sites present in the solution.  The 
application of their analysis to the BHMT extracts should afford an estimate of the active BHMT 
concentration.  It is also possible that the boronic acid betaine developed by Lee et al may be useful 
in these studies.2  Zinc measurements may also be conducted and used to estimate the 
concentration of BHMT in solution, however, this would require the use of zinc-free solutions 
throughout the purification of BHMT. 
Anion exchange chromatography of the rat extract gave a solution in which the BHMT was 
initially active, however, that activity was reduced to undetectable levels after approximately 48-60 
h.  This is consistent with a previous report that BHMT from Sprague-Dawley rats was labile when 
purified.2  This group also obtained a protein comprised of 45 kDa subunits and having a total mass 
of ~260-270 kDa.  This is consistent with hexameric BHMT, which they purified to near 
homogeneity.  They found that the BHMT activity was labile unless dimethylglycine and 
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homocysteine were present in the solution.  Both of these results imply that there is a stabilising 
factor present in impure BHMT solutions which is not removed in the procedures described in 
Chapter 2.  It is also possible that there is some inhibitor which slowly leaches out of the DEAE 
Sephadex, removing BHMT activity: although it is not clear why this would lead to a slow loss of 
activity. 
The quaternary structure of liver BHMT is subject to an ongoing debate, with recombinant 
human BHMT having been shown to be a tetramer of 45 kDa subunits by X-ray crystal structure 
analysis.3-5  Analysis of most liver extracts have estimated the native enzyme to be larger, 
approximately 250-270 kDa in size, being consistent with a hexameric structure.  The results 
presented in Chapter 2 are consistent with a hexameric structure, although the measurements 
indicated a size slightly smaller than expected.  Further work needs to be done to explain the 
differences observed.  It is possible that the naturally occurring BHMT is a hexamer, but that the 
recombinant protein is not.  Some post-translational modification may occur in the mammalian 
liver.  Analytical ultracentrifugation may allow the elucidation of the true quaternary structure of 
BHMT.  Ultracentrifugation accompanied with mass spectrometry may also show any glycosylation 
which may occur on the protein.  One simple first experiment should include the same gel filtration 
analysis exploring the quaternary structure of recombinant and liver BHMT.  This should reveal any 
differences between the two proteins. 
The kinetic and specificity results obtained in this thesis are in good agreement with other 
measurements made internationally, implying that the protein extracted was of a similar nature to 
those obtained by other groups.2,6-10  Furthermore, the same purification procedures were employed 
on several occasions during the progress of the research presented in this thesis, and always gave 
similar purification when visualised with SDS-PAGE analysis. 
N-terminal sequence analysis revealed a variable N-terminal sequence suggesting that 
amino-peptidase had modified the BHMT during preparation.  Protease inhibitors have been used 
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in the BHMT purification by some research groups,2 and it may be possible to improve the yield and 
integrity of active BHMT by adding protease inhibitors to the buffers used in the procedures 
developed in this thesis.  This would need care as EDTA, commonly used as a metal-protease 
inhibitor, could chelate the zinc cation from the active site of BHMT, particularly if it was present 
during the high temperatures involved in the denaturing of the homogenate.  It is unknown if the 
amino-peptidase activity observed is a consequence of liver enzymes, or bacterial proteases 
introduced after the heat denaturation step. 
 
8.3 1H-NMR Spectroscopic Assay for BHMT and Kinetic Measurements 
 Once BHMT had been reproducibly purified, work proceeded on the development of a 
1H-NMR assays for physiological betaines and BHMT activity.  Spin lattice relaxation constants were 
determined for glycine betaine, DMG and methionine in water, and appropriate delays were then 
built into the basic pulse sequences. Water suppression with pulsed field gradients (DPFGSE) and 
presaturation of the water resonance were also explored, and for kinetic measurements, DPFGSE 
was used to ensure adequate suppression of water.  The assay was based on integrations of the 1H-
NMR singlet resonances of glycine betaine, DMG and methionine (3.22, 2.86 and 2.10 ppm 
respectively) all compared to the tert-butanol signal (1.15 ppm).  Standard lines of glycine betaine, 
DMG and methionine were determined with respect to tert-butanol, allowing quantification of each 
reaction component during the assay. Plots of the concentration of DMG over time were used to 
determine the rate of methyl transfer.  The reaction was modelled on the Michaelis Menten steady-
state equation, and the Km for glycine betaine was determined to be 0.19 ± 0.03 mM, and Vmax for 
BHMT was 17  ± 0.7 nmol min-1 mg-1, converting to a turnover number for each active site of ~0.8 
min-1.  These results are in good agreement with previous estimates of Km  and Vmax for the rat liver 
enzyme.2,11 
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8.4 Methyl Donor Substrate Specificity 
 The 1H-NMR spectroscopic assay developed in Chapter 3 allowed, for the first time, direct 
monitoring of methyl transfer from a range of potential substrates.  The work of Ericson from 1960 
was reviewed and investigated, and several new betaines were tested for activity and inhibition 
against rat liver BHMT.12  It was found that BHMT activity is affected by chain length, methylated 
heteroatom and α-substitution in the donor betaine, but that DMT, DMSP, trimethylsulfonium ions, 
selenobetaine and DMSeP can all act as methyl donors in BHMT.  Co-incubation of glycine betaine 
and betaine analogues did not provide clear evidence of inhibition.  These findings were in contrast 
to the work performed by Ericson and Mulligan et al who found BHMT activity with several 
alternative betaine sources, including proline betaine, via the colorimetric and microbiological 
assays, respectively.12,13 
 The results presented by Ericson and Mulligan may be a result of problems with the 
colorimetric and microbiological assays.  The nitroprusside dye used in this assay might react with 
some of the betaine analogues, leading to positive readings when no methionine is being 
produced.  This may lead to false positive readings in the BHMT assay, as the nitroprusside that 
they used may give a colour change without the production of methionine.  Similarly, the 
microbiological assay may not be linear at low levels of activity, with a small concentration of 
methionine giving a rapid growth in E. coli. 
 Molecular modelling of the chemical reaction thermodynamics was performed for some of 
the more active betaines, including glycine betaine, propiobetaine, DMT, DMSP, selenobetaine and 
the tetramethylammonium and trimethylsulfonium ions to elucidate any thermodynamic reasons for 
the differences in BHMT activity seen.  It was shown that at higher levels of computational 
modelling, thermodynamic differences between the ammonium and sulfonium analogues could be 
seen, partially explaining the much higher activities of the sulfonium analogues.  Similar results 
were seen with the sulfonio and selenonio analogues.  These results, however, all support the 
Chapter 8 – Conclusion and Future Work    
 
206 
 
experimental result that the sulfonio and seleno-betaines are much faster methyl donors in BHMT 
than the amino betaines.  The modelling also verified that there was a thermodynamic reason for 
the loss of activity from glycine betaine (nitrogen heteroatom) to phosphonio and arseno-betaine 
(phosphorus and arseno- heteroatoms, respectively).  This is likely to be due to the effect of empty 
d orbitals, which phosphorus and arsenic both have at their disposal. 
 The lack of activity seen with the α-substituted betaines, the betaines with increased chain 
length, and the naturally occurring betaines is likely to be due to a steric effect, where interactions 
between the betaine and critical residues in BHMT have either been disrupted, or the larger size of 
the betaine prevents access to the active site of BHMT.  There was, however, potentially a small 
allosteric effect observed with phenylalanine betaine, and with ectoine, which led to enhanced 
methyl transfer when they were co-incubated with glycine betaine.  This may be a consequence of 
conformational changes in BHMT as the phenylalanine betaine and ectoine bind to the active site, 
inducing a greater catalytic efficiency at the other active sites in the active BHMT protein. 
 Recent work which has elucidated the crystal structure of BHMT will provide the next 
advances in this work.  Molecular modelling of the active site of BHMT, with the analogues 
identified here, should provide a much greater understanding of how BHMT achieves methylation, 
and the catalytic rate seen in the enzyme.  Furthermore, NMR spectroscopic elucidation of the 
solution state structure may be employed to explore the binding of betaines to the known betaine 
binding amino-acid residues in the BHMT active site.5,14  There are several experiments that are 
available to the NMR researcher, notably diffusion experiments,15 which may be able to add to the 
IF experiments to further expand and explain the role of betaine analogues in the BHMT reaction. 
 
8.5 Comparison of Agnathan and Mammalian Liver BHMT 
The distribution of BHMT in nature poses an interesting study. The methionine-
homocysteine cycle is of vital importance to basic biochemistry.  It has been shown that the known 
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mammalian forms of BHMT are all remarkably similar, sharing a high degree of gene and amino 
acid identity [Figure 6.1].  This evidence, including the discovery of BHMT activity in agnathan 
liver, implies a common ancestral enzyme. 
N-terminal sequencing of rat protein conclusively revealed the presence of the expected 
BHMT subunit in the active rat fractions.  No sequence could be obtained from the hagfish 
samples.  The likely cause of this is acetylation on the N-terminus of the hagfish BHMT.  In situ 
acid/alcohol washing of the hagfish PVDF did not yield any N-terminal sequence data.  Further 
work is required to improve the purification of BHMT from the hagfish and to resolve the protein 
sequence to allow evolutionary comparison.  Cyanogen bromide cleavage of the 45 kDa PVDF band 
which has already been isolated might further afford information on the structure of the protein 
seen.  Cyanogen bromide cleaves peptides at methionine residues, and (using rat BHMT as a 
model) would be expected to give 9 shorter polypeptides, one of which will remain N-terminally 
blocked.  If this work is done in solution, preparative HPLC analysis may be able to resolve and 
isolate these fragments for N-terminal sequencing or mass spectroscopic analysis. 
Hagfish and lamprey liver cDNA libraries were prepared by Dr Victoria Metcalf working 
with the group.  These may be employed to further isolate a BHMT cDNA from the hagfish liver.  
One approach would be to use functional complementation, using E. coli J5-3, a methionine 
auxotroph.  Here the J5-3 would be transformed with a cDNA plasmid library, and clones coding for 
a functional BHMT activity can be selected for sequencing which will lead to the  identification of 
the active BHMT.13 
The hagfish BHMT was shown to have similar substrate specificity to the rat liver BHMT, 
indicating that it potentially shares a common betaine and homocysteine binding motif.  These 
studies can be expanded to include the libraries of betaines investigated in Chapter 5 here in 
mammalian liver BHMT, as well as others, including trimethyltelluride and trimethylselenonium 
ions. 
Chapter 8 – Conclusion and Future Work    
 
208 
 
The investigations on Agnathan BHMT should also be expanded to include more distant 
animals, potentially the swan-mussel, in which BHMT activity was identified during Ericson’s 
investigations.16  Furthermore, BHMT activity has been identified in plants, bacteria and fungi.17-20  
The investigations of the acetone powders presented in Chapter 6, imply that there is either no 
BHMT in lemon shark livers, or that it is not stable as an acetone powder.  Fresh homogenates of 
shark livers should be prepared and assayed for BHMT activity, to elucidate the absence or 
presence of BHMT in shark livers.  Also, purification of BHMT activity from these livers should be 
refined to give a higher purity than what was obtained in this work. 
 
8.6 1H-NMR Spectroscopic Assay for Methylamines in Urine 
The NMR-based assay for glycine betaine used in the kinetic assay was expanded and 
verified to allow clinical assays of various betaines in urine.  Clinically, there are several 
methylamines which are useful indicators of disease.  These include creatine, creatinine, 
trimethyamine, trimethyamine N-oxide, proline betaine, trigonelline and dimethylglycine.21-29  NMR 
spectroscopy has been used to measure each of these metabolites before, but there has never been 
a validation process published, verifying the suitability of NMR spectroscopy for clinical studies. 
The within and inter-batch coefficients of variance for each of the metabolites listed above 
were below 7.5 % and 8.5 % respectively, with limits of detection (s/n >3) of 15-25 μM.  Previous 
research into the measurement of small molecules in urine has employed complicated chemical 
manipulation to help remove water signals, often dehydrating or freeze drying the samples, then 
replacing the solvent with D2O, providing an internal lock standard.  It was found that presaturation 
of the water resonance for 3 s prior to the 90° pulse and acquisition was sufficient to remove the 
water signal for quantifiable results.  Carnitine was also identified in the spectrum, and was not co-
resonant with any of the metabolites measured. 
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Metabonomics/Metabolomics is a rapidly developing field, being driven by developments in 
high-field NMR spectroscopy.  Metabolomic analyses involve running ‘fingerprint’ spectra, with 
rapid throughput, and using automated computerised systems to analysis and diagnose metabolic 
disorders from those spectra.  The NMR spectroscopic techniques developed here were labour 
intensive, but can be automated.  Implementation of the metabolomic software being developed by 
Varian and Bruker will allow much faster processing and analysis.  Current HPLC techniques in use 
at Canterbury Health Laboratories for the measurement of methylamines involve 60 min run-times 
and large volumes of acetonitrile.  The NMR spectroscopic assay takes less than 2 min, and is 
capable of discerning DMG and TMA/TMAO, both of which are difficult to detect, resolve and 
quantify by HPLC.  The versatility of the NMR assay was demonstrated during the rat experiment 
[Chapter 7] and the rapid adaptation of the currently existent assay to measure the sulfoxide of the 
DMT demethylation reaction. 
The potential exists to expand this work to encompass a much larger range of metabolites.  
There is precedent for a number of metabolites to be analysed via NMR spectroscopy, including 
citrate, alanine and glucose, amongst numerous other metabolites.30-32  There are many other 
potential metabolites which could be measured using 1H-NMR spectroscopy, including acetyl-
carnitine and carnitine.  As metabolomics develops, along with high-field NMR spectrometers, the 
list of metabolites measurable should grow to make NMR spectroscopy a valuable tool in diagnosis. 
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8.7 Future Experiments 
 There are four experiments which could be conducted initially to clarify some of the results 
observed in this thesis. 
1. Protein sequencing of hagfish BHMT should identify the protein responsible for 
BHMT activity.  Better purification is likely to be needed, but if N-terminal blocking 
remains a problem, cyanogen bromide cleavage, followed by reverse-phase HPLC 
and collection of the fragments should help identify the protein. 
2. Kinetic analysis of DMT and DMSP in the presence of DMG should determine the Ki 
for DMG. 
3. Incubation of hagfish BHMT in the presence of a wider array of betaine analogues 
should be conducted to better compare the two enzymes. 
4. Carnitine was identified in the urine 1H-NMR spectroscopic assay, but not used in 
any of the validation work.  Carnitine would be useful for clinical work at 
Canterbury Health Laboratories, so the validation work outlined in Chapter 4 
could be repeated with carnitine. 
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8.8 Conclusion  
There is little question about the necessity of research into homocysteine and CVD.  
Despite recent reports which found that although plasma homocysteine concentration is reduced 
after supplementation with folate and vitamin B12, there was no associated reduction in further 
CVD risk (with the exception of stroke, the risk of which was reduced by their intervention).  These 
studies have all ignored the potential for BHMT to also reduce plasma homocysteine, so there is 
still potential for BHMT to be explored for CVD therapeutics.  Infact, BHMT might be a more 
important junction than MS, because the link between homocysteine and CVD is well described, yet 
folate treatment does not appear to protect against a second atherosclerotic events (although the 
risk of stroke is reduced by this intervention). 
However, the interaction between glycine betaine and homocysteine is not yet fully 
elucidated.  There is only one known enzyme which can demethylate glycine betaine and remove 
homocysteine to form methionine (BHMT), but there are several betaine analogues, and other 
naturally occurring chemicals which may affect BHMT activity in vivo, which have not been 
explored.  The NMR spectroscopic assay is the best technique for the exploration of these effects, 
because it offers a continuous method for monitoring the reaction, is applicable for all potential 
analogues and is a direct measure of the reaction, unlike some of the microbiological assays.  
Furthermore, NMR spectroscopy also allows for further investigation of the binding of betaine 
analogues using diffusion measurements.  NMR spectroscopy may also be used to solve the 
solution-state structure of the enzyme, which should help in the exploration of 
betaine/homocysteine relationships in vivo. 
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Appendices 
 
 
 
A little nonsense now and then, is cherished by the wisest men. 
- Roald Dahl, (Willy Wonka) Charlie and the Chocolate Factory 
 
 
The case has, in some respects, been not entirely devoid of interest. 
-     Sir Arthur Conan Doyle, (Sherlock Holmes) 
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Appendix 1 
Tryptic Digest of BHMT 
 
 
Complete table of Tryptic digest fragments from rat liver BHMT including predicted mass 
spectral peaks. 
Fragment Fragment Sequence Mass 
(Daltons) 
M+1 M+2 M+3 M+4 M+5 
T1 APIAGK 555.34 556.35 278.68 186.12 139.84 112.08
T2 K 146.11 147.11 74.06 49.71 37.53 30.23
T3 AK 217.14 218.15 109.58 73.39 55.29 44.44
T4 R 174.11 175.12 88.06 59.05 44.54 35.83
T5 GILER 586.34 587.35 294.18 196.46 147.59 118.28
T6 
LNAGEVVIGDGGFVFALE
K 1934.01 1935.02 968.02 645.68 484.51 387.81
T7 R 174.11 175.12 88.06 59.05 44.54 35.83
T8 GYVK 465.26 466.27 233.64 156.09 117.32 94.06
T9 AGPWTPEAAVEHPEAVR 1815.89 1816.9 908.95 606.3 454.98 364.19
T10 QLHR 552.31 553.32 277.16 185.11 139.09 111.47
T11 EFLR 563.31 564.31 282.66 188.78 141.83 113.67
T12 AGSNVMQTFTFYASEDK 1894.84 1895.85 948.43 632.62 474.72 379.98
T13 LENR 530.28 531.29 266.15 177.77 133.58 107.06
T14 GNYVAEK 779.38 780.39 390.7 260.8 195.85 156.88
T15 ISGQK 531.3 532.31 266.66 178.11 133.83 107.27
T16 VNEAAJDIAR 1117.52 1118.53 559.77 373.51 280.39 224.51
T17 
QVADEGDALVAGGVSQT
PSYLSJK 2451.16 2452.17 1226.59 818.06 613.8 491.24
T18 SETEVK 691.34 692.35 346.68 231.45 173.84 139.28
T19 K 146.11 147.11 74.06 49.71 37.53 30.23
T20 IFHQQLEVFMK 1418.74 1419.75 710.38 473.92 355.69 284.76
T21 K 146.11 147.11 74.06 49.71 37.53 30.23
T22 
NVDFLIAEYFEHVEEAVW
AVEALK 2820.4 2821.41 1411.21 941.14 706.11 565.09
T23 
TSGKPIAATMJIGPEGDLH
GVSPGEJAVR 2966.4 2967.41 1484.21 989.81 742.61 594.29
T24 LVK 358.26 359.27 180.14 120.43 90.57 72.66
T25 
AGAAIVGVNJHFDPSTSL
QTIK 2285.15 2286.16 1143.58 762.72 572.29 458.04
T26 LMK 390.23 391.24 196.12 131.08 98.57 79.05
T27 EGLEAAR 744.38 745.38 373.2 249.13 187.1 149.88
T28 LK 259.19 260.2 130.6 87.4 65.81 52.85
T29 AYLMSHALAYHTPDJGK 1933.88 1934.89 967.95 645.63 484.48 387.78
T30 QGFIDLPEFPFGLEPR 1860.94 1861.95 931.48 621.32 466.24 373.2
T31 VATR 445.26 446.27 223.64 149.43 112.32 90.06
T32 WDIQK 688.35 689.36 345.19 230.46 173.1 138.68
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T33 YAR 408.21 409.22 205.11 137.08 103.06 82.65
T34 EAYNLGVR 920.47 921.48 461.24 307.83 231.13 185.1
T35 YIGGJJGFEPYHIR 1727.75 1728.76 864.89 576.93 432.95 346.56
T36 AIAEELAPER 1097.57 1098.58 549.79 366.87 275.4 220.52
T37 GFLPPASEK 944.5 945.5 473.26 315.84 237.13 189.91
T38 HGSWGSGLDMHTKPWIR 1963.95 1964.96 982.98 655.66 491.99 393.8
T39 AR 245.15 246.16 123.58 82.72 62.3 50.04
T40 AR 245.15 246.16 123.58 82.72 62.3 50.04
T41 K 146.11 147.11 74.06 49.71 37.53 30.23
T42 EYWQNLR 1007.48 1008.49 504.75 336.84 252.88 202.5
T43 
IASGRRPYNPSMSKPDA
WGVTK 2261.13 2262.13 1131.57 754.72 566.29 453.23
T44 GAAELMQQK 974.49 975.49 488.25 325.84 244.63 195.9
T45 EATTEQQLR 1074.53 1075.54 538.27 359.18 269.64 215.91
T46 ALFEK 606.34 607.35 304.18 203.12 152.59 122.28
T47 QK 274.16 275.17 138.09 92.4 69.55 55.84
T48 FK 293.17 294.18 147.59 98.73 74.3 59.64
T49 SAQ 304.14 305.15 153.08 102.39 77.04 61.84
 
